

Introduction to the recommendations from the National Association workgroups on diagnostic guidelines for Al

Alzheimer's and Dementia

7, 257-262

DOI: [10.1016/j.jalz.2011.03.004](https://doi.org/10.1016/j.jalz.2011.03.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Polyadenylation of nascent RNA during the embryogenesis of <i>Ilyanassa obsoleta</i> . <i>Experimental Cell Research</i> , 1975, 95, 263-268.	1.2	12
2	Patient self-report for evaluating mild cognitive impairment and prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2011, 3, 35.	3.0	40
3	Long-term Consequences of Repetitive Brain Trauma: Chronic Traumatic Encephalopathy. <i>PM and R</i> , 2011, 3, S460-7.	0.9	393
4	The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. <i>Nature Reviews Drug Discovery</i> , 2011, 10, 698-712.	21.5	1,766
5	Amyloid imaging for Alzheimer's disease. <i>Expert Opinion on Medical Diagnostics</i> , 2011, 5, 527-538.	1.6	2
6	Neuropsychological assessment of patients with dementing illness. <i>Nature Reviews Neurology</i> , 2011, 7, 677-687.	4.9	55
7	Biomarkers: Warning signs. <i>Nature</i> , 2011, 475, S5-S7.	13.7	16
8	The role of gene expression profiling in drug discovery. <i>Current Opinion in Pharmacology</i> , 2011, 11, 549-556.	1.7	24
11	Evidence for Ordering of Alzheimer Disease Biomarkers. <i>Archives of Neurology</i> , 2011, 68, 1526.	4.9	195
12	Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 280-292.	0.4	5,550
13	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 263-269.	0.4	12,681
14	The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 270-279.	0.4	7,498
15	Commentary on "Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease." Addressing the challenge of Alzheimer's disease in the 21st century. <i>Alzheimer's and Dementia</i> , 2011, 7, 335-337.	0.4	26
16	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 474.	0.4	176
17	Assessment of cognition in early dementia. <i>Alzheimer's and Dementia</i> , 2011, 7, e60-e76.	0.4	75
18	Uncertain Progress on the Fuzzy Boundaries of Alzheimer's Disease: Reading Between the Guidelines. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 1-5.	1.2	17
19	Imaging the Alzheimer Brain. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 1-27.	1.2	41
20	Evaluation and Tracking of Alzheimer's Disease Severity Using Resting-State Magnetoencephalography. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 239-255.	1.2	19

#	ARTICLE	IF	CITATIONS
21	Age, Alzheimer's disease, and the big picture. <i>International Psychogeriatrics</i> , 2011, 23, 1531-1534.	0.6	16
22	Revised NIA-AA criteria for the diagnosis of Alzheimer's disease: a step forward but not yet ready for widespread clinical use. <i>International Psychogeriatrics</i> , 2011, 23, 1191-1196.	0.6	42
23	Obesity, leptin, and Alzheimer's disease. <i>Annals of the New York Academy of Sciences</i> , 2011, 1243, 15-29.	1.8	104
24	Simulated brain biopsy for diagnosing neurodegeneration using autopsy-confirmed cases. <i>Acta Neuropathologica</i> , 2011, 122, 737-745.	3.9	15
25	A perspective on the proposal for neurocognitive disorder criteria in DSM-5 as applied to HIV-associated neurocognitive disorders. <i>Neuropsychiatry</i> , 2011, 1, 431-440.	0.4	7
26	Changing Concepts of Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2458.	3.8	82
27	Sense and sensitivity of novel criteria for frontotemporal dementia. <i>Brain</i> , 2011, 134, 2450-2453.	3.7	2
28	Protocol for a randomised controlled trial to improve cognitive functioning in older adults: the Iowa Healthy and Active Minds Study. <i>BMJ Open</i> , 2011, 1, e000218-e000218.	0.8	11
29	The vasculature in Alzheimer's disease: a new therapeutic target for an old disease?. <i>Therapy: Open Access in Clinical Medicine</i> , 2011, 8, 463-465.	0.2	0
31	Dementia has a categorical, not dimensional, latent structure.. <i>Psychology and Aging</i> , 2012, 27, 791-797.	1.4	7
32	Molecular Brain Imaging in the Multimodality Era. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1377-1392.	2.4	16
33	Road to the Nursing Home. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2012, 27, 90-99.	0.9	7
35	Neuroimaging in dementias. <i>Current Opinion in Psychiatry</i> , 2012, 25, 473-479.	3.1	21
36	New Criteria for Alzheimer Disease and Mild Cognitive Impairment. <i>Neurologist</i> , 2012, 18, 356-363.	0.4	45
37	Postmortem Pittsburgh Compound B (PiB) Binding Increases with Alzheimer's Disease Progression. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 127-138.	1.2	18
38	Using Pittsburgh Compound B for In Vivo PET Imaging of Fibrillar Amyloid-Beta. <i>Advances in Pharmacology</i> , 2012, 64, 27-81.	1.2	78
39	Impact of Beta-Amyloid-Specific Florbetaben PET Imaging on Confidence in Early Diagnosis of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 33, 416-422.	0.7	59
40	Preclinical Characterization of a Novel Class of ¹⁸ F-Labeled PET Tracers for Amyloid- β . <i>Journal of Nuclear Medicine</i> , 2012, 53, 1794-1801.	2.8	20

#	ARTICLE	IF	CITATIONS
41	Biomarker trajectories across stages of Alzheimer disease. <i>Nature Reviews Neurology</i> , 2012, 8, 299-300.	4.9	22
42	Dramatic impairment of prediction due to frontal lobe degeneration. <i>Journal of Neurophysiology</i> , 2012, 108, 2957-2966.	0.9	21
43	Alzheimer's Disease in the Retina: Imaging Retinal A β Plaques for Early Diagnosis and Therapy Assessment. <i>Neurodegenerative Diseases</i> , 2012, 10, 285-293.	0.8	184
44	Amyloid pathology in persons with "normal" cognition. <i>Neurology</i> , 2012, 78, 228-229.	1.5	10
45	Volumetric Analysis of the Pons, Cerebellum and Hippocampi in Patients with Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 224-234.	0.7	16
46	P300 and Neuropsychological Assessment in Mild Cognitive Impairment and Alzheimer Dementia. <i>Frontiers in Neurology</i> , 2012, 3, 172.	1.1	60
47	Alzheimer disease. <i>Nursing Management</i> , 2012, 43, 26-31.	0.2	0
48	Added Diagnostic Value of 11C-PiB-PET in Memory Clinic Patients with Uncertain Diagnosis. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 610-621.	0.6	44
49	Managing memory impairment in patients with Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 459-469.	1.2	0
50	Will the Revised MCI Criteria Mean Fewer Alzheimer Disease Diagnoses?. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2012, 12, 1.	0.0	0
51	Neuropathological Basis of Alzheimer's Disease and Alzheimer's Disease Diagnosis. <i>Advances in Biological Psychiatry</i> , 2012, , 49-70.	0.2	1
52	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 362-381.	0.9	1,599
53	CME ARTICLE Updated guidelines for the diagnosis of Alzheimer disease: A clinical review. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2012, 25, 50-55.	0.1	6
54	Amyloid and Alzheimer's Disease: Inside and Out. <i>Canadian Journal of Neurological Sciences</i> , 2012, 39, 286-298.	0.3	56
55	Aging and mental health in the decade ahead: What psychologists need to know.. <i>American Psychologist</i> , 2012, 67, 184-198.	3.8	177
56	Mild cognitive impairment is associated with selected functional markers: Integrating concurrent, longitudinal, and stability effects.. <i>Neuropsychology</i> , 2012, 26, 209-223.	1.0	35
57	Comparison of Cerebrospinal Fluid Levels of Tau and A β 1-42 in Alzheimer Disease and Frontotemporal Degeneration Using 2 Analytical Platforms. <i>Archives of Neurology</i> , 2012, 69, 1018-25.	4.9	100
59	2012 Alzheimer's disease facts and figures Alzheimer's Association ^â. <i>Alzheimer's and Dementia</i> , 2012, 8, 131-168.	0.4	829

#	ARTICLE	IF	CITATIONS
60	Worldwide Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2012, 8, 337-342.	0.4	84
61	Advancing Alzheimer's disease diagnosis, treatment, and care: Recommendations from the Ware Invitational Summit. <i>Alzheimer's and Dementia</i> , 2012, 8, 445-452.	0.4	46
66	Encuesta sobre la enfermedad de Alzheimer en el contexto de los nuevos paradigmas diagn3sticos. <i>Neurologia Argentina</i> , 2012, 4, 118-125.	0.1	5
68	Identification of Mild Alzheimer's Disease through automated classification of structural MRI features. , 2012, 2012, 428-31.		12
69	New diagnostic criteria for Alzheimer's disease and mild cognitive impairment for the practical neurologist. <i>Practical Neurology</i> , 2012, 12, 88-96.	0.5	37
70	Structural and functional neural correlates of visuospatial information processing in normal aging and amnesic mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2782-2797.	1.5	35
71	Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia. <i>Progress in Neurobiology</i> , 2012, 97, 38-51.	2.8	153
72	Alzheimer Mechanisms and Therapeutic Strategies. <i>Cell</i> , 2012, 148, 1204-1222.	13.5	1,548
73	Diagnostic and economic evaluation of new biomarkers for Alzheimerâ€™s disease: the research protocol of a prospective cohort study. <i>BMC Neurology</i> , 2012, 12, 72.	0.8	24
74	Recommendations to standardize preanalytical confounding factors in Alzheimerâ€™s and Parkinsonâ€™s disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	0.6	280
76	Diagnostic neuroimaging across diseases. <i>NeuroImage</i> , 2012, 61, 457-463.	2.1	240
77	The application of Fourier transform infrared microspectroscopy for the study of diseased central nervous system tissue. <i>NeuroImage</i> , 2012, 59, 3624-3640.	2.1	95
78	Neurocognitive disorders in DSM 5 project â€” Personal comments. <i>Journal of the Neurological Sciences</i> , 2012, 322, 17-19.	0.3	8
79	Hippocampal atrophy in Alzheimerâ€™s disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 197-209.	1.2	2
80	CSF tau and amyloid β levels in Alzheimerâ€™s diseaseâ€”A meta-analysis. <i>Advances in Alzheimer's Disease</i> , 2012, 01, 30-44.	0.3	7
81	Spatial Distribution and Secular Trends in the Epidemiology of Alzheimer's Disease. <i>Neuroimaging Clinics of North America</i> , 2012, 22, 1-10.	0.5	15
82	Clinical and Research Diagnostic Criteria for Alzheimer's Disease. <i>Neuroimaging Clinics of North America</i> , 2012, 22, 23-32.	0.5	51
83	Current application of neurochemical biomarkers in the prediction and differential diagnosis of Alzheimerâ€™s disease and other neurodegenerative dementias. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2012, 262, 71-77.	1.8	24

#	ARTICLE	IF	CITATIONS
84	Assessing Dementia in Resource-Poor Regions. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 511-519.	2.0	45
85	Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer's disease. <i>Neuroscience Bulletin</i> , 2012, 28, 641-648.	1.5	51
86	Optimizing diagnosis and management in mild-to-moderate Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2012, 2, 291-304.	1.2	9
87	Small-Animal PET Imaging of Amyloid-Beta Plaques with [11C]PiB and Its Multi-Modal Validation in an APP/PS1 Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2012, 7, e31310.	1.1	102
88	CSF and Brain Structural Imaging Markers of the Alzheimer's Pathological Cascade. <i>PLoS ONE</i> , 2012, 7, e47406.	1.1	36
89	A Peephole into the Brain: Neuropathological Features of Alzheimer's Disease Revealed by in vivo Two-Photon Imaging. <i>Frontiers in Psychiatry</i> , 2012, 3, 26.	1.3	29
90	The Impact of Experience with a Family Member with Alzheimer's Disease on Views about the Disease across Five Countries. <i>International Journal of Alzheimer's Disease</i> , 2012, 2012, 1-9.	1.1	23
91	Perspectives for Multimodal Neurochemical and Imaging Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 33, S329-S347.	1.2	21
92	Historical perspectives on the discovery and development of drugs to treat neurological disorders. , 0, , 129-148.		5
93	Bioprofile Analysis: A New Approach for the Analysis of Biomedical Data in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 32, 997-1010.	1.2	6
94	Alzheimer Disease: New Concepts on Its Neurobiology and the Clinical Role Imaging Will Play. <i>Radiology</i> , 2012, 263, 344-361.	3.6	192
95	Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer's disease?. <i>Neuroradiology</i> , 2012, 54, 1321-1330.	1.1	39
96	Olfactory identification testing as a predictor of the development of Alzheimer's dementia: A systematic review. <i>Laryngoscope</i> , 2012, 122, 1455-1462.	1.1	72
98	Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma. <i>Brain Imaging and Behavior</i> , 2012, 6, 244-254.	1.1	397
99	Alzheimer's disease therapeutic trials: EU/US task force report on recruitment, retention, and methodology. <i>Journal of Nutrition, Health and Aging</i> , 2012, 16, 339-345.	1.5	38
101	The prognostic value of amyloid imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1207-1219.	3.3	29
102	Dementia, Stroke, and Vascular Risk Factors; a Review. <i>International Journal of Stroke</i> , 2012, 7, 61-73.	2.9	181
103	Cerebrospinal Fluid Biomarkers in Alzheimer's Disease and Geriatric Depression: Preliminary Findings from Brazil. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 524-529.	1.9	22

#	ARTICLE	IF	CITATIONS
104	Subjective cognitive complaints: not to be dismissed. <i>European Journal of Neurology</i> , 2012, 19, 665-665.	1.7	2
105	Neuroimaging Results Impose New Views on Alzheimer's Disease—the Role of Amyloid Revised. <i>Molecular Neurobiology</i> , 2012, 45, 153-172.	1.9	44
106	Progress in Alzheimer's disease. <i>Journal of Neurology</i> , 2012, 259, 201-211.	1.8	79
107	The development of effective biomarkers for Alzheimer's disease: a review. <i>International Journal of Geriatric Psychiatry</i> , 2013, 28, 331-340.	1.3	46
108	Making sense of nonsense: experiences of mild cognitive impairment. <i>Sociology of Health and Illness</i> , 2013, 35, 130-146.	1.1	89
109	Fluid biomarkers in Alzheimer's disease — current concepts. <i>Molecular Neurodegeneration</i> , 2013, 8, 20.	4.4	180
110	Neuroprotective effects of D-Ala2GIP on Alzheimer's disease biomarkers in an APP/PS1 mouse model. <i>Alzheimer's Research and Therapy</i> , 2013, 5, 20.	3.0	59
111	Discrimination of dementia with Lewy bodies from Alzheimer's disease using voxel-based morphometry of white matter by statistical parametric mapping 8 plus diffeomorphic anatomic registration through exponentiated Lie algebra. <i>Neuroradiology</i> , 2013, 55, 559-566.	1.1	35
112	Molecular imaging of dementia. <i>Geriatric Mental Health Care</i> , 2013, 1, 56-62.	0.3	4
113	Insights on altered mitochondrial function and dynamics in the pathogenesis of neurodegeneration. <i>Translational Neurodegeneration</i> , 2013, 2, 12.	3.6	57
114	Magnetic Resonance Spectroscopy in Common Dementias. <i>Neuroimaging Clinics of North America</i> , 2013, 23, 393-406.	0.5	44
115	Action perception predicts action performance. <i>Neuropsychologia</i> , 2013, 51, 2294-2304.	0.7	66
116	Practical geriatric assessment. <i>Aging Health</i> , 2013, 9, 579-591.	0.3	2
117	2013 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2013, 9, 208-245.	0.4	1,151
118	Clinical stages of patients with Alzheimer disease treated in specialist clinics in Spain. The EACE study. <i>Neurología (English Edition)</i> , 2013, 28, 477-487.	0.2	2
119	Personalized medicine in Alzheimer's disease and depression. <i>Contemporary Clinical Trials</i> , 2013, 36, 616-623.	0.8	17
120	Cerebral amyloid PET imaging in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2013, 126, 643-657.	3.9	99
121	Stability of Clinical Etiologic Diagnosis in Dementia and Mild Cognitive Impairment. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2013, 28, 750-758.	0.9	19

#	ARTICLE	IF	CITATIONS
122	Biomarker Modeling of Alzheimer's Disease. <i>Neuron</i> , 2013, 80, 1347-1358.	3.8	773
123	Meta-analysis of functional network alterations in Alzheimer's disease: Toward a network biomarker. <i>Neuroscience and Biobehavioral Reviews</i> , 2013, 37, 753-765.	2.9	107
125	Molecular neuroimaging in degenerative dementias. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2013, 32, 301-309.	0.1	3
126	Biomarkers for Alzheimer's: the sequel of an original model. <i>Lancet Neurology, The</i> , 2013, 12, 126-128.	4.9	18
127	Pre-Diagnosis Excess Acute Care Costs in Alzheimer's Patients among a US Medicaid Population. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 407-413.	1.0	39
128	Do preclinical Alzheimer's disease criteria work?. <i>Lancet Neurology, The</i> , 2013, 12, 933-935.	4.9	7
130	Machine Learning-Based Method for Personalized and Cost-Effective Detection of Alzheimer's Disease. <i>IEEE Transactions on Biomedical Engineering</i> , 2013, 60, 164-168.	2.5	68
131	ICITST-2013: Keynote speaker 4: Writing a sustainable research paper. , 2013, , .		2
132	Fluid biomarkers for diagnosing dementia: rationale and the Canadian Consensus on Diagnosis and Treatment of Dementia recommendations for Canadian physicians. <i>Alzheimer's Research and Therapy</i> , 2013, 5, S8.	3.0	17
133	Editorial. , 2013, 9, 619-621.		0
134	Revisiting the framework of the National Institute on Aging's Alzheimer's Association diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2013, 9, 594-601.	0.4	42
136	The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress. <i>Alzheimer's and Dementia</i> , 2013, 9, 657-665.	0.4	385
138	La neuroimagen molecular en las demencias degenerativas. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2013, 32, 301-309.	0.0	5
139	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20
140	Longitudinal, region-specific course of diffusion tensor imaging measures in mild cognitive impairment and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2013, 9, 519-528.	0.4	91
141	Comparative accuracies of two common screening instruments for classification of Alzheimer's disease, mild cognitive impairment, and healthy aging. <i>Alzheimer's and Dementia</i> , 2013, 9, 529-537.	0.4	292
143	Screening for predementia AD. <i>Neurology</i> , 2013, 80, 1307-1314.	1.5	96
144	Effects of acetylcholinesterase inhibitors and memantine on resting-state electroencephalographic rhythms in Alzheimer's disease patients. <i>Clinical Neurophysiology</i> , 2013, 124, 837-850.	0.7	77

#	ARTICLE	IF	CITATIONS
145	Are subjective cognitive complaints relevant in preclinical Alzheimer's disease? A review and guidelines for healthcare professionals. <i>Reviews in Clinical Gerontology</i> , 2013, 23, 61-74.	0.5	26
146	Depressive symptoms in clinical and incipient Alzheimer's disease. <i>Neurodegenerative Disease Management</i> , 2013, 3, 147-155.	1.2	13
147	Alzheimer's Disease Biomarkers: More Than Molecular Diagnostics. <i>Drug Development Research</i> , 2013, 74, 92-111.	1.4	6
148	Alzheimer's therapeutics: Continued clinical failures question the validity of the amyloid hypothesis—but what lies beyond?. <i>Biochemical Pharmacology</i> , 2013, 85, 289-305.	2.0	181
149	Clinical Trials in Predementia Stages of Alzheimer Disease. <i>Medical Clinics of North America</i> , 2013, 97, 439-457.	1.1	46
150	Alzheimer's Disease, Dementia, Mild Cognitive Impairment and the Menopause: A Window of Opportunity?. <i>Women's Health</i> , 2013, 9, 279-290.	0.7	26
151	Brain Changes in Older Adults at Very Low Risk for Alzheimer's Disease. <i>Journal of Neuroscience</i> , 2013, 33, 8237-8242.	1.7	184
152	Synchrotron FTIR reveals lipid around and within amyloid plaques in transgenic mice and Alzheimer's disease brain. <i>Analyst</i> , 2013, 138, 3991.	1.7	75
153	FDG-PET in Early AD Diagnosis. <i>Medical Clinics of North America</i> , 2013, 97, 485-494.	1.1	12
154	Prediction of Long-Term (5 Years) Conversion to Dementia Using Neuropsychological Tests in a Memory Clinic Setting. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 681-689.	1.2	21
156	After the Diagnosis of Dementia: Considerations in Disease Management. , 2013, , 59-77.		0
157	Neuropsychological tests for the diagnosis of Alzheimer's disease dementia and other dementias: a generic protocol for cross-sectional and delayed-verification studies. <i>The Cochrane Library</i> , 2013, , .	1.5	72
158	Cerebrospinal Fluid A β ₄₂ , Phosphorylated Tau ₁₈₁ , and Resting-State Functional Connectivity. <i>JAMA Neurology</i> , 2013, 70, 1242-8.	4.5	89
159	Detecting amyloid biomarkers: Embodied risk and Alzheimer prevention. <i>BioSocieties</i> , 2013, 8, 107-123.	0.8	9
160	Can the DSM-5 framework enhance the diagnosis of MCI?. <i>Neurology</i> , 2013, 81, 2045-2050.	1.5	19
161	New diagnostic concepts in Alzheimer's disease. <i>Advances in Psychiatric Treatment</i> , 2013, 19, 242-249.	0.6	3
162	SPION-Enhanced Magnetic Resonance Imaging of Alzheimer's Disease Plaques in A β _{PP} /PS-1 Transgenic Mouse Brain. <i>Journal of Alzheimer's Disease</i> , 2013, 34, 349-365.	1.2	86
163	A literature review of AD7c-ntp as a biomarker for Alzheimer's disease. <i>Annals of Indian Academy of Neurology</i> , 2013, 16, 307.	0.2	11

#	ARTICLE	IF	CITATIONS
164	Circulating miRNA Biomarkers for Alzheimer's Disease. PLoS ONE, 2013, 8, e69807.	1.1	295
165	Novel fluorescent microarray platforms: a case study in neurodegenerative disorders. Expert Review of Molecular Diagnostics, 2013, 13, 863-873.	1.5	5
166	Variations in Self-Reported Practice of Physicians Providing Clinical Care to Individuals with Dementia: A Systematic Review. Journal of the American Geriatrics Society, 2013, 61, 1277-1285.	1.3	11
167	Association between EEG Abnormalities and CSF Biomarkers in a Memory Clinic Cohort. Dementia and Geriatric Cognitive Disorders, 2013, 36, 319-328.	0.7	26
168	Current guidelines for dementia screening: shortcomings and recommended changes. Neurodegenerative Disease Management, 2013, 3, 565-573.	1.2	13
169	Renovating Alzheimer's: "Constructive" Reflections on the New Clinical and Research Diagnostic Guidelines. Gerontologist, The, 2013, 53, 378-387.	2.3	21
170	Alzheimer's Disease Clinical and Research Update for Health Care Practitioners. Journal of Aging Research, 2013, 2013, 1-9.	0.4	48
171	Proton MRS in mild cognitive impairment. Journal of Magnetic Resonance Imaging, 2013, 37, 770-777.	1.9	62
172	CSF levels of the neuronal injury biomarker visinin-like protein-1 in Alzheimer's disease and dementia with Lewy bodies. Journal of Neurochemistry, 2013, 127, 681-690.	2.1	52
173	Disease-modifying therapy for Alzheimer's disease: Challenges and hopes. Neurology and Clinical Neuroscience, 2013, 1, 49-54.	0.2	9
174	Biomarker-Driven Therapeutic Management of Alzheimer's Disease: Establishing the Foundations. Clinical Pharmacology and Therapeutics, 2013, 95, 67-77.	2.3	19
176	Cortical atrophy in presymptomatic Alzheimer's disease presenilin 1 mutation carriers. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 556-561.	0.9	44
177	A Blood Gene Expression Marker of Early Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 33, 737-753.	1.2	91
179	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
181	Commentary. International Psychogeriatrics, 2013, 25, 181-184.	0.6	1
182	Correlation between Topographic N400 Anomalies and Reduced Cerebral Blood Flow in the Anterior Temporal Lobes of Patients with Dementia. Journal of Alzheimer's Disease, 2013, 36, 711-731.	1.2	23
184	Prevention of Alzheimer's Disease: Intervention Studies. , 0, , .		1
185	Frontal presentation of Alzheimer's disease: A series of patients with biological evidence by CSF biomarkers. Dementia E Neuropsychologia, 2013, 7, 66-74.	0.3	29

#	ARTICLE	IF	CITATIONS
186	Neuropsychiatric symptoms and severity of dementia. <i>Dementia E Neuropsychologia</i> , 2013, 7, 171-175.	0.3	0
187	Improved Design of Prodromal Alzheimer's Disease Trials through Cohort Enrichment and Surrogate Endpoints. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 475-486.	1.2	6
188	Predicting AD Conversion: Comparison between Prodromal AD Guidelines and Computer Assisted PredictAD Tool. <i>PLoS ONE</i> , 2013, 8, e55246.	1.1	31
189	Internet-Based Screening for Dementia Risk. <i>PLoS ONE</i> , 2013, 8, e57476.	1.1	12
190	Single-Subject Grey Matter Graphs in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e58921.	1.1	107
191	Faster cognitive decline in the years prior to MR imaging is associated with smaller hippocampal volumes in cognitively healthy older persons. <i>Frontiers in Aging Neuroscience</i> , 2013, 5, 21.	1.7	10
192	Magnetic resonance spectroscopy in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 687.	1.0	61
193	Predicting Cognitive Decline in Alzheimer's Disease (AD): The Role of Clinical, Cognitive Characteristics and Biomarkers. , 2013, , .		0
194	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. <i>PLoS ONE</i> , 2014, 9, e100784.	1.1	72
195	T1-weighted Axial Visual Rating Scale for an Assessment of Medial Temporal Atrophy in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 169-178.	1.2	19
196	Currently Available Biomarkers and Strategies for the Validation of Novel Candidates for Neurochemical Dementia Diagnostics in Alzheimer's Disease and Mild Cognitive Impairment. <i>Advances in Geriatrics</i> , 2014, 2014, 1-15.	1.6	2
197	Role of EEG as Biomarker in the Early Detection and Classification of Dementia. <i>Scientific World Journal</i> , The, 2014, 2014, 1-16.	0.8	120
198	CSF Biomarkers of Alzheimer's Disease: Impact on Disease Concept, Diagnosis, and Clinical Trial Design. <i>Advances in Geriatrics</i> , 2014, 2014, 1-14.	1.6	15
199	Meta-Review of CSF Core Biomarkers in Alzheimer's Disease: The State-of-the-Art after the New Revised Diagnostic Criteria. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 47.	1.7	105
200	Science to Practice: Translating Automated Brain MRI Volumetry in Alzheimer's Disease from Research to Routine Diagnostic Use in the Work-Up of Dementia. <i>Frontiers in Neurology</i> , 2014, 4, 216.	1.1	16
201	Enhancing cognition before clinical symptoms of dementia. <i>Frontiers in Systems Neuroscience</i> , 2014, 8, 240.	1.2	1
202	Cognitive impairment and memory dysfunction after a stroke diagnosis: a post-stroke memory assessment. <i>Neuropsychiatric Disease and Treatment</i> , 2014, 10, 1677.	1.0	142
203	The link between cardiovascular risk, Alzheimer's disease, and mild cognitive impairment: support from recent functional neuroimaging studies. <i>Revista Brasileira De Psiquiatria</i> , 2014, 36, 344-357.	0.9	10

#	ARTICLE	IF	CITATIONS
204	Radiotracers Used to Image the Brains of Patients with Alzheimer's Disease. , 2014, , 407-416.		5
205	Alzheimer's Disease and Animal Models in Retrospect. , 2014, 4, .		2
206	Increased Myeloperoxidase Plasma Levels in Patients with Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 39, 557-564.	1.2	55
207	Nicotinic Acetylcholine Receptors in Alzheimer's and Parkinson's Disease. , 2014, , 383-415.		0
208	Amyloid imaging in Alzheimer's disease: A literature review. Journal of Nutrition, Health and Aging, 2014, 18, 723-740.	1.5	8
209	Protein-Based Biomarkers in Cerebrospinal Fluid and Blood for Alzheimer's Disease. Journal of Molecular Neuroscience, 2014, 54, 739-747.	1.1	15
210	Alzheimer's disease and infections, where we stand and where we go. Immunity and Ageing, 2014, 11, 26.	1.8	13
212	Diagnostic tools for alzheimer's disease dementia and other dementias: an overview of diagnostic test accuracy (DTA) systematic reviews. BMC Neurology, 2014, 14, 183.	0.8	22
213	Retinal manifestations of Alzheimer's disease. Neurodegenerative Disease Management, 2014, 4, 241-252.	1.2	27
214	Plasma DYRK1A as a novel risk factor for Alzheimer's disease. Translational Psychiatry, 2014, 4, e425-e425.	2.4	36
215	Validación en español del test TYM para cribado de demencia en una población argentina. Universitas Psychologica, 2014, 13, .	0.6	0
216	Alzheimer's Disease In African Americans: Risk Factors And Challenges For The Future. Health Affairs, 2014, 33, 580-586.	2.5	233
217	Molecular Imaging of Alzheimer Disease Pathology. American Journal of Neuroradiology, 2014, 35, S12-S17.	1.2	15
218	Validation of an optimized SPM procedure for FDG-PET in dementia diagnosis in a clinical setting. Neurolmage: Clinical, 2014, 6, 445-454.	1.4	172
219	Nonamyloid PET biomarkers and Alzheimer's disease: current and future perspectives. Future Neurology, 2014, 9, 597-613.	0.9	3
220	Longitudinal Alteration of Amygdalar Functional Connectivity in Mild Cognitive Impairment Subjects Revealed by Resting-State fMRI. Brain Connectivity, 2014, 4, 361-370.	0.8	26
221	¹⁸ F-FDG PET and Perfusion SPECT in the Diagnosis of Alzheimer and Lewy Body Dementias. Journal of Nuclear Medicine, 2014, 55, 1959-1965.	2.8	172
222	Structural covariance of superficial white matter in mild Alzheimer's disease compared to normal aging. Brain and Behavior, 2014, 4, 721-737.	1.0	25

#	ARTICLE	IF	CITATIONS
223	Cognition in movement disorders: Where can we hope to be in ten years?. <i>Movement Disorders</i> , 2014, 29, 704-711.	2.2	15
225	The efficacy of plasma biomarkers in early diagnosis of Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 713-719.	1.3	49
226	Early Alzheimer's Disease Neuropathology Detected by Proton MR Spectroscopy. <i>Journal of Neuroscience</i> , 2014, 34, 16247-16255.	1.7	117
227	Cognitively elite, cognitively normal, and cognitively impaired aging: Neurocognitive status and stability moderate memory performance. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2014, 36, 418-430.	0.8	10
228	PART and SNAP. <i>Acta Neuropathologica</i> , 2014, 128, 773-776.	3.9	78
229	A Standardized [18F]-FDG-PET Template for Spatial Normalization in Statistical Parametric Mapping of Dementia. <i>Neuroinformatics</i> , 2014, 12, 575-593.	1.5	240
230	Clinical subtypes of chronic traumatic encephalopathy: literature review and proposed research diagnostic criteria for traumatic encephalopathy syndrome. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 68.	3.0	257
231	How to Diagnose and Define Alzheimer's. <i>Neurology Today: an Official Publication of the American Academy of Neurology</i> , 2014, 14, 1.	0.0	0
232	Correlational Analysis of 5 Commonly Used Measures of Cognitive Functioning and Mental Status. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2014, 29, 718-722.	0.9	20
233	Histopathology: A Canvas and Landscape of Disease in Drug and Diagnostic Development. <i>Methods in Pharmacology and Toxicology</i> , 2014, , 1-26.	0.1	0
234	How Are We Going To Live With Alzheimer's Disease?. <i>Health Affairs</i> , 2014, 33, 541-546.	2.5	9
235	Associative Learning and Regional White Matter Deficits in Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 421-430.	1.2	6
236	<i>Medizin</i> , 2014, 38, 25-34.	0.1	0
237	Attempted and Successful Compensation in Preclinical and Early Manifest Neurodegeneration – A Review of Task fMRI Studies. <i>Frontiers in Psychiatry</i> , 2014, 5, 132.	1.3	61
238	Biomarkers for neurological disorders “ call for standardization. <i>Laboratoriums Medizin</i> , 2014, 38, .	0.1	0
239	Analysis of Barriers to Cognitive Screening in Rural Populations in the United States. <i>Advances in Nursing Science</i> , 2014, 37, 327-339.	0.6	25
240	The unbearable lightness of MCI. <i>International Psychogeriatrics</i> , 2014, 26, 353-359.	0.6	8
241	Cortical sources of resting state electroencephalographic alpha rhythms deteriorate across time in subjects with amnesic mild cognitive impairment. <i>Neurobiology of Aging</i> , 2014, 35, 130-142.	1.5	61

#	ARTICLE	IF	CITATIONS
242	Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 271-278.	1.5	256
243	Dihydrotestosterone treatment delays the conversion from mild cognitive impairment to Alzheimer's disease in SAMP8 mice. <i>Hormones and Behavior</i> , 2014, 65, 505-515.	1.0	41
244	Can dementia be diagnosed during hospitalisation?. <i>European Geriatric Medicine</i> , 2014, 5, 314-318.	1.2	2
246	Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2014, 35, 143-151.	1.5	109
247	[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 290-300.	3.3	89
248	Magnetic Resonance Imaging Predictors of Treatment Response in Late-Life Depression. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2014, 27, 24-32.	1.2	42
249	Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. <i>Biochemical Pharmacology</i> , 2014, 88, 508-516.	2.0	196
250	An algorithmic approach to structural imaging in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 692-698.	0.9	98
251	2014 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2014, 10, e47-92.	0.4	750
252	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.4	1,863
253	What is normal in normal aging? Effects of aging, amyloid and Alzheimer's disease on the cerebral cortex and the hippocampus. <i>Progress in Neurobiology</i> , 2014, 117, 20-40.	2.8	608
254	Nutrition and the brain: what advice should we give?. <i>Neurobiology of Aging</i> , 2014, 35, S79-S83.	1.5	18
255	Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. <i>Lancet Neurology</i> , The, 2014, 13, 614-629.	4.9	2,657
256	Determinants, MRI Correlates, and Prognosis of Mild Cognitive Impairment: The Rotterdam Study. <i>Journal of Alzheimer's Disease</i> , 2014, 42, S239-S249.	1.2	59
257	Altered Serum Levels of Adipokines and Insulin in Probable Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 525-533.	1.2	91
258	Impaired Long Distance Functional Connectivity and Weighted Network Architecture in Alzheimer's Disease. <i>Cerebral Cortex</i> , 2014, 24, 1422-1435.	1.6	202
259	Validity of dementia and Alzheimer's disease diagnoses in Finnish national registers. <i>Alzheimer's and Dementia</i> , 2014, 10, 303-309.	0.4	103
260	Unbiased Approaches to Biomarker Discovery in Neurodegenerative Diseases. <i>Neuron</i> , 2014, 84, 594-607.	3.8	51

#	ARTICLE	IF	CITATIONS
261	Cholinesterase inhibitors should not be prescribed for mild cognitive impairment. Evidence-Based Medicine, 2014, 19, 101-101.	0.6	17
262	Editorial. Alzheimer's and Dementia, 2014, 10, 590-591.	0.4	0
263	Comparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis. European Radiology, 2014, 24, 2800-2809.	2.3	25
264	Brain insulin resistance in Alzheimer's disease and its potential treatment with GLP-1 analogs. Neurodegenerative Disease Management, 2014, 4, 31-40.	1.2	90
265	Association of Apolipoprotein E Genetic Variation in Alzheimer's Disease in Indian Population. American Journal of Alzheimer's Disease and Other Dementias, 2014, 29, 575-582.	0.9	26
266	The emerging agenda of stratified medicine in neurology. Nature Reviews Neurology, 2014, 10, 15-26.	4.9	30
267	Harmonized diagnostic criteria for Alzheimer's disease: recommendations. Journal of Internal Medicine, 2014, 275, 204-213.	2.7	101
268	Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathologica, 2014, 128, 755-766.	3.9	1,060
269	Insulin resistance in Alzheimer's disease. Neurobiology of Disease, 2014, 72, 92-103.	2.1	92
270	Current advances in systems and integrative biology. Computational and Structural Biotechnology Journal, 2014, 11, 35-46.	1.9	29
271	Standardization of MRI and Amyloid Imaging. , 2014, , 131-156.		2
272	Alzheimer's disease and vascular dementia: one potentially preventable and modifiable disease. Part I: Pathology, diagnosis and screening. Neurodegenerative Disease Management, 2014, 4, 253-259.	1.2	9
273	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's and Dementia, 2014, 10, 808-817.	0.4	163
274	Functional and Structural MRI in Alzheimer's Disease: A Multimodal Approach. , 2014, , 371-422.		0
275	Ecological assessment of mild cognitive impairment and Alzheimer disease using the Rivermead Behavioural Memory Test. Neurologia (English Edition), 2014, 29, 339-345.	0.2	8
276	Detection of volume loss in hippocampal layers in Alzheimer's disease using 7T MRI: A feasibility study. NeuroImage: Clinical, 2014, 5, 341-348.	1.4	74
277	Lewy body compared with Alzheimer dementia is associated with decreased functional connectivity in resting state networks. Psychiatry Research - Neuroimaging, 2014, 223, 192-201.	0.9	52
278	Vitamin D in Relation to Cognitive Impairment, Cerebrospinal Fluid Biomarkers, and Brain Volumes. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 1132-1138.	1.7	68

#	ARTICLE	IF	CITATIONS
279	Preventing Alzheimer's Disease. , 2014, , 33-46.		1
280	The need for "objective measurements" in FDG and amyloid PET neuroimaging. Clinical and Translational Imaging, 2014, 2, 331-342.	1.1	4
281	Targeting Brain $\alpha 7$ Nicotinic Acetylcholine Receptors in Alzheimer's Disease: Rationale and Current Status. CNS Drugs, 2014, 28, 975-987.	2.7	48
283	Amyloid imaging in depression: a predictor of Alzheimer's disease?. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 711-713.	3.3	1
284	Gray-matter macrostructure in cognitively healthy older persons: associations with age and cognition. Brain Structure and Function, 2014, 219, 2029-2049.	1.2	37
285	Alzheimer, dementia and the living will: a proposal. Medicine, Health Care and Philosophy, 2014, 17, 389-395.	0.9	47
286	Diagnostic effectiveness of quantitative [18F]flutemetamol PET imaging for detection of fibrillar amyloid $A\beta$ using cortical biopsy histopathology as the standard of truth in subjects with idiopathic normal pressure hydrocephalus. Acta Neuropathologica Communications, 2014, 2, 46.	2.4	19
287	Late-Onset Alzheimer's Disease, Heating up and Foxed by Several Proteins: Pathomolecular Effects of the Aging Process. Journal of Alzheimer's Disease, 2014, 40, 1-17.	1.2	30
288	A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. International Journal of Geriatric Psychiatry, 2014, 29, 551-561.	1.3	58
289	Implications of early treatment among Medicaid patients with Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 214-224.	0.4	39
290	Patient and carer views on participating in clinical trials for prodromal Alzheimer's disease and mild cognitive impairment. International Journal of Geriatric Psychiatry, 2014, 29, 22-31.	1.3	29
291	Cost-Effectiveness of the Use of Biomarkers in Cerebrospinal Fluid for Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 42, 777-788.	1.2	32
292	Quantitative Evaluation of Disease Progression in a Longitudinal Mild Cognitive Impairment Cohort. Journal of Alzheimer's Disease, 2014, 39, 49-61.	1.2	21
293	Disrupted structural and functional brain connectomes in mild cognitive impairment and Alzheimer's disease. Neuroscience Bulletin, 2014, 30, 217-232.	1.5	135
294	Grey-matter volume as a potential feature for the classification of Alzheimer's disease and mild cognitive impairment: an exploratory study. Neuroscience Bulletin, 2014, 30, 477-489.	1.5	45
295	Harm avoidance is associated with progression of parkinsonism in community-dwelling older adults: a prospective cohort study. BMC Geriatrics, 2014, 14, 54.	1.1	8
296	Neurotransmitter receptor and time dependence of the synaptic plasticity disrupting actions of Alzheimer's disease $A\beta$ <i>in vivo</i> . Philosophical Transactions of the Royal Society B: Biological Sciences, 2014, 369, 20130147.	1.8	23
297	Soluble amyloid precursor proteins and secretases as Alzheimer's disease biomarkers. Trends in Molecular Medicine, 2014, 20, 8-15.	3.5	35

#	ARTICLE	IF	CITATIONS
298	Detecting gene mutations in Japanese Alzheimer's patients by semiconductor sequencing. <i>Neurobiology of Aging</i> , 2014, 35, 1780.e1-1780.e5.	1.5	19
299	Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. <i>Alzheimer's and Dementia</i> , 2014, 10, S344-53.	0.4	79
300	Alzheimer's Association Update for January 2014. , 2014, 10, 132-133.		1
301	The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S12-25.	0.4	106
302	Amyloid burden and neural function in people at risk for Alzheimer's Disease. <i>Neurobiology of Aging</i> , 2014, 35, 576-584.	1.5	166
303	Evaluación ecológica en el deterioro cognitivo leve y enfermedad de Alzheimer mediante el Rivermead Behavioural Memory Test. <i>Neurología</i> , 2014, 29, 339-345.	0.3	15
304	A comparison of three brain atlases for MCI prediction. <i>Journal of Neuroscience Methods</i> , 2014, 221, 139-150.	1.3	47
305	Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: A long-range point of view beyond 2020. <i>Biochemical Pharmacology</i> , 2014, 88, 426-449.	2.0	105
306	A Bayesian network decision model for supporting the diagnosis of dementia, Alzheimer's disease and mild cognitive impairment. <i>Computers in Biology and Medicine</i> , 2014, 51, 140-158.	3.9	154
307	Progress Update: Fluid and Imaging Biomarkers in Alzheimer's Disease. <i>Biological Psychiatry</i> , 2014, 75, 520-526.	0.7	22
308	Diagnosing Alzheimer's disease: A systematic review of economic evaluations. <i>Alzheimer's and Dementia</i> , 2014, 10, 225-237.	0.4	33
309	Multivariate Data Analysis and Machine Learning in Alzheimer's Disease with a Focus on Structural Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 685-708.	1.2	165
310	Classification of Non-Demented Patients Attending a Memory Clinic using the New Diagnostic Criteria for Alzheimer's Disease with Disease-Related Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 835-847.	1.2	29
311	Initial Memory Deficit Profiles in Patients with a Cerebrospinal Fluid Alzheimer's Disease Signature. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 1109-1116.	1.2	11
312	Low levels of cerebrospinal fluid complement 3 and factor H predict faster cognitive decline in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 36.	3.0	26
313	Additional Use of A β ₄₂ /A β ₄₀ Ratio with Cerebrospinal Fluid Biomarkers P-Tau and A β ₄₂ Increases the Level of Evidence of Alzheimer's Disease Pathophysiological Process in Routine Practice. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 377-386.	1.2	52
314	Widespread Alterations in Functional Brain Network Architecture in Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 213-220.	1.2	35
315	How Can We Improve Transfer of Outcomes from Randomized Clinical Trials to Clinical Practice with Disease-Modifying Drugs in Alzheimer's Disease?. <i>Neurodegenerative Diseases</i> , 2014, 13, 197-199.	0.8	3

#	ARTICLE	IF	CITATIONS
316	A systematic review and meta-analysis of ¹⁸ F-labeled amyloid imaging in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 5-13.	1.2	59
317	A practical algorithm for managing Alzheimer's disease: what, when, and why?. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 307-323.	1.7	68
318	Clinical impact of ¹¹ C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment. <i>Psychiatry and Clinical Neurosciences</i> , 2015, 69, 741-751.	1.0	11
319	Unirhinal Olfactory Testing for the Diagnostic Workup of Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 253-270.	1.2	12
320	Aberrant intra- and inter-network connectivity architectures in Alzheimer's disease and mild cognitive impairment. <i>Scientific Reports</i> , 2015, 5, 14824.	1.6	99
321	Validation of the Erlangen Score Algorithm for the Prediction of the Development of Dementia due to Alzheimer's Disease in Pre-Dementia Subjects. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 433-441.	1.2	41
322	Projecting Burden of Dementia in Spain, 2010-2050: Impact of Modifying Risk Factors. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 721-730.	1.2	33
323	Informants' Perception of Subjective Cognitive Decline Helps to Discriminate Preclinical Alzheimer's Disease from Normal Aging. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S87-S98.	1.2	50
324	The Role of Visinin-Like Protein-1 in the Pathophysiology of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 17-32.	1.2	36
325	Human ApoE Isoforms Differentially Modulate Glucose and Amyloid Metabolic Pathways in Female Brain: Evidence of the Mechanism of Neuroprotection by ApoE2 and Implications for Alzheimer's Disease Prevention and Early Intervention. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 411-424.	1.2	76
326	Alzheimer's disease cerebrospinal fluid biomarkers are not influenced by gravity drip or aspiration extraction methodology. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 71.	3.0	14
327	Cognitive Severity-Specific Neuronal Degenerative Network in Charcoal Burning Suicide-Related Carbon Monoxide Intoxication. <i>Medicine (United States)</i> , 2015, 94, e783.	0.4	10
328	Brainstem morphological changes in Alzheimer's disease. <i>NeuroReport</i> , 2015, 26, 411-415.	0.6	55
329	A Meta-Analysis of fMRI Activation Differences during Episodic Memory in Alzheimer's Disease and Mild Cognitive Impairment. <i>Journal of Neuroimaging</i> , 2015, 25, 849-860.	1.0	41
330	Cattle encephalon glycoside and igitonin injection improves cognitive impairment in APP ^{swe} /PS1 ^{dE9} mice used as multitarget anti-Alzheimer's drug candidates. <i>Neuropsychiatric Disease and Treatment</i> , 2015, 11, 537.	1.0	12
331	Amyloid- β Protein Precursor Cleavage Products in Postmortem Ventricular Cerebrospinal Fluid of Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 365-372.	1.2	3
332	Amyloid accumulation is a late event in sporadic Alzheimer's disease-like pathology in nontransgenic rats. <i>Oncotarget</i> , 2015, 6, 1396-1413.	0.8	58
333	Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease. <i>International Journal of Nanomedicine</i> , 2015, 10, 4981.	3.3	211

#	ARTICLE	IF	CITATIONS
334	Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 271-276.	1.2	22
335	Post-mortem brain pathology is related to declining respiratory function in community-dwelling older adults. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 197.	1.7	14
336	Preanalytical Confounding Factors in the Analysis of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: The Issue of Diurnal Variation. <i>Frontiers in Neurology</i> , 2015, 6, 143.	1.1	23
337	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. <i>Frontiers in Neurology</i> , 2015, 6, 202.	1.1	24
338	Multimodality Imaging Approach in Alzheimer disease. Part I: Structural MRI, Functional MRI, Diffusion Tensor Imaging and Magnetization Transfer Imaging. <i>Dementia E Neuropsychologia</i> , 2015, 9, 318-329.	0.3	19
339	Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals. <i>Journal of Alzheimer's Disease</i> , 2015, 49, 493-502.	1.2	12
340	MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0126423.	1.1	184
341	Current Developments in Dementia Risk Prediction Modelling: An Updated Systematic Review. <i>PLoS ONE</i> , 2015, 10, e0136181.	1.1	129
342	Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0142756.	1.1	83
343	Diagnostic Value of Subjective Memory Complaints Assessed with a Single Item in Dominantly Inherited Alzheimer's Disease: Results of the DIAN Study. <i>BioMed Research International</i> , 2015, 2015, 1-7.	0.9	7
344	Improved Diagnostic Multimodal Biomarkers for Alzheimer's Disease and Mild Cognitive Impairment. <i>BioMed Research International</i> , 2015, 2015, 1-11.	0.9	16
345	Neuroplastic Effects of Combined Computerized Physical and Cognitive Training in Elderly Individuals at Risk for Dementia: An eLORETA Controlled Study on Resting States. <i>Neural Plasticity</i> , 2015, 2015, 1-12.	1.0	70
346	The Alzheimer's Patient in the Emergency Department - Specificities of Care. , 2015, , .		0
348	Smell identification function and Alzheimer's disease. <i>Current Opinion in Psychiatry</i> , 2015, 28, 173-179.	3.1	48
349	<i>APOE ε4</i> genotype predicts memory for everyday activities. <i>Aging, Neuropsychology, and Cognition</i> , 2015, 22, 639-666.	0.7	8
350	Caring for dementia: A population-based study examining variations in guideline-consistent medical care. , 2015, 11, 906-916.		12
351	Mini-Mental State Examination (MMSE) for the detection of Alzheimer's disease and other dementias in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 2015, , CD010783.	1.5	395
352	Tract-based analysis of white matter degeneration in Alzheimer's disease. <i>Neuroscience</i> , 2015, 301, 79-89.	1.1	70

#	ARTICLE	IF	CITATIONS
353	Cognitive and Physical Demands of Activities of Daily Living in Older Adults: Validation of Expert Panel Ratings. <i>PM and R</i> , 2015, 7, 727-735.	0.9	17
354	Laminar specific detection of APP induced neurodegeneration and recovery using MEMRI in an olfactory based Alzheimer's disease mouse model. <i>NeuroImage</i> , 2015, 118, 183-192.	2.1	23
355	Apolipoprotein E ϵ 4 as a genetic determinant of Alzheimer's disease heterogeneity. <i>Degenerative Neurological and Neuromuscular Disease</i> , 2015, 5, 9.	0.7	4
356	Annual Cognitive Assessment for Older Adults: Update for Nurses. <i>Journal of Community Health Nursing</i> , 2015, 32, 187-198.	0.1	8
357	Souvenaid for Alzheimer's disease. <i>The Cochrane Library</i> , 2015, , .	1.5	2
358	Medical application: Diagnosis of Alzheimer disease from MRI and documents. , 2015, , .		0
359	Molecular regulation of dendritic spine dynamics and their potential impact on synaptic plasticity and neurological diseases. <i>Neuroscience and Biobehavioral Reviews</i> , 2015, 59, 208-237.	2.9	100
360	Estimating in-home walking speed distributions for unobtrusive detection of mild cognitive impairment in older adults. , 2015, 2015, 5175-8.		8
361	Correlations Between Mini-Mental State Examination Score, Cerebrospinal Fluid Biomarkers, and Pathology Observed in Brain Biopsies of Patients With Normal-Pressure Hydrocephalus. <i>Journal of Neuropathology and Experimental Neurology</i> , 2015, 74, 470-479.	0.9	48
362	Quantitative EEG Applying the Statistical Recognition Pattern Method: A Useful Tool in Dementia Diagnostic Workup. <i>Dementia and Geriatric Cognitive Disorders</i> , 2015, 40, 1-12.	0.7	58
363	Cerebrospinal fluid proteomics and protein biomarkers in frontotemporal lobar degeneration: Current status and future perspectives. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 757-768.	1.1	21
364	Posterior compensatory network in cognitively intact elders with hippocampal atrophy. <i>Hippocampus</i> , 2015, 25, 581-593.	0.9	7
365	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. <i>NeuroImage</i> , 2015, 111, 562-579.	2.1	266
366	The Family Series Workshop. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2015, 30, 573-583.	0.9	18
367	Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 4365-4382.	2.9	88
368	Supportive CSF biomarker evidence to enhance the National Institute on Aging-Alzheimer's Association criteria for diagnosis of Alzheimer's type dementia – A study from Southern India. <i>Asian Journal of Psychiatry</i> , 2015, 13, 44-47.	0.9	4
369	Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia. <i>NeuroImage: Clinical</i> , 2015, 7, 187-194.	1.4	94
370	Do NIA's criteria distinguish Alzheimer's disease from frontotemporal dementia?. <i>Alzheimer's and Dementia</i> , 2015, 11, 207-215.	0.4	23

#	ARTICLE	IF	CITATIONS
371	Biomarkers of Alzheimer's disease and mild cognitive impairment: A current perspective. <i>Advances in Medical Sciences</i> , 2015, 60, 76-82.	0.9	56
372	Biomarkers. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2015, 127, 245-265.	1.0	25
373	Clinical utility and applicability of biomarker-based diagnostic criteria for Alzheimer's disease: a BeDeCo survey. <i>Acta Neurologica Belgica</i> , 2015, 115, 547-555.	0.5	7
374	Principles and management of neuropsychiatric symptoms in Alzheimer's dementia. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 12.	3.0	96
375	Enfermedad de Alzheimer. <i>Medicine</i> , 2015, 11, 4306-4315.	0.0	4
376	Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. <i>Acta Neuropathologica</i> , 2015, 129, 729-748.	3.9	168
377	Mild cognitive impairment definitions: more evolution than revolution. <i>Neurodegenerative Disease Management</i> , 2015, 5, 11-17.	1.2	8
378	Clinicopathologic and ¹¹ C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. <i>Brain</i> , 2015, 138, 1370-1381.	3.7	270
379	Dementia: timely diagnosis and early intervention. <i>BMJ, The</i> , 2015, 350, h3029-h3029.	3.0	315
380	Prodromal posterior cortical atrophy: clinical, neuropsychological, and radiological correlation. <i>Neurocase</i> , 2015, 21, 44-55.	0.2	13
381	Amyloid- β as a biomarker for Alzheimer's disease: quantification methods in body fluids. <i>Expert Review of Proteomics</i> , 2015, 12, 343-354.	1.3	27
382	Where is hippocampal activity in the cascade of Alzheimer's disease biomarkers?. <i>Brain</i> , 2015, 138, 831-833.	3.7	8
383	Should we screen for cognitive decline and dementia?. <i>Maturitas</i> , 2015, 82, 28-35.	1.0	24
384	[¹⁸ F]Florbetaben: A Review in β -Amyloid PET Imaging in Cognitive Impairment. <i>CNS Drugs</i> , 2015, 29, 605-613.	2.7	24
385	Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. <i>Molecular Aspects of Medicine</i> , 2015, 43-44, 16-24.	2.7	14
386	Magnetic resonance imaging in Alzheimer's Disease Neuroimaging Initiative 2. <i>Alzheimer's and Dementia</i> , 2015, 11, 740-756.	0.4	142
387	The impact of the Alzheimer's Disease Neuroimaging Initiative 2: What role do public-private partnerships have in pushing the boundaries of clinical and basic science research on Alzheimer's disease?. <i>Alzheimer's and Dementia</i> , 2015, 11, 860-864.	0.4	16
388	d-serine levels in Alzheimer's disease: implications for novel biomarker development. <i>Translational Psychiatry</i> , 2015, 5, e561-e561.	2.4	172

#	ARTICLE	IF	CITATIONS
389	Advances in the prevention of Alzheimer's Disease. F1000prime Reports, 2015, 7, 50.	5.9	72
390	One glasses too many: A case report of Benson's syndrome. Indian Journal of Ophthalmology, 2015, 63, 277.	0.5	0
391	Bilingualism delays clinical manifestation of Alzheimer's disease. Bilingualism, 2015, 18, 568-574.	1.0	128
392	Reversing Ribot: Does regression hold in language of prodromal Alzheimer's disease?. Brain and Language, 2015, 143, 1-10.	0.8	8
394	IT Infrastructure to Support the Secondary Use of Routinely Acquired Clinical Imaging Data for Research. Neuroinformatics, 2015, 13, 65-81.	1.5	7
395	Insights into cognitive aging and Alzheimer's disease using amyloid PET and structural MRI scans. Clinical and Translational Imaging, 2015, 3, 65-74.	1.1	7
396	Fitting the epidemiology and neuropathology of the early stages of Alzheimer's disease to prevent dementia. Alzheimer's Research and Therapy, 2015, 7, 2.	3.0	19
397	Early neurone loss in Alzheimer's disease: cortical or subcortical?. Acta Neuropathologica Communications, 2015, 3, 10.	2.4	150
398	Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly. Brain, 2015, 138, 761-771.	3.7	222
399	The Diagnostic Utility of ^{99m}Tc -HMPAO SPECT Imaging: A Retrospective Case Series from a Tertiary Referral Early-Onset Cognitive Disorders Clinic. Dementia and Geriatric Cognitive Disorders, 2015, 39, 186-193.	0.7	9
400	2015 Alzheimer's disease facts and figures. Alzheimer's and Dementia, 2015, 11, 332-384.	0.4	1,501
401	Alzheimer's Disease: Behavioral and Social Aspects. , 2015, , 584-590.		1
402	Perfusion Single Photon Emission Computed Tomography in a Mouse Model of Neurofibromatosis Type 1: Towards a Biomarker of Neurologic Deficits. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 1304-1312.	2.4	7
403	A Blood-Based, 7-Metabolite Signature for the Early Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 1157-1173.	1.2	91
404	Mild cognitive impairment: an update in Parkinson's disease and lessons learned from Alzheimer's disease. Neurodegenerative Disease Management, 2015, 5, 425-443.	1.2	28
406	Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings. Brain, 2015, 138, 3747-3759.	3.7	170
407	Development of a straightforward and sensitive scale for MCI and early AD clinical trials. , 2015, 11, 404-414.		17
408	Predicting the conversion of mild cognitive impairment to Alzheimer's disease based on the volumetric measurements of the selected brain structures in magnetic resonance imaging. Neurologia I Neurochirurgia Polska, 2015, 49, 349-353.	0.6	14

#	ARTICLE	IF	CITATIONS
409	Cerebrospinal fluid biomarkers in Alzheimer's disease: Diagnostic accuracy and prediction of dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 455-463.	1.2	77
410	How many biomarkers to discriminate neurodegenerative dementia?. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2015, 52, 314-326.	2.7	16
411	Regional mosaic genomic heterogeneity in the elderly and in Alzheimer's disease as a correlate of neuronal vulnerability. <i>Acta Neuropathologica</i> , 2015, 130, 501-510.	3.9	35
412	Clinical use of amyloid- β positron emission tomography neuroimaging: Practical and bioethical considerations. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2015, 1, 358-367.	1.2	33
413	FDG-PET Contributions to the Pathophysiology of Memory Impairment. <i>Neuropsychology Review</i> , 2015, 25, 326-355.	2.5	23
414	Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2015, 256, 168-183.	1.3	55
415	Cerebrospinal fluid biomarkers in dementias. <i>Nature Reviews Neurology</i> , 2015, 11, 549-550.	4.9	5
416	Alzheimer dementia with sparse amyloid- β AD mimic or variant?. <i>Nature Reviews Neurology</i> , 2015, 11, 674-675.	4.9	2
417	Charting a path toward combination therapy for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 107-113.	1.4	38
418	Innovative diagnostic tools for early detection of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015, 11, 561-578.	0.4	213
419	Toward an integrated pipeline for protein biomarker development. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 677-686.	1.1	56
420	Bioactive Nutrients for Brain Health. , 2015, , 49-56.		0
421	Olfactory dysfunction in Alzheimer's disease. <i>Neuropsychiatric Disease and Treatment</i> , 2016, 12, 869.	1.0	127
422	Imaging Alzheimer's disease pathophysiology with PET. <i>Dementia E Neuropsychologia</i> , 2016, 10, 79-90.	0.3	33
423	Quality of Life in the Patients with Alzheimer's Disease and their Caregivers: Caregivers' Point of View. <i>Korean Journal of Adult Nursing</i> , 2016, 28, 367.	0.2	0
424	Perspectives on the Tertiary Prevention Strategy for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2016, 13, 307-316.	0.7	15
425	Folic Acid Supplementation Mitigates Alzheimer's Disease by Reducing Inflammation: A Randomized Controlled Trial. <i>Mediators of Inflammation</i> , 2016, 2016, 1-10.	1.4	119
426	Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 256.	1.7	597

#	ARTICLE	IF	CITATIONS
427	Association of Cerebral Amyloidosis, Blood Pressure, and Neuronal Injury with Late-Life Onset Depression. <i>Frontiers in Aging Neuroscience</i> , 2016, 8, 236.	1.7	5
428	Structural MR Imaging in the Diagnosis of Alzheimer's Disease and Other Neurodegenerative Dementia: Current Imaging Approach and Future Perspectives. <i>Korean Journal of Radiology</i> , 2016, 17, 827.	1.5	61
429	What can imaging tell us about cognitive impairment and dementia?. <i>World Journal of Radiology</i> , 2016, 8, 240.	0.5	33
430	Development of a Novel Urine Alzheimer-Associated Neuronal Thread Protein ELISA Kit and Its Potential Use in the Diagnosis of Alzheimer's Disease. <i>Journal of Clinical Laboratory Analysis</i> , 2016, 30, 308-314.	0.9	21
431	Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting. <i>Clinical Nuclear Medicine</i> , 2016, 41, e18-e23.	0.7	22
432	A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. <i>Neurology</i> , 2016, 87, 539-547.	1.5	1,216
433	Solid-Phase Synthesis and Characterization of N-Terminally Elongated A β Peptides. <i>Chemistry - A European Journal</i> , 2016, 22, 8685-8693.	1.7	8
434	Effects of change in FreeSurfer version on classification accuracy of patients with Alzheimer's disease and mild cognitive impairment. <i>Human Brain Mapping</i> , 2016, 37, 1831-1841.	1.9	30
435	Associations between APOE polymorphisms and seven diseases with cognitive impairment including Alzheimer's disease, frontotemporal dementia, and dementia with Lewy bodies in southeast China. <i>Psychiatric Genetics</i> , 2016, 26, 124-131.	0.6	21
436	Pre-existing cognitive impairment and post-operative cognitive dysfunction: should we be talking the same language?. <i>International Psychogeriatrics</i> , 2016, 28, 1053-1055.	0.6	16
437	Mitochondrial Regulatory Pathways in the Pathogenesis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1257-1270.	1.2	22
438	A Phase II Study of Fornix Deep Brain Stimulation in Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 777-787.	1.2	263
439	Longitudinal Study of Impaired Intra- and Inter-Network Brain Connectivity in Subjects at High Risk for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 913-927.	1.2	54
440	Application of the IWG-2 Diagnostic Criteria for Alzheimer's Disease to the ADNI. <i>Journal of Alzheimer's Disease</i> , 2016, 51, 227-236.	1.2	14
441	Validation of a Commercial Chemiluminescence Immunoassay for the Simultaneous Measurement of Three Different Amyloid- β Peptides in Human Cerebrospinal Fluid and Application to a Clinical Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 691-705.	1.2	14
442	Usefulness of 3-dimensional stereotactic surface projection FDG PET images for the diagnosis of dementia. <i>Medicine (United States)</i> , 2016, 95, e5622.	0.4	13
443	Evaluation and management of dementia. , 2016, , 125-147.		0
444	Quantitative T2 mapping of white matter: applications for ageing and cognitive decline. <i>Physics in Medicine and Biology</i> , 2016, 61, 5587-5605.	1.6	29

#	ARTICLE	IF	CITATIONS
446	The ONDRISeq panel: custom-designed next-generation sequencing of genes related to neurodegeneration. <i>Npj Genomic Medicine</i> , 2016, 1, 16032.	1.7	26
447	Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype. <i>Neurobiology of Aging</i> , 2016, 40, 155-163.	1.5	35
448	Analysis of mean square error surface and its corresponding contour plots of spontaneous speech signals in Alzheimer's disease with adaptive wiener filter. <i>Computers in Human Behavior</i> , 2016, 61, 364-371.	5.1	12
449	Acceleration of hippocampal atrophy rates in asymptomatic amyloidosis. <i>Neurobiology of Aging</i> , 2016, 39, 99-107.	1.5	34
450	Function and clinical meaningfulness of treatments for mild Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 2, 105-112.	1.2	13
451	Neuroimaging in dementia and Alzheimer's disease: Current protocols and practice in the Republic of Ireland. <i>Radiography</i> , 2016, 22, 177-184.	1.1	2
452	Robust imaging of hippocampal inner structure at 7T: in vivo acquisition protocol and methodological choices. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2016, 29, 475-489.	1.1	7
453	An evidence-based algorithm for the utility of FDG-PET for diagnosing Alzheimer's disease according to presence of medial temporal lobe atrophy. <i>British Journal of Psychiatry</i> , 2016, 208, 491-496.	1.7	12
454	2016 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2016, 12, 459-509.	0.4	2,219
455	Lowered Levels of Carbonyl Proteins after Vitamin B Supplementation in Patients with Mild Cognitive Impairment and Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2016, 16, 284-289.	0.8	22
456	Plasma soluble neuregulin-1 as a diagnostic biomarker for Alzheimer's disease. <i>Neurochemistry International</i> , 2016, 97, 1-7.	1.9	28
457	Cortical sources of resting state EEG rhythms are related to brain hypometabolism in subjects with Alzheimer's disease: an EEG-PET study. <i>Neurobiology of Aging</i> , 2016, 48, 122-134.	1.5	53
458	Healthy cognitive aging and dementia prevention... <i>American Psychologist</i> , 2016, 71, 268-275.	3.8	49
459	Emerging drugs to reduce abnormal β -amyloid protein in Alzheimer's disease patients. <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 377-391.	1.0	54
460	Effects of dihydrotestosterone on synaptic plasticity of the hippocampus in mild cognitive impairment male SAMP8 mice. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 1455-1463.	0.8	42
461	Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in Synucleinopathies. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 3126-3138.	2.5	92
462	Dementias. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 138, 123-151.	1.0	35
463	Incident parkinsonism in older adults without Parkinson disease. <i>Neurology</i> , 2016, 87, 1036-1044.	1.5	61

#	ARTICLE	IF	CITATIONS
464	Alzheimer Disease and Its Growing Epidemic. <i>Neurologic Clinics</i> , 2016, 34, 941-953.	0.8	114
465	Spontaneous Reversion of Mild Cognitive Impairment to Normal Cognition: A Systematic Review of Literature and Meta-Analysis. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 943-948.	1.2	128
466	Protein biomarkers in Parkinson's disease: Focus on cerebrospinal fluid markers and synaptic proteins. <i>Movement Disorders</i> , 2016, 31, 848-860.	2.2	52
467	Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update. <i>Journal of Neurochemistry</i> , 2016, 138, 184-192.	2.1	26
468	The effect of β -amyloid positivity on cerebral metabolism in cognitively normal seniors. <i>Alzheimer's and Dementia</i> , 2016, 12, 1250-1258.	0.4	8
469	A Smart Near-Infrared Fluorescence Probe for Selective Detection of Tau Fibrils in Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1474-1481.	1.7	40
470	Introduction to Alzheimer's Disease Biomarkers. , 2016, , 3-23.		6
471	Clinical Diagnosis of Alzheimer's Disease. , 2016, , 27-48.		14
472	Alzheimer's disease patient groups derived from a multivariate analysis of cognitive test outcomes in the Coalition Against Major Diseases dataset. <i>Future Science OA</i> , 2016, 2, FSO140.	0.9	3
473	DL0410, a novel dual cholinesterase inhibitor, protects mouse brains against $A\beta$ -induced neuronal damage via the Akt/JNK signaling pathway. <i>Acta Pharmacologica Sinica</i> , 2016, 37, 1401-1412.	2.8	29
474	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	1.2	18
475	Alzheimer's disease diagnostics by adaptation of 3D convolutional network. , 2016, , .		160
476	Ocular indicators of Alzheimer's: exploring disease in the retina. <i>Acta Neuropathologica</i> , 2016, 132, 767-787.	3.9	205
477	A novel method for early diagnosis of Alzheimer's disease based on higher-order spectral estimation of spontaneous speech signals. <i>Cognitive Neurodynamics</i> , 2016, 10, 495-503.	2.3	17
478	Imaging of neurodegenerative cognitive and behavioral disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 136, 971-984.	1.0	14
479	Drug treatments in Alzheimer's disease. <i>Clinical Medicine</i> , 2016, 16, 247-253.	0.8	344
480	Automatic determination of white matter hyperintensity properties in relation to the development of Alzheimer's disease. <i>Proceedings of SPIE</i> , 2016, , .	0.8	0
481	Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 1259-1272.	0.4	86

#	ARTICLE	IF	CITATIONS
482	Label-free quantitative comparison of cerebrospinal fluid glycoproteins and endogenous peptides in subjects with Alzheimer's disease, mild cognitive impairment, and healthy individuals. <i>Proteomics - Clinical Applications</i> , 2016, 10, 1225-1241.	0.8	30
483	Impaired episodic memory network in subjects at high risk for Alzheimer's disease. , 2016, 2016, 4017-4020.		3
484	Validation of the Chinese Version of Montreal Cognitive Assessment Basic for Screening Mild Cognitive Impairment. <i>Journal of the American Geriatrics Society</i> , 2016, 64, e285-e290.	1.3	211
485	Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer's disease cohorts. <i>Scientific Reports</i> , 2016, 6, 26027.	1.6	48
486	Clustering home activity distributions for automatic detection of mild cognitive impairment in older adults1. <i>Journal of Ambient Intelligence and Smart Environments</i> , 2016, 8, 437-451.	0.8	36
487	Promising Role of Neuromodulation in Predicting the Progression of Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1375-1388.	1.2	31
488	Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnesic and nonamnesic mild cognitive impairment patients. <i>Nuclear Medicine Communications</i> , 2016, 37, 1189-1196.	0.5	7
489	Neurologic Diseases in Special Care Patients. <i>Dental Clinics of North America</i> , 2016, 60, 707-735.	0.8	6
490	Cerebrospinal fluid soluble TREM2 in aging and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 17.	3.0	105
491	Genetic variants in Alzheimer disease – molecular and brain network approaches. <i>Nature Reviews Neurology</i> , 2016, 12, 413-427.	4.9	97
492	Cerebrovascular pathology and Alzheimer's disease. <i>Lancet Neurology</i> , The, 2016, 15, 895-896.	4.9	4
493	ACR's ASNR Practice Parameter for Brain PET/CT Imaging Dementia. <i>Clinical Nuclear Medicine</i> , 2016, 41, 118-125.	0.7	10
494	Serum-based protein profiles of Alzheimer's disease and mild cognitive impairment in elderly Hispanics. <i>Neurodegenerative Disease Management</i> , 2016, 6, 203-213.	1.2	23
495	Quantitative multimodal multiparametric imaging in Alzheimer's disease. <i>Brain Informatics</i> , 2016, 3, 29-37.	1.8	13
496	Quality Improvement in Skilled Nursing Facilities for Residents With Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 156-162.	0.9	1
497	Early detection of Alzheimer's disease using MRI hippocampal texture. <i>Human Brain Mapping</i> , 2016, 37, 1148-1161.	1.9	165
498	Suspected non-Alzheimer disease pathophysiology – concept and controversy. <i>Nature Reviews Neurology</i> , 2016, 12, 117-124.	4.9	230
499	Advances in PET Imaging of Degenerative, Cerebrovascular, and Traumatic Causes of Dementia. <i>Seminars in Nuclear Medicine</i> , 2016, 46, 57-87.	2.5	16

#	ARTICLE	IF	CITATIONS
500	Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 409-425.	2.5	79
501	A methodological critique of the National Institute of Aging and Alzheimer's Association Guidelines for Alzheimer's disease, dementia, and mild cognitive impairments. <i>Dementia</i> , 2016, 15, 239-254.	1.0	11
502	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. <i>Alzheimer's and Dementia</i> , 2016, 12, 292-323.	0.4	1,318
503	Brain fluorodeoxyglucose (FDG) PET in dementia. <i>Ageing Research Reviews</i> , 2016, 30, 73-84.	5.0	175
504	Retinal Nerve Fiber Layer Thinning in Alzheimer's Disease. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 430-436.	0.9	79
505	Amyloid- β -Secondary Structure Distribution in Cerebrospinal Fluid and Blood Measured by an Immuno-Infrared-Sensor: A Biomarker Candidate for Alzheimer's Disease. <i>Analytical Chemistry</i> , 2016, 88, 2755-2762.	3.2	97
506	Hippocampal neurogenesis: Learning to remember. <i>Progress in Neurobiology</i> , 2016, 138-140, 1-18.	2.8	184
507	CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. <i>Neurobiology of Aging</i> , 2016, 38, 47-55.	1.5	54
508	The Contribution of Prospective Memory Performance to the Neuropsychological Assessment of Mild Cognitive Impairment. <i>Clinical Neuropsychologist</i> , 2016, 30, 131-149.	1.5	16
509	Diagnostic Profiles of Patients Differentially Failing Executive Functioning Measures. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2016, 31, 214-222.	0.9	0
510	Cross-validation of biomarkers for the early differential diagnosis and prognosis of dementia in a clinical setting. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 499-508.	3.3	66
511	Examination of Variables That May Affect the Relationship Between Cognition and Functional Status in Individuals with Mild Cognitive Impairment: A Meta-Analysis. <i>Archives of Clinical Neuropsychology</i> , 2016, 31, acv089.	0.3	67
512	Age-Related Sex-Specific Changes in Brain Metabolism and Morphology. <i>Journal of Nuclear Medicine</i> , 2016, 57, 221-225.	2.8	60
513	Plasma Proteomics Biomarkers in Alzheimer's Disease: Latest Advances and Challenges. <i>Methods in Molecular Biology</i> , 2016, 1303, 521-529.	0.4	11
514	The role of cerebrovascular disease when there is concomitant Alzheimer disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 952-956.	1.8	41
515	Parkinsonism in Older Adults and Its Association With Adverse Health Outcomes and Neuropathology. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 549-556.	1.7	51
516	Approach to the Patient with Memory Loss, Mild Cognitive Impairment, or Dementia. , 2016, , 39-45.		0
517	Relationship and stage of dementia differences in caregiver perspectives on the meaning of activity. <i>Dementia</i> , 2017, 16, 178-191.	1.0	6

#	ARTICLE	IF	CITATIONS
518	Unobtrusive Detection of Mild Cognitive Impairment in Older Adults Through Home Monitoring. IEEE Journal of Biomedical and Health Informatics, 2017, 21, 339-348.	3.9	36
519	Medicare and Amyloid PET Imaging: The Battle Over Evidence. Journal of Aging and Social Policy, 2017, 29, 105-122.	0.9	2
520	HLA-A2 Alleles Mediate Alzheimer's Disease by Altering Hippocampal Volume. Molecular Neurobiology, 2017, 54, 2469-2476.	1.9	11
521	Genetic Association of HLA Gene Variants with MRI Brain Structure in Alzheimer's Disease. Molecular Neurobiology, 2017, 54, 3195-3204.	1.9	24
522	Development of Phenothiazine-Based Theranostic Compounds That Act Both as Inhibitors of β -Amyloid Aggregation and as Imaging Probes for Amyloid Plaques in Alzheimer's Disease. ACS Chemical Neuroscience, 2017, 8, 798-806.	1.7	57
523	Rey's Auditory Verbal Learning Test scores can be predicted from whole brain MRI in Alzheimer's disease. NeuroImage: Clinical, 2017, 13, 415-427.	1.4	114
524	Repetitive head impact exposure and later-life plasma total tau in former National Football League players. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 33-40.	1.2	79
525	The <i>APOE</i> ϵ 4 genotype modulates CSF YKL40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 6, 50-59.	1.2	36
526	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
527	Acidity and Acid-Sensing Ion Channels in the Normal and Alzheimer's Disease Brain. Journal of Alzheimer's Disease, 2017, 57, 1137-1144.	1.2	28
528	Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2017, 7, 69-87.	1.2	283
529	Advances at the intersection of normal brain aging and Alzheimer's disease. Behavioural Brain Research, 2017, 322, 187-190.	1.2	1
530	Challenges in Screening and Recruitment for a Neuroimaging Study in Cognitively Impaired Geriatric Inpatients. Journal of Alzheimer's Disease, 2017, 56, 197-204.	1.2	7
531	Is sporadic Alzheimer's disease a developmental disorder?. Journal of Neurochemistry, 2017, 143, 396-408.	2.1	61
532	Overview of Neurocognitive Disorders. Focus (American Psychiatric Publishing), 2017, 15, 4-12.	0.4	20
533	The Role of Neuroimaging in the Assessment of the Cognitively Impaired Elderly. Neurologic Clinics, 2017, 35, 231-262.	0.8	5
534	Biomarkers for Early Diagnosis of Alzheimer's Disease in the Oldest Old: Yes or No?. Journal of Alzheimer's Disease, 2017, 58, 323-335.	1.2	11
535	Cross-Cultural Applicability of the Montreal Cognitive Assessment (MoCA): A Systematic Review. Journal of Alzheimer's Disease, 2017, 58, 789-801.	1.2	127

#	ARTICLE	IF	CITATIONS
536	Impact of multiple pathologies on the threshold for clinically overt dementia. <i>Acta Neuropathologica</i> , 2017, 134, 171-186.	3.9	429
537	Age-specific and sex-specific prevalence of cerebral β -amyloidosis, tauopathy, and neurodegeneration in cognitively unimpaired individuals aged 50-95 years: a cross-sectional study. <i>Lancet Neurology</i> , The, 2017, 16, 435-444.	4.9	241
538	Patients' and caregivers' views on conversations and shared decision making in diagnostic testing for Alzheimer's disease: The ABIDE project. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 314-322.	1.8	47
539	Reduced Cardiovascular Functions in Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 919-925.	1.2	17
540	Quantitative 3D Telomeric Imaging of Buccal Cells Reveals Alzheimer's Disease-Specific Signatures. <i>Journal of Alzheimer's Disease</i> , 2017, 58, 139-145.	1.2	10
541	Inhibitors of Tau-Phosphorylating Kinases. <i>Topics in Medicinal Chemistry</i> , 2017, , 119-158.	0.4	1
542	PET Imaging for Early Detection of Alzheimer's Disease. <i>PET Clinics</i> , 2017, 12, 329-350.	1.5	44
543	Reimagining Alzheimer's disease - the diminishing importance of amyloid and a glimpse of what lies ahead. <i>Journal of Neurochemistry</i> , 2017, 143, 432-444.	2.1	83
544	Linking Amyloid- β and Tau Deposition in Alzheimer Disease. <i>JAMA Neurology</i> , 2017, 74, 766.	4.5	10
545	Longitudinal evaluation of criteria for subjective cognitive decline and preclinical Alzheimer's disease in a memory clinic sample. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 96-107.	1.2	29
546	Treatment of Alzheimer's disease. , 0, , 415-424.		3
547	Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 8, 1-10.	1.2	28
548	Early classification of Alzheimer's disease using hippocampal texture from structural MRI. <i>Proceedings of SPIE</i> , 2017, , .	0.8	2
549	Typing competencies in Alzheimer's disease: An exploration of copy tasks. <i>Computers in Human Behavior</i> , 2017, 73, 311-319.	5.1	27
550	Randomized controlled trials in mild cognitive impairment. <i>Neurology</i> , 2017, 88, 1751-1758.	1.5	35
551	Color perception differentiates Alzheimer's Disease (AD) from Vascular Dementia (VaD) patients. <i>International Psychogeriatrics</i> , 2017, 29, 1355-1361.	0.6	11
552	2017 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2017, 13, 325-373.	0.4	969
553	Alzheimer's disease: The next frontier - Special Report 2017. <i>Alzheimer's and Dementia</i> , 2017, 13, 374-380.	0.4	88

#	ARTICLE	IF	CITATIONS
554	Currents of memory: recent progress, translational challenges, and ethical considerations in fornix deep brain stimulation trials for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2017, 56, 202-210.	1.5	29
555	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 167-182.e1.	1.5	60
556	Metabolomicâ€guided discovery of Alzheimer's disease biomarkers from body fluid. <i>Journal of Neuroscience Research</i> , 2017, 95, 2005-2024.	1.3	39
557	Biomarkers for the diagnosis of Alzheimer's disease in clinical practice: an Italian intersocietal roadmap. <i>Neurobiology of Aging</i> , 2017, 52, 119-131.	1.5	23
558	Clinical validity of delayed recall tests as a gateway biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 153-166.	1.5	49
559	Raman Spectrometric Detection Methods for Early and Non-Invasive Diagnosis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1145-1156.	1.2	13
560	Alzheimer's disease biomarker development: a call to funding bodies. <i>Neurobiology of Aging</i> , 2017, 52, 117-118.	1.5	3
561	Clinical validity of brain fluorodeoxyglucose positron emission tomography as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 183-195.	1.5	85
562	Clinical validity of presynaptic dopaminergic imaging with ¹²³ I-ioflupane and noradrenergic imaging with ¹²³ I-MIBG in the differential diagnosis between Alzheimer's disease and dementia with Lewy bodies in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 228-242.	1.5	34
563	Metabolic network failures in Alzheimer's disease: A biochemical roadmap. <i>Alzheimer's and Dementia</i> , 2017, 13, 965-984.	0.4	362
564	Alzheimer's disease: experimental models and reality. <i>Acta Neuropathologica</i> , 2017, 133, 155-175.	3.9	513
565	Differential diagnosis of mild cognitive impairment and Alzheimer's disease using structural MRI cortical thickness, hippocampal shape, hippocampal texture, and volumetry. <i>NeuroImage: Clinical</i> , 2017, 13, 470-482.	1.4	134
566	Imaging Biomarkers in Alzheimer's Disease: A Practical Guide for Clinicians. <i>Journal of Alzheimer's Disease Reports</i> , 2017, 1, 71-88.	1.2	18
567	Research Gaps and Controversies in Chronic Traumatic Encephalopathy. <i>JAMA Neurology</i> , 2017, 74, 1255.	4.5	114
568	Cost-Utility of Using Alzheimer's Disease Biomarkers in Cerebrospinal Fluid to Predict Progression from Mild Cognitive Impairment to Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1477-1487.	1.2	31
569	Entorhinal and transentorhinal atrophy in mild cognitive impairment using longitudinal diffeomorphometry. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 41-50.	1.2	24
570	A Cytomic Approach Towards Genomic Individuality of Neurons. <i>Neuromethods</i> , 2017, , 81-106.	0.2	1
572	Diagnostic Accuracy of Memory Measures in Alzheimer's Dementia and Mild Cognitive Impairment: a Systematic Review and Meta-Analysis. <i>Neuropsychology Review</i> , 2017, 27, 354-388.	2.5	101

#	ARTICLE	IF	CITATIONS
573	A whole-brain computational modeling approach to explain the alterations in resting-state functional connectivity during progression of Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2017, 16, 343-354.	1.4	73
574	Near-infrared spectroscopy (NIRS) and vagus somatosensory evoked potentials (VSEP) in the early diagnosis of Alzheimer's disease: rationale, design, methods, and first baseline data of the Vogel study. <i>Journal of Neural Transmission</i> , 2017, 124, 1473-1488.	1.4	15
575	Dementia prevention, intervention, and care. <i>Lancet, The</i> , 2017, 390, 2673-2734.	6.3	4,228
576	Advancing Alzheimer's research: A review of big data promises. <i>International Journal of Medical Informatics</i> , 2017, 106, 48-56.	1.6	56
577	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 76-83.	1.2	39
578	Alzheimer's Disease—Current Status and Future Directions. <i>Journal of Medicinal Food</i> , 2017, 20, 1141-1151.	0.8	21
579	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , 2017, 16, 661-676.	4.9	464
580	Weighted Manhattan Distance Classifier; SELDI data for Alzheimer's disease diagnosis. , 2017, , .		3
581	Self-reported traumatic brain injury and in vivo measure of AD-vulnerable cortical thickness and AD-related biomarkers in the ADNI cohort. <i>Neuroscience Letters</i> , 2017, 655, 115-120.	1.0	13
582	Radiosynthesis of [18F]AV1451 in pharmaceutical conditions and its biological characteristics. <i>Applied Radiation and Isotopes</i> , 2017, 128, 101-107.	0.7	5
583	Blood Biomarkers for Alzheimer's Disease: Much Promise, Cautious Progress. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 13-22.	1.6	29
584	Imaging Approaches to Cerebral Cortex Pathology. , 2017, , 57-80.		0
585	Inhomogeneous distribution of Alzheimer pathology along the isocortical relief. Are cortical convolutions an Achilles heel of evolution?. <i>Brain Pathology</i> , 2017, 27, 603-611.	2.1	21
586	Defining imaging biomarker cut points for brain aging and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 205-216.	0.4	581
587	Nutrition for the ageing brain: Towards evidence for an optimal diet. <i>Ageing Research Reviews</i> , 2017, 35, 222-240.	5.0	161
588	Pupillary responses and memory-guided visual search reveal age-related and Alzheimer's-related memory decline. <i>Behavioural Brain Research</i> , 2017, 322, 351-361.	1.2	22
589	Examining the impact of grape consumption on brain metabolism and cognitive function in patients with mild decline in cognition: A double-blinded placebo controlled pilot study. <i>Experimental Gerontology</i> , 2017, 87, 121-128.	1.2	80
590	Alzheimer's disease classification based on combination of multi-model convolutional networks. , 2017, , .		33

#	ARTICLE	IF	CITATIONS
591	High Caregiver Burden in Young Onset Dementia: What Factors Need Attention?. Journal of Alzheimer's Disease, 2017, 61, 537-543.	1.2	22
592	APOE ϵ 4 Genotype and Cognitive Reserve Effects on the Cognitive Functioning of Healthy Elders. Dementia and Geriatric Cognitive Disorders, 2017, 44, 328-342.	0.7	18
594	The Cerebrospinal Fluid A β 42/A β 40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting. Journal of Alzheimer's Disease, 2017, 60, 561-576.	1.2	82
595	Executive and Language Subjective Cognitive Decline Complaints Discriminate Preclinical Alzheimer's Disease from Normal Aging. Journal of Alzheimer's Disease, 2017, 61, 689-703.	1.2	33
598	Current Clinical Issues and Future Perspectives of Dementia in the Aging Society. Health Evaluation and Promotion, 2017, 44, 360-369.	0.0	0
599	A coupled feature representation based MRI biomarker for Alzheimer's disease prediction. , 2017, , .		0
600	Cognitive and Functional Considerations in Alzheimer's Disease Diagnosis. , 2017, , 17-26.		0
601	Diagnosis of Alzheimer's Standard-of-Care. , 2017, , 52-77.		2
602	Of Energy and Entropy: The Ineluctable Impact of Aging in Old Age Dementia. International Journal of Molecular Sciences, 2017, 18, 2672.	1.8	28
603	Blood Beta-Amyloid and Tau in Down Syndrome: A Comparison with Alzheimer's Disease. Frontiers in Aging Neuroscience, 2016, 8, 316.	1.7	44
604	Tuning Up the Old Brain with New Tricks: Attention Training via Neurofeedback. Frontiers in Aging Neuroscience, 2017, 9, 52.	1.7	40
605	Early Changes in Alpha Band Power and DMN BOLD Activity in Alzheimer's Disease: A Simultaneous Resting State EEG-fMRI Study. Frontiers in Aging Neuroscience, 2017, 9, 319.	1.7	38
606	Brain MRI Pattern Recognition Translated to Clinical Scenarios. Frontiers in Neuroscience, 2017, 11, 578.	1.4	12
607	Low-Frequency Pulsed Electromagnetic Field Is Able to Modulate miRNAs in an Experimental Cell Model of Alzheimer's Disease. Journal of Healthcare Engineering, 2017, 2017, 1-10.	1.1	29
608	Mixed dementia: A review of the evidence. Dementia E Neuropsychologia, 2017, 11, 364-370.	0.3	81
609	Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnesic Mild Cognitive Impairment-Storage Subtype. Journal of Alzheimer's Disease, 2017, 57, 447-459.	1.2	26
610	Hippocampal Volumetry as a Biomarker for Dementia in People with Low Education. Dementia and Geriatric Cognitive Disorders Extra, 2017, 6, 486-499.	0.6	9
611	Neurocognitive and Behavioral Indexes for Identifying the Amnesic Subtypes of Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 60, 633-649.	1.2	19

#	ARTICLE	IF	CITATIONS
612	Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward. <i>Current Alzheimer Research</i> , 2017, 14, 426-440.	0.7	68
613	Antibodies to Signaling Molecules and Receptors in Alzheimer's Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 929-939.	1.2	15
614	Spectrum of noncerebrovascular rapidly progressive cognitive deterioration: a 2-year retrospective study. <i>Clinical Interventions in Aging</i> , 2017, Volume 12, 1655-1659.	1.3	4
615	Korean Brain Aging Study for the Early Diagnosis and Prediction of Alzheimer's Disease: Methodology and Baseline Sample Characteristics. <i>Psychiatry Investigation</i> , 2017, 14, 851.	0.7	75
617	Multiplex immunoassay measurement of amyloid- β ²⁴² to amyloid- β ²⁴⁰ ratio in plasma discriminates between dementia due to Alzheimer's disease and dementia not due to Alzheimer's disease. <i>Experimental Brain Research</i> , 2018, 236, 1241-1250.	0.7	28
618	Medial temporal lobe atrophy ratings in a large 75-year-old population-based cohort: gender-corrected and education-corrected normative data. <i>European Radiology</i> , 2018, 28, 1739-1747.	2.3	18
619	Integrated neurodegenerative disease autopsy diagnosis. <i>Acta Neuropathologica</i> , 2018, 135, 643-646.	3.9	12
620	Connected speech and language in mild cognitive impairment and Alzheimer's disease: A review of picture description tasks. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2018, 40, 917-939.	0.8	148
621	NIA's Research Framework: Towards a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 576-578.	0.4	63
622	Patrones de retención de 11 C-PIB en la sustancia blanca y en la sustancia gris cerebral de pacientes con hidrocefalia a presión normal idiopática. Un análisis visual. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 87-93.	0.1	0
623	Some Methodological Characteristics of Alzheimer-Associated Urine Neuronal Thread Protein Detected by Enzyme-Linked Immunosorbent Assay. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 255-262.	1.2	6
624	NIA's Research Framework: Toward a biological definition of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 535-562.	0.4	5,861
625	The National Institute on Aging and the Alzheimer's Association Research Framework for Alzheimer's disease: Perspectives from the Research Roundtable. <i>Alzheimer's and Dementia</i> , 2018, 14, 563-575.	0.4	98
626	Negative 11C-PIB PET Predicts Lack of Alzheimer's Disease Pathology in Postmortem Examination. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 79-85.	1.2	1
627	Structural Connectivity Alterations Along the Alzheimer's Disease Continuum: Reproducibility Across Two Independent Samples and Correlation with Cerebrospinal Fluid Amyloid- β and Tau. <i>Journal of Alzheimer's Disease</i> , 2018, 61, 1575-1587.	1.2	25
628	Vision in Alzheimer's disease: a focus on the anterior afferent pathway. <i>Neurodegenerative Disease Management</i> , 2018, 8, 49-67.	1.2	14
629	Progress and Challenges in the Diagnosis of Dementia: A Critical Review. <i>ACS Chemical Neuroscience</i> , 2018, 9, 446-461.	1.7	22
630	Associations of the Top 20 Alzheimer Disease Risk Variants With Brain Amyloidosis. <i>JAMA Neurology</i> , 2018, 75, 328.	4.5	101

#	ARTICLE	IF	CITATIONS
631	Neuropsychological Profiles and Trajectories in Preclinical Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 693-702.	1.2	30
632	Imaging A β and tau in early stage Alzheimer's disease with [18F]AV45 and [18F]AV1451. <i>EJNMMI Research</i> , 2018, 8, 19.	1.1	14
633	Biomarkers in Cerebrospinal Fluid: Analysis of Cell-Free Circulating Mitochondrial DNA by Digital PCR. <i>Methods in Molecular Biology</i> , 2018, 1768, 111-126.	0.4	12
634	Clinical utility of FDG-PET for the clinical diagnosis in MCI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1497-1508.	3.3	61
635	Targeting Insulin for Alzheimer's Disease: Mechanisms, Status and Potential Directions. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S427-S453.	1.2	22
636	2018 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2018, 14, 367-429.	0.4	1,522
637	Understanding Alzheimer Disease at the Interface between Genetics and Transcriptomics. <i>Trends in Genetics</i> , 2018, 34, 434-447.	2.9	148
638	Gatekeeping and trailblazing: The role of biomarkers in novel guidelines for diagnosing Alzheimer's disease. <i>BioSocieties</i> , 2018, 13, 213-231.	0.8	11
639	Sunlight Incidence, Vitamin D Deficiency, and Alzheimer's Disease. <i>Journal of Medicinal Food</i> , 2018, 21, 841-848.	0.8	9
640	Metabolic Dysfunction in Alzheimer's Disease: From Basic Neurobiology to Clinical Approaches. <i>Journal of Alzheimer's Disease</i> , 2018, 64, S405-S426.	1.2	66
641	T1, diffusion tensor, and quantitative magnetization transfer imaging of the hippocampus in an Alzheimer's disease mouse model. <i>Magnetic Resonance Imaging</i> , 2018, 50, 26-37.	1.0	8
642	Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer's disease?. <i>Journal of Drug Targeting</i> , 2018, 26, 182-193.	2.1	62
643	Cortical microstructural changes along the Alzheimer's disease continuum. <i>Alzheimer's and Dementia</i> , 2018, 14, 340-351.	0.4	122
644	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	1.3	215
645	Patrones de retención de 11 C-PIB en la sustancia blanca y en la sustancia gris cerebral de pacientes con hidrocefalia a presión normal idiopática. Un análisis visual. <i>Revista Española De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 87-93.	0.0	1
646	Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson's disease. <i>Brain Pathology</i> , 2018, 28, 560-568.	2.1	18
647	The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 25-35.	1.4	34
648	Electrophoretic Determination of Formaldehyde in Human Urine: Application to Alzheimer's Disease. <i>Analytical Letters</i> , 2018, 51, 1358-1372.	1.0	6

#	ARTICLE	IF	CITATIONS
649	Mild cognitive impairment due to Alzheimer disease: Contemporary approaches to diagnostics and pharmacological intervention. <i>Pharmacological Research</i> , 2018, 129, 216-226.	3.1	56
650	Alzheimer Disease. <i>Journal for Nurse Practitioners</i> , 2018, 14, 129-135.	0.4	64
651	Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease. <i>Molecular Psychiatry</i> , 2018, 23, 81-93.	4.1	74
653	Introduction: A Framework for Understanding Impacts of Dementia and Supporting Quality of Life With Disease Progression. , 2018, , xxix-l.		0
654	Do We Need a Human post mortem Whole-Brain Anatomical Ground Truth in in vivo Magnetic Resonance Imaging?. <i>Frontiers in Neuroanatomy</i> , 2018, 12, 110.	0.9	13
655	A two-step immunoassay for the simultaneous assessment of A β ²³⁸ , A β ²⁴⁰ and A β ²⁴² in human blood plasma supports the A β ²⁴² /A β ²⁴⁰ ratio as a promising biomarker candidate of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 121.	3.0	39
656	Visual Features in Alzheimer's Disease: From Basic Mechanisms to Clinical Overview. <i>Neural Plasticity</i> , 2018, 2018, 1-21.	1.0	31
657	Identification of Optimum Panel of Blood-based Biomarkers for Alzheimer's Disease Diagnosis Using Machine Learning. , 2018, 2018, 3991-3994.		10
658	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. <i>Innovation in Aging</i> , 2018, 2, igy025.	0.0	15
659	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. <i>Clinical Neuropsychologist</i> , 2018, 32, 1193-1225.	1.5	10
660	GPCR-specific autoantibody signatures are associated with physiological and pathological immune homeostasis. <i>Nature Communications</i> , 2018, 9, 5224.	5.8	116
661	Una nueva etapa en el diagnostico de la enfermedad de Alzheimer. <i>Revista Espanola De Medicina Nuclear E Imagen Molecular</i> , 2018, 37, 339-340.	0.0	0
662	Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer's Disease. <i>International Journal of Alzheimer's Disease</i> , 2018, 2018, 1-9.	1.1	44
663	Amphiphilic Nanocarrier Systems for Curcumin Delivery in Neurodegenerative Disorders. <i>Medicines (Basel, Switzerland)</i> , 2018, 5, 126.	0.7	62
664	Standardized quality metric system for structural brain magnetic resonance images in multi-center neuroimaging study. <i>BMC Medical Imaging</i> , 2018, 18, 31.	1.4	2
665	Neuropsychological comparison of incident MCI and prevalent MCI. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 599-603.	1.2	3
666	Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches. <i>Bioconjugate Chemistry</i> , 2018, 29, 3937-3966.	1.8	23
667	Plasma β -Amyloids and Tau Proteins in Patients with Vascular Cognitive Impairment. <i>NeuroMolecular Medicine</i> , 2018, 20, 498-503.	1.8	18

#	ARTICLE	IF	CITATIONS
668	Chinese Medicine for Alzheimer's Disease: A Meta-Analysis of Randomized Controlled Trials. Chinese Journal of Integrative Medicine, 2018, 24, 938-943.	0.7	14
669	Alzheimer's disease diagnosis based on multiple cluster dense convolutional networks. Computerized Medical Imaging and Graphics, 2018, 70, 101-110.	3.5	114
670	A Nomogram for Predicting Amyloid PET Positivity in Amnesic Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2018, 66, 681-691.	1.2	38
671	Elevated Glutamate and Glutamine Levels in the Cerebrospinal Fluid of Patients With Probable Alzheimer's Disease and Depression. Frontiers in Psychiatry, 2018, 9, 561.	1.3	126
672	Systematic Review on Resting-State EEG for Alzheimer's Disease Diagnosis and Progression Assessment. Disease Markers, 2018, 2018, 1-26.	0.6	195
673	CSF total tau levels are associated with hippocampal novelty irrespective of hippocampal volume. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 782-790.	1.2	26
674	Manual Dexterity and Aging: A Pilot Study Disentangling Sensorimotor From Cognitive Decline. Frontiers in Neurology, 2018, 9, 910.	1.1	46
675	Population Health Solutions for Assessing Cognitive Impairment in Geriatric Patients. Archives of Clinical Neuropsychology, 2018, 33, 655-675.	0.3	5
676	Neuropsychological Assessment of Dementia and Cognitive Disorders. Journal of Korean Neuropsychiatric Association, 2018, 57, 2.	0.2	12
677	Chinese version of Montreal Cognitive Assessment Basic for discrimination among different severities of Alzheimer's disease. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2133-2140.	1.0	59
678	Chronic Traumatic Encephalopathy and Neurodegeneration in Contact Sports and American Football. Journal of Alzheimer's Disease, 2018, 66, 37-55.	1.2	16
679	Novel CSF biomarkers to discriminate FTL and its pathological subtypes. Annals of Clinical and Translational Neurology, 2018, 5, 1163-1175.	1.7	20
680	Abnormal Functional Brain Networks in Mild Cognitive Impairment and Alzheimer's Disease: A Minimum Spanning Tree Analysis. Journal of Alzheimer's Disease, 2018, 65, 1093-1107.	1.2	22
681	Callosal circularity as an early marker for Alzheimer's disease. NeuroImage: Clinical, 2018, 19, 516-526.	1.4	12
682	Does Integrated PET/MR Have a Role in the Management of Patients with Dementia?. Radiology, 2018, 288, 207-208.	3.6	3
684	Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies. NeuroImage: Clinical, 2018, 19, 406-416.	1.4	76
685	Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2018, 4, 326-329.	1.8	3
686	Clinical PET/MRI: 2018 Update. American Journal of Roentgenology, 2018, 211, 295-313.	1.0	59

#	ARTICLE	IF	CITATIONS
687	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.4	87
688	Biomarkers and the diagnosis of preclinical dementia. <i>BJ Psych Advances</i> , 2018, 24, 422-430.	0.5	5
689	Exploring the Profile of Incidental Memory in Patients with Amnesic Mild Cognitive Impairment and Mild Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 617-627.	1.2	7
690	A Retrospective Belgian Multi-Center MRI Biomarker Study in Alzheimer's Disease (REMEMBER). <i>Journal of Alzheimer's Disease</i> , 2018, 63, 1509-1522.	1.2	17
691	MRI-Based Screening of Preclinical Alzheimer's Disease for Prevention Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1099-1112.	1.2	18
692	A Systematic Review and Aggregated Analysis on the Impact of Amyloid PET Brain Imaging on the Diagnosis, Diagnostic Confidence, and Management of Patients being Evaluated for Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 63, 783-796.	1.2	50
693	Immunotherapy to improve cognition and reduce pathological species in an Alzheimer's disease mouse model. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 54.	3.0	24
694	Exosomes as possible spread factor and potential biomarkers in Alzheimer's disease: current concepts. <i>Biomarkers in Medicine</i> , 2018, 12, 1025-1033.	0.6	15
695	Corpus Callosum Radiomics-Based Classification Model in Alzheimer's Disease: A Case-Control Study. <i>Frontiers in Neurology</i> , 2018, 9, 618.	1.1	52
696	Genetic association of the cytochrome c oxidase-related genes with Alzheimer's disease in Han Chinese. <i>Neuropsychopharmacology</i> , 2018, 43, 2264-2276.	2.8	29
697	Age-Specific Cutoff Scores on a T1-Weighted Axial Medial Temporal-Lobe Atrophy Visual Rating Scale in Alzheimer's Disease Using Clinical Research Center for Dementia of South Korea Data. <i>Journal of</i>		

#	ARTICLE	IF	CITATIONS
705	Distribution of Cerebrospinal Fluid Biomarker Profiles in Patients Explored for Cognitive Disorders. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 889-897.	1.2	9
706	Use of Curcumin, a Natural Polyphenol for Targeting Molecular Pathways in Treating Age-Related Neurodegenerative Diseases. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1637.	1.8	151
707	Assessing Synaptic Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. <i>JAMA Neurology</i> , 2018, 75, 1215.	4.5	304
708	A similarity-based approach to leverage multi-cohort medical data on the diagnosis and prognosis of Alzheimer's disease. <i>GigaScience</i> , 2018, 7, .	3.3	5
709	How the Brain Is Affected. , 2018, , 3-21.		0
710	Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimer's Disease: A Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 761-774.	1.2	7
711	Reproducible evaluation of classification methods in Alzheimer's disease: Framework and application to MRI and PET data. <i>NeuroImage</i> , 2018, 183, 504-521.	2.1	132
712	Computational modeling and biomarker studies of pharmacological treatment of Alzheimer's disease (Review). <i>Molecular Medicine Reports</i> , 2018, 18, 639-655.	1.1	15
713	Identifying stage of Alzheimer disease using multiclass particle swarm optimisation technique. <i>Journal of Experimental and Theoretical Artificial Intelligence</i> , 2018, 30, 911-925.	1.8	4
714	Left lateralized cerebral glucose metabolism declines in amyloid- β^2 positive persons with mild cognitive impairment. <i>NeuroImage: Clinical</i> , 2018, 20, 286-296.	1.4	64
715	Imaging Biomarkers of Neurodegeneration in Alzheimer's Disease: Distinct Contributions of Cortical MRI Atrophy and FDG-PET Hypometabolism. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 1147-1157.	1.2	17
716	How early can we diagnose Alzheimer disease (and is it sufficient)?. <i>Neurology</i> , 2018, 91, 395-402.	1.5	60
717	Non-white matter tissue extraction and deep convolutional neural network for Alzheimer's disease detection. <i>Soft Computing</i> , 2018, 22, 6825-6833.	2.1	45
718	Time Trends in the Prevalence of Neurocognitive Disorders and Cognitive Impairment in the United States: The Effects of Disease Severity and Improved Ascertainment. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 137-148.	1.2	23
719	Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial. <i>Frontiers in Neurology</i> , 2018, 9, 662.	1.1	142
720	A "Comprehensive Visual Rating Scale" for predicting progression to dementia in patients with mild cognitive impairment. <i>PLoS ONE</i> , 2018, 13, e0201852.	1.1	8
721	Attentional ERPs distinguish aging and early Alzheimer's dementia. <i>Neurobiology of Aging</i> , 2018, 70, 51-58.	1.5	3
722	Postoperative Cognitive Dysfunction and Noncardiac Surgery. <i>Anesthesia and Analgesia</i> , 2018, 127, 496-505.	1.1	261

#	ARTICLE	IF	CITATIONS
723	Deep Brain Stimulation Targeting the Fornix for Mild Alzheimer Dementia (the ADvance Trial): A Two Year Follow-up Including Results of Delayed Activation. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 597-606.	1.2	69
724	Evaluation of Cerebrospinal Fluid Neurofilament Light Chain as a Routine Biomarker in a Memory Clinic. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2019, 74, 442-445.	1.7	17
725	Multilevel Feature Representation of FDG-PET Brain Images for Diagnosing Alzheimer's Disease. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 1499-1506.	3.9	24
726	Prediction of amyloid pathology in cognitively unimpaired individuals using voxel-wise analysis of longitudinal structural brain MRI. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 72.	3.0	23
727	Clinical utility of the normal database of 123I-iodoamphetamine brain perfusion single photon emission computed tomography for statistical analysis using computed tomography-based attenuation correction: a multicenter study. <i>Annals of Nuclear Medicine</i> , 2019, 33, 835-841.	1.2	2
728	Altered Redox State in Whole Blood Cells from Patients with Mild Cognitive Impairment and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 71, 153-163.	1.2	24
729	COMPARING THE STANDARD AND ELECTRONIC VERSIONS OF THE ALZHEIMER'S DISEASE ASSESSMENT SCALE - COGNITIVE SUBSCALE: A VALIDATION STUDY. <i>Journal of prevention of Alzheimer's disease</i> , The, 2019, 6, 1-5.	1.5	2
730	Detecting Alzheimer's Disease from Continuous Speech Using Language Models. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 1163-1174.	1.2	19
731	Cognitive and functional progression of dementia in two longitudinal studies. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1623-1632.	1.3	6
732	Effects of vitamin D supplementation on cognitive function and blood A β -related biomarkers in older adults with Alzheimer's disease: a randomised, double-blind, placebo-controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, jnnp-2018-320199.	0.9	75
733	Obesity, Cognitive Functioning, and Dementia: A Lifespan Prospective. , 2019, , 421-456.		2
734	Developing Measures of Cognitive Impairment in the Real World from Consumer-Grade Multimodal Sensor Streams. , 2019, , .		76
735	FDG-PET as an independent biomarker for Alzheimer's biological diagnosis: a longitudinal study. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 57.	3.0	90
736	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
737	The Efficacy of General Practitioner Assessment of Cognition in Chinese Elders Aged 80 and Older. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2019, 34, 523-529.	0.9	1
740	Developments and debates on latent variable modeling in diagnostic studies when there is no gold standard. <i>Biostatistics and Epidemiology</i> , 2019, , 1-18.	0.4	0
741	In Vivo Assessment of Retinal Biomarkers by Hyperspectral Imaging: Early Detection of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 4492-4501.	1.7	37
742	Hypersynchronization in mild cognitive impairment: the "X" model. <i>Brain</i> , 2019, 142, 3936-3950.	3.7	68

#	ARTICLE	IF	CITATIONS
743	Curcumin, Hormesis and the Nervous System. <i>Nutrients</i> , 2019, 11, 2417.	1.7	89
744	The Discipline of Neurology. , 2019, , 1-5.		1
745	The Scientific Study of Religion. , 2019, , 6-11.		0
746	Methodological Hazards in the Neuroscientific Study of Religion. , 2019, , 12-24.		0
747	Embodied Cognition and the Neurology of Religion. , 2019, , 25-34.		0
748	Phenomenology, Neurology, Psychiatry and Religious Commitment. , 2019, , 35-47.		0
749	Philosophical Hazards in the Neuroscientific Study of Religion. , 2019, , 48-70.		0
750	The Glass Onion. , 2019, , 71-79.		0
751	Towards an Islamic Neuropsychiatry. , 2019, , 80-88.		1
752	Temporal Lobe Epilepsy, Dostoyevsky and Irrational Significance. , 2019, , 89-100.		0
753	Parkinsonâ€™s Disease, Religious Belief and Spirituality. , 2019, , 101-114.		1
754	Beyond Reasonable Doubt. , 2019, , 115-129.		0
755	Ramadam Fasting and Neurologic Disorders. , 2019, , 130-138.		1
756	Autism and the Panoply of Religious Belief, Disbelief and Experience. , 2019, , 139-148.		1
757	Personhood and Religion in People with Dementia. , 2019, , 149-160.		1
758	Religion and Frontotemporal Dementia. , 2019, , 161-170.		2
759	Examining the Continuum of Life to Determine Death. , 2019, , 214-229.		0
760	Near-Death and Out-of-Body Experiences. , 2019, , 230-253.		0

#	ARTICLE	IF	CITATIONS
763	Religion and Spirituality in Neuro-Rehabilitation. , 2019, , 171-190.		1
764	Eastern Spirituality, Mindâ€“Body Practices and Neuro-Rehabilitation. , 2019, , 191-213.		1
765	Estimating Functional Connectivity Networks via Low-rank Tensor Approximation with Applications to MCI Identification. IEEE Transactions on Biomedical Engineering, 2019, 67, 1-1.	2.5	19
766	Associations Between the Subjective Cognitive Decline-Questionnaireâ€™s Scores, Gray Matter Volume, and Amyloid- β^2 Levels. Journal of Alzheimer's Disease, 2019, 72, 1287-1302.	1.2	6
767	Alzheimer's Disease Diagnosis and Severity Level Detection Based on Electroencephalography Modulation Spectral â€œPatchâ€•Features. IEEE Journal of Biomedical and Health Informatics, 2019, 24, 1-1.	3.9	12
768	The items in the Chinese version of the Montreal cognitive assessment basic discriminate among different severities of Alzheimerâ€™s disease. BMC Neurology, 2019, 19, 269.	0.8	6
769	Association of serum cystatin C with white matter abnormalities in patients with amnesic mild cognitive impairment. Geriatrics and Gerontology International, 2019, 19, 1036-1040.	0.7	9
770	Association between Apolipoprotein E Gene Polymorphism and Alzheimer's Disease in an Iranian Population: A Meta-Analysis. Journal of Molecular Neuroscience, 2019, 69, 557-562.	1.1	25
771	Neuroimaging of Alzheimerâ€™s disease: focus on amyloid and tau PET. Japanese Journal of Radiology, 2019, 37, 735-749.	1.0	35
772	Vibrational Spectroscopy Fingerprinting in Medicine: from Molecular to Clinical Practice. Materials, 2019, 12, 2884.	1.3	223
773	Urinary Alzheimer-Associated Neuronal Thread Protein is not Elevated in Patients with Subjective Cognitive Decline and Patients with Depressive State. Journal of Alzheimer's Disease, 2019, 71, 1115-1123.	1.2	10
774	New Horizons in Early Dementia Diagnosis: Can Cerebellar Stimulation Untangle the Knot?. Journal of Clinical Medicine, 2019, 8, 1470.	1.0	4
775	A novel kit for early diagnosis of Alzheimerâ€™s disease using a fluorescent nanoparticle imaging. Scientific Reports, 2019, 9, 13184.	1.6	17
776	Longitudinal Assessment of Amyloid- β^2 Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimerâ€™s Disease. Frontiers in Aging Neuroscience, 2019, 11, 251.	1.7	11
777	Cerebral Amyloid Angiopathy, Alzheimerâ€™s Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets. NeuroMolecular Medicine, 2019, 21, 369-390.	1.8	18
778	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 69-73.	1.2	13
779	Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimerâ€™s Disease and Correlates with Cognitive Impairment. Journal of Alzheimer's Disease, 2019, 67, 481-488.	1.2	171
780	A hybrid Convolutional and Recurrent Neural Network for Hippocampus Analysis in Alzheimer's Disease. Journal of Neuroscience Methods, 2019, 323, 108-118.	1.3	110

#	ARTICLE	IF	CITATIONS
781	Diagnosis of Alzheimer's Disease via Multi-Modality 3D Convolutional Neural Network. <i>Frontiers in Neuroscience</i> , 2019, 13, 509.	1.4	149
782	Electrophysiological brain signatures for the classification of subjective cognitive decline: towards an individual detection in the preclinical stages of dementia. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 49.	3.0	21
783	Potential Value of Plasma Amyloid- β , Total Tau, and Neurofilament Light for Identification of Early Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 3479-3485.	1.7	44
784	Correlation between CSF biomarkers of Alzheimer's disease and global cognition in a psychogeriatric clinic cohort. <i>Revista Brasileira De Psiquiatria</i> , 2019, 41, 479-484.	0.9	6
785	Differential medial temporal lobe and default-mode network functional connectivity and morphometric changes in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 23, 101860.	1.4	21
786	Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease. <i>Alzheimer's and Dementia</i> , 2019, 15, 927-939.	0.4	48
787	Chronic traumatic encephalopathy is a common co-morbidity, but less frequent primary dementia in former soccer and rugby players. <i>Acta Neuropathologica</i> , 2019, 138, 389-399.	3.9	108
788	Disentangling Heterogeneity in Alzheimer's Disease: Two Empirically-Derived Subtypes. <i>Journal of Alzheimer's Disease</i> , 2019, 70, 227-239.	1.2	10
789	Complex Differential Diagnosis of Cognitive Impairments. <i>Neuroscience and Behavioral Physiology</i> , 2019, 49, 422-428.	0.2	0
790	Vascular Cognitive Impairment: Information from Animal Models on the Pathogenic Mechanisms of Cognitive Deficits. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2405.	1.8	20
791	Small Non-coding RNAs: New Class of Biomarkers and Potential Therapeutic Targets in Neurodegenerative Disease. <i>Frontiers in Genetics</i> , 2019, 10, 364.	1.1	101
792	Retinal Nerve Fiber Layer Thinning Is Associated With Brain Atrophy: A Longitudinal Study in Nondemented Older Adults. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 69.	1.7	33
795	Biopathological Significance of Early-Phase Amyloid Imaging in the Spectrum of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 69, 529-538.	1.2	4
796	Neurochemical Aspects of Alzheimer's Type of Dementia. , 2019, , 73-112.		1
797	Neurodegenerative Diseases and Ageing. <i>Sub-Cellular Biochemistry</i> , 2019, 91, 75-106.	1.0	8
798	2019 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2019, 15, 321-387.	0.4	1,633
799	Multiple Visual Rating Scales Based on Structural MRI and a Novel Prediction Model Combining Visual Rating Scales and Age Stratification in the Diagnosis of Alzheimer's Disease in the Chinese Population. <i>Frontiers in Neurology</i> , 2019, 10, 93.	1.1	13
800	The Dichotomy of Alzheimer's Disease Pathology: Amyloid- β and Tau. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 77-83.	1.2	14

#	ARTICLE	IF	CITATIONS
801	Amyloid β^2 deposition and glucose metabolism on the long-term progression of preclinical Alzheimer's disease. <i>Future Science OA</i> , 2019, 5, FSO356.	0.9	6
802	Understanding the Amyloid Hypothesis in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 493-510.	1.2	77
803	Blood-based molecular signature of Alzheimer's disease via spectroscopy and metabolomics. <i>Clinical Biochemistry</i> , 2019, 72, 58-63.	0.8	20
804	Mutation and association analyses of dementia-causal genes in Han Chinese patients with early-onset and familial Alzheimer's disease. <i>Journal of Psychiatric Research</i> , 2019, 113, 141-147.	1.5	20
805	Mobile-Health Applications for the Efficient Delivery of Health Care Facility to People with Dementia (PwD) and Support to Their Carers: A Survey. <i>BioMed Research International</i> , 2019, 2019, 1-26.	0.9	75
806	Alzheimer's Disease Including Focal Presentations. <i>Seminars in Neurology</i> , 2019, 39, 213-226.	0.5	72
807	Search for biomarkers of Alzheimer's disease: Recent insights, current challenges and future prospects. <i>Clinical Biochemistry</i> , 2019, 72, 39-51.	0.8	17
808	Late Effects. , 2019, , 496-554.		0
809	Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. <i>Journal of Neural Transmission</i> , 2019, 126, 327-337.	1.4	33
810	After-effects of repetitive anodal transcranial direct current stimulation on learning and memory in a rat model of Alzheimer's disease. <i>Neurobiology of Learning and Memory</i> , 2019, 161, 37-45.	1.0	18
811	Is the regional cerebral blood flow always decreased in the occipital lobe of patients with dementia with Lewy bodies? A SPECT easy Z score imaging system perfusion study. <i>Neurology and Clinical Neuroscience</i> , 2019, 7, 112-118.	0.2	1
812	Cerebrospinal fluid biomarkers for understanding multiple aspects of Alzheimer's disease pathogenesis. <i>Cellular and Molecular Life Sciences</i> , 2019, 76, 1833-1863.	2.4	75
813	Statistical Methodology for Multiclass Classifications: Applications to Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 173-186.	1.2	1
814	Midlife Long-Hour Working and Later-life Social Engagement Are Associated with Reduced Risks of Mild Cognitive Impairment among Community-Living Singapore Elderly. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 1067-1077.	1.2	8
815	Elevation of pS262-Tau and Demethylated PP2A in Retina Occurs Earlier than in Hippocampus During Hyperhomocysteinemia. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 367-381.	1.2	7
816	Cerebrovascular Reactivity Impairment in Preclinical Alzheimer's Disease. <i>Journal of Neuroimaging</i> , 2019, 29, 493-498.	1.0	14
817	Predicting Alzheimer's disease progression using multi-modal deep learning approach. <i>Scientific Reports</i> , 2019, 9, 1952.	1.6	178
818	Dance for People with Alzheimer's Disease: A Systematic Review. <i>Current Alzheimer Research</i> , 2019, 16, 919-933.	0.7	48

#	ARTICLE	IF	CITATIONS
820	Cognitive and neuropsychological examination of the elderly. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 89-104.	1.0	5
821	Neuropsychology of aging. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 149-180.	1.0	50
822	Schizoaffective disorder comorbid with type 2 diabetes mellitus accompanied by frontotemporal atrophy and impaired cognition. Medicine (United States), 2019, 98, e15292.	0.4	0
823	The long-term consequences of repetitive head impacts: Chronic traumatic encephalopathy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 167, 337-355.	1.0	16
824	The Consortium for the early identification of Alzheimer's diseaseâ€œQuebec (CIMAâ€œQ). Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 787-796.	1.2	21
825	An Algorithm to Characterize a Dementia Population by Disease Subtype. Alzheimer Disease and Associated Disorders, 2019, 33, 118-123.	0.6	2
826	Diet Associated with Inflammation and Alzheimerâ€™s Disease. Journal of Alzheimer's Disease Reports, 2019, 3, 299-309.	1.2	13
827	Precision Medicine: Role of Biomarkers in Early Prediction and Diagnosis of Alzheimerâ€™s Disease. , 2019, , .		5
828	Automated Alzheimerâ€™s Disease Diagnosis using a Low-Density EEG Layout and New Features based on the Power of Modulation Spectral â€œPatchesâ€œ, 2019, , .		1
829	Reflections on the Utility of the Retina as a Biomarker for Alzheimerâ€™s Disease: A Literature Review. Neurology and Therapy, 2019, 8, 57-72.	1.4	39
830	Cognitive symptoms of Alzheimerâ€™s disease: clinical management and prevention. BMJ, The, 2019, 367, l6217.	3.0	162
831	Progression to dementia in memory clinic patients with mild cognitive impairment and normal Î²-amyloid. Alzheimer's Research and Therapy, 2019, 11, 99.	3.0	23
832	Neuroimaging of the Aging Brain. , 2019, , 28-53.		0
833	Neurodegenerative Patterns of Cognitive Clusters of Early-Onset Alzheimerâ€™s Disease Subjects: Evidence for Disease Heterogeneity. Dementia and Geriatric Cognitive Disorders, 2019, 48, 131-142.	0.7	9
834	An abbreviated version of Silhouettes test: a brief validated mild cognitive impairment screening tool. International Psychogeriatrics, 2019, 31, 849-856.	0.6	9
835	A Deep Learning Model to Predict a Diagnosis of Alzheimer Disease by Using ¹⁸ F-FDG PET of the Brain. Radiology, 2019, 290, 456-464.	3.6	413
836	Subjective cognitive decline: preclinical manifestation of Alzheimerâ€™s disease. Neurological Sciences, 2019, 40, 41-49.	0.9	50
837	Blood-based redox-signature and their association to the cognitive scores in MCI and Alzheimerâ€™s disease patients. Free Radical Biology and Medicine, 2019, 130, 499-511.	1.3	24

#	ARTICLE	IF	CITATIONS
838	The involvement of microglia in Alzheimer's disease: a new dog in the fight. <i>British Journal of Pharmacology</i> , 2019, 176, 3533-3543.	2.7	27
839	Complement C7 is a novel risk gene for Alzheimer's disease in Han Chinese. <i>National Science Review</i> , 2019, 6, 257-274.	4.6	55
840	MicroRNAs and mild cognitive impairment: A systematic review. <i>Ageing Research Reviews</i> , 2019, 50, 131-141.	5.0	34
841	Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer's disease: A randomized, double-blind, controlled trial. <i>Clinical Nutrition</i> , 2019, 38, 2569-2575.	2.3	221
842	Tau PET imaging in neurodegenerative tauopathies—still a challenge. <i>Molecular Psychiatry</i> , 2019, 24, 1112-1134.	4.1	409
843	Association between serum cholesterol levels and Alzheimer's disease in China: a case-control study. <i>International Journal of Food Sciences and Nutrition</i> , 2019, 70, 405-411.	1.3	32
844	Dendritic spines: Revisiting the physiological role. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 92, 161-193.	2.5	165
845	The Number of Items on Each Stroop Test Card Is Unrelated to Its Sensitivity. <i>Neuropsychobiology</i> , 2019, 77, 38-44.	0.9	10
846	CSF soluble TREM2 as a measure of immune response along the Alzheimer's disease continuum. <i>Neurobiology of Aging</i> , 2019, 74, 182-190.	1.5	45
847	Disorders of Higher Cortical Visual Function. , 2019, , 341-364.		0
848	Hippocampus Analysis by Combination of 3-D DenseNet and Shapes for Alzheimer's Disease Diagnosis. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2019, 23, 2099-2107.	3.9	85
849	Altered plasma visfatin levels and insulin resistance in patients with Alzheimer's disease. <i>Acta Neurologica Belgica</i> , 2020, 120, 901-906.	0.5	7
850	Three plasma metabolites in elderly patients differentiate mild cognitive impairment and Alzheimer's disease: a pilot study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 483-488.	1.8	10
851	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. <i>Neurobiology of Aging</i> , 2020, 89, 132-141.	1.5	28
852	Historic concepts of dementia and Alzheimer's disease: From ancient times to the present. <i>Revue Neurologique</i> , 2020, 176, 140-147.	0.6	16
853	Motion-induced position mislocalization predicts the severity of Alzheimer's disease. <i>Journal of Neuropsychology</i> , 2020, 14, 333-345.	0.6	4
854	Cognitive profiles and optimal cutoffs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition. <i>Psychogeriatrics</i> , 2020, 20, 20-27.	0.6	4
855	Biographical films as a person-centered approach to reduce neuropsychiatric symptoms of dementia in residential care: A feasibility study. <i>Journal of Clinical Psychology</i> , 2020, 76, 137-145.	1.0	3

#	ARTICLE	IF	CITATIONS
856	IC-SMART: IoTCloud enabled Seamless Monitoring for Alzheimer Diagnosis and Rehabilitation SysTem. Journal of Ambient Intelligence and Humanized Computing, 2020, 11, 3387-3403.	3.3	10
857	An Experimental Pilot Study of Global Postural Reeducation Concerning the Cognitive Approach of Patients With Alzheimer's Disease. American Journal of Alzheimer's Disease and Other Dementias, 2020, 35, 153331751986782.	0.9	5
858	Shared Latent Structures Between Imaging Features and Biomarkers in Early Stages of Alzheimer's Disease: A Predictive Study. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 365-376.	3.9	1
859	Ultrasmlal superparamagnetic iron oxide nanoparticles-bound NIR dyes: Novel theranostic agents for Alzheimer's disease. Dyes and Pigments, 2020, 173, 107968.	2.0	29
860	Communicating uncertainties when disclosing diagnostic test results for (Alzheimer's) dementia in the memory clinic: The ABIDE project. Health Expectations, 2020, 23, 52-62.	1.1	20
861	Cholesterol and Dementia: A Long and Complicated Relationship. Current Aging Science, 2020, 13, 42-51.	0.4	22
862	Staging of tau distribution by positron emission tomography may be useful in clinical staging of Alzheimer disease. Neurology and Clinical Neuroscience, 2020, 8, 61-67.	0.2	6
863	Buildout of Methodology for Meticulous Diagnosis of K-Complex in EEG for Aiding the Detection of Alzheimer's by Artificial Intelligence. Augmented Human Research, 2020, 5, 1.	3.5	31
864	Clinical significance of focal Aβ-amyloid deposition measured by 18F-flutemetamol PET. Alzheimer's Research and Therapy, 2020, 12, 6.	3.0	12
865	MRI and cognitive scores complement each other to accurately predict Alzheimer's dementia 2 to 7 years before clinical onset. NeuroImage: Clinical, 2020, 25, 102121.	1.4	16
866	A multi-model deep convolutional neural network for automatic hippocampus segmentation and classification in Alzheimer's disease. NeuroImage, 2020, 208, 116459.	2.1	306
867	Quantifying the diagnostic pathway for patients with cognitive impairment: real-world data from Australia. International Psychogeriatrics, 2020, 32, 601-610.	0.6	8
868	The A/T/N model applied through imaging biomarkers in a memory clinic. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 247-255.	3.3	23
869	Deep learning to detect Alzheimer's disease from neuroimaging: A systematic literature review. Computer Methods and Programs in Biomedicine, 2020, 187, 105242.	2.6	198
870	Profile of pathogenic proteins in total circulating extracellular vesicles in mild cognitive impairment and during the progression of Alzheimer's disease. Neurobiology of Aging, 2020, 86, 102-111.	1.5	34
871	Salvage of the retinal ganglion cells in transition phase in Alzheimer's disease with topical coenzyme Q10: is it possible?. Graef's Archive for Clinical and Experimental Ophthalmology, 2020, 258, 411-418.	1.0	7
872	Hippocampal Neuroimaging-Informed Clinical Trial Enrichment Tool for Amnesic Mild Cognitive Impairment Using Open Data. Clinical Pharmacology and Therapeutics, 2020, 107, 903-914.	2.3	2
873	Decomposed Temporal Complexity Analysis of Neural Oscillations and Machine Learning Applied to Alzheimer's Disease Diagnosis. Frontiers in Psychiatry, 2020, 11, 531801.	1.3	3

#	ARTICLE	IF	CITATIONS
874	CRISPR-Cas9: A Promising Genome Editing Therapeutic Tool for Alzheimer's Disease—A Narrative Review. <i>Neurology and Therapy</i> , 2020, 9, 419-434.	1.4	24
875	Differential Impact of Cognitive Impairment in MCI Patients: A Case-Based Report. <i>Case Reports in Neurology</i> , 2020, 12, 222-231.	0.3	2
876	Development and Validation of a Deep Learning-Based Automatic Brain Segmentation and Classification Algorithm for Alzheimer Disease Using 3D T1-Weighted Volumetric Images. <i>American Journal of Neuroradiology</i> , 2020, 41, 2227-2234.	1.2	37
877	Fluid Candidate Biomarkers for Alzheimer's Disease: A Precision Medicine Approach. <i>Journal of Personalized Medicine</i> , 2020, 10, 221.	1.1	20
878	Genetic associations of in vivo pathology influence Alzheimer's disease susceptibility. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 156.	3.0	11
879	A Robust Discriminant Framework Based on Functional Biomarkers of EEG and Its Potential for Diagnosis of Alzheimer's Disease. <i>Healthcare (Switzerland)</i> , 2020, 8, 476.	1.0	9
880	Cerebrospinal Fluid and Serum d-Serine Levels in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 3840.	1.0	11
881	An Increased Plasma Level of ApoCIII-Rich Electronegative High-Density Lipoprotein May Contribute to Cognitive Impairment in Alzheimer's Disease. <i>Biomedicines</i> , 2020, 8, 542.	1.4	6
882	Translating the REACH OUT dementia caregiver intervention into a primary care setting: a pilot study. <i>Aging and Mental Health</i> , 2021, 25, 1483-1492.	1.5	3
883	Interleukin-12/23 deficiency differentially affects pathology in male and female Alzheimer's disease-like mice. <i>EMBO Reports</i> , 2020, 21, e48530.	2.0	24
884	Decreased salivary lactoferrin levels are specific to Alzheimer's disease. <i>EBioMedicine</i> , 2020, 57, 102834.	2.7	59
885	The Validation of Multifactor Model of Plasma A β 242 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 212.	1.7	18
886	Projection to Latent Spaces Disentangles Pathological Effects on Brain Morphology in the Asymptomatic Phase of Alzheimer's Disease. <i>Frontiers in Neurology</i> , 2020, 11, 648.	1.1	6
887	Health Outcome Prioritization in Alzheimer's Disease: Understanding the Ethical Landscape. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 339-353.	1.2	3
888	Restoring regulatory T-cell dysfunction in Alzheimer's disease through ex vivo expansion. <i>Brain Communications</i> , 2020, 2, fcaa112.	1.5	48
889	Use of Biomarkers in Ongoing Research Protocols on Alzheimer's Disease. <i>Journal of Personalized Medicine</i> , 2020, 10, 68.	1.1	9
890	Clinical and biomarker trajectories in sporadic Alzheimer's disease: A longitudinal study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12095.	1.2	14
891	Insights from RNA-Seq analysis of Alzheimer's data suggest upregulation of GPCRs. <i>Gene Reports</i> , 2020, 21, 100921.	0.4	1

#	ARTICLE	IF	CITATIONS
892	Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions. <i>Seminars in Ultrasound, CT and MRI</i> , 2020, 41, 572-583.	0.7	12
893	THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER'S DISEASE (TRC-PAD) PROJECT: AN OVERVIEW. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2020, 7, 1-5.	1.5	17
894	Validation of the Greek version of the Abbreviated Mental Test Score: Preliminary findings for cognitively impaired patients of different etiology. <i>Applied Neuropsychology Adult</i> , 2020, , 1-12.	0.7	2
895	A multivariate model of time to conversion from mild cognitive impairment to Alzheimer's disease. <i>GeroScience</i> , 2020, 42, 1715-1732.	2.1	9
898	What Can Person-Centred Care in Dementia Learn from the Recovery Movement?. , 2020, , 202-212.		0
899	Epidemiology and Mental Health in Old Age. , 2020, , 5-23.		0
901	Young-Onset Dementias. , 2020, , 38-49.		0
902	Rare and Unusual Dementias. , 2020, , 50-77.		0
903	Mania in Late Life. , 2020, , 78-91.		0
904	Alcohol Misuse in Older People. , 2020, , 92-104.		0
905	Drug Misuse in Older People. , 2020, , 105-115.		0
906	Mental Health in Parkinson's Disease. , 2020, , 116-128.		0
907	The Home Assessment in Old Age Psychiatry. , 2020, , 129-138.		0
908	Driving in Dementia. , 2020, , 139-148.		0
909	Mini-Mental State Examination for the Detection and Prediction of Dementia in People with and without Mild Cognitive Impairment. , 2020, , 149-160.		0
910	Biomarkers and the Diagnosis of Preclinical Alzheimer's Disease. , 2020, , 161-172.		0
911	To Scan or Not to Scan. , 2020, , 173-190.		0
912	Supporting Self-Management in Early Dementia. , 2020, , 191-201.		0

#	ARTICLE	IF	CITATIONS
913	Psychosocial Interventions in Dementia. , 2020, , 213-222.		0
914	Palliative Care in Dementia. , 2020, , 223-242.		0
915	Review of Treatment for Late-Life Depression. , 2020, , 243-253.		0
916	Reducing the Healthcare Burden of Delirium. , 2020, , 254-265.		0
917	Controlling the Confusion. , 2020, , 266-278.		0
918	Residence Capacity. , 2020, , 305-316.		0
922	Mental Health Laws from All UK Jurisdictions. , 2020, , 279-292.		0
923	Deprivation of Liberty. , 2020, , 293-304.		0
924	Understanding the Person with Dementia. , 2020, , 317-327.		0
925	Digital biomarker-based individualized prognosis for people at risk of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12073.	1.2	28
926	Significance of Blood and Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Sensitivity, Specificity and Potential for Clinical Use. Journal of Personalized Medicine, 2020, 10, 116.	1.1	26
927	The Peripheral Hearing and Central Auditory Processing Skills of Individuals With Subjective Memory Complaints. Frontiers in Neuroscience, 2020, 14, 888.	1.4	7
928	An analytic framework for conceptualisations of disease: nine structuring questions and how some conceptualisations of Alzheimer's disease can lead to "diseaseisation". Medicine, Health Care and Philosophy, 2020, 23, 677-693.	0.9	2
929	Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders. Journal of Alzheimer's Disease, 2020, 77, 935-947.	1.2	5
930	The Latin American Spanish version of the Face-Name Associative Memory Exam is sensitive to cognitive and pathological changes in preclinical autosomal dominant Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 104.	3.0	7
931	Identification of Earlier Biomarkers for Alzheimer's Disease: A Multimodal Neuroimaging Study of Individuals with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2020, 77, 1067-1076.	1.2	12
932	Souvenaid for Alzheimer's disease. The Cochrane Library, 2020, 2020, CD011679.	1.5	4
933	Differentiating among stages of cognitive impairment in aging: Version 3 of the Uniform Data Set (UDS) neuropsychological test battery and MoCA index scores. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12103.	1.8	19

#	ARTICLE	IF	CITATIONS
934	When real life conditions do not follow textbook diagnosis: A diagnostic challenge from a neuropsychiatric clinic. <i>International Journal of Psychiatry in Medicine</i> , 2021, 56, 459-469.	0.8	0
935	Use of Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Risk in Mild Cognitive Impairment and Subjective Cognitive Decline in Routine Clinical Care in Germany. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 1137-1148.	1.2	5
936	On the impact of age, gender and educational level on cognitive function in Alzheimer's disease: A quantitative approach. <i>Archives of Gerontology and Geriatrics</i> , 2020, 89, 104090.	1.4	7
937	Profiles of Cognitive Change in Preclinical and Prodromal Alzheimer's Disease Using Change-Point Analysis. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 1169-1180.	1.2	21
938	Comparison of Two Analytical Platforms in Cerebrospinal Fluid Biomarkers for the Classification of Alzheimer's Disease Spectrum with Amyloid PET Imaging. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 949-958.	1.2	7
939	Behavioral and Psychological Symptoms that Predict Cognitive Decline or Impairment in Cognitively Normal Middle-Aged or Older Adults: a Meta-Analysis. <i>Neuropsychology Review</i> , 2020, 30, 558-579.	2.5	24
940	Machine learning technique for early detection of Alzheimer's disease. <i>Microsystem Technologies</i> , 2020, 26, 3935-3944.	1.2	14
941	The dynamics of biomarkers across the clinical spectrum of Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 74.	3.0	53
942	Volume Analysis of Brain Cognitive Areas in Alzheimer's Disease: Interim 3-Year Results from the ASCOMALVA Trial. <i>Journal of Alzheimer's Disease</i> , 2020, 76, 317-329.	1.2	10
943	A typology of clinical conditions. <i>Studies in History and Philosophy of Science Part C: Studies in History and Philosophy of Biological and Biomedical Sciences</i> , 2020, 83, 101291.	0.8	12
944	2020 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2020, 16, 391-460.	0.4	1,802
945	Nanoparticle-based immunomagnetic assay of plasma biomarkers for differentiating dementia and prodromal states of Alzheimer's disease – A cross-validation study. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 28, 102182.	1.7	17
946	Complex network analysis of MCI-AD EEG signals under cognitive and resting state. <i>Brain Research</i> , 2020, 1735, 146743.	1.1	32
947	Norms for Testing Visual Binding Using the Memory Associative Test (TMA-93) in Older Educationally-Diverse Adults. <i>Journal of Alzheimer's Disease</i> , 2020, 75, 871-878.	1.2	7
948	Diagnostic accuracy of the repeatable battery of the assessment of neuropsychological status update, Spanish version, in predicting Alzheimer's disease among Hispanic older adults in the United States reporting memory problems. <i>Applied Neuropsychology Adult</i> , 2022, 29, 509-519.	0.7	2
949	Short-term exposure to dietary cholesterol is associated with downregulation of interleukin-15, reduced thigmotaxis and memory impairment in mice. <i>Behavioural Brain Research</i> , 2020, 393, 112779.	1.2	4
950	The Development of New Diagnostic Tests for Neurologic Disorders in the Commercial Laboratory Environment. <i>Clinics in Laboratory Medicine</i> , 2020, 40, 331-339.	0.7	0
951	Subtle voices, distant futures: a critical look at conditions for patient involvement in Alzheimer's biomarker research and beyond. <i>Journal of Responsible Innovation</i> , 2020, 7, 170-192.	2.3	9

#	ARTICLE	IF	CITATIONS
952	Traitement de la maladie d'Alzheimer: une lueur au bout du tunnel?. Pratique Neurologique - FMC, 2020, 11, 46-48.	0.1	0
953	US, EU, and Japanese Regulatory Guidelines for Development of Drugs for Treatment of Alzheimer's Disease: Implications for Global Drug Development. Clinical and Translational Science, 2020, 13, 652-664.	1.5	11
954	Challenges in Alzheimer's Disease Drug Discovery and Development: The Role of Modeling, Simulation, and Open Data. Clinical Pharmacology and Therapeutics, 2020, 107, 796-805.	2.3	14
955	Accelerated brain aging towards transcriptional inversion in a zebrafish model of the K115fs mutation of human PSEN2. PLoS ONE, 2020, 15, e0227258.	1.1	38
956	Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer's Disease. Journal of Alzheimer's Disease Reports, 2020, 4, 21-37.	1.2	30
957	Age-stratified longitudinal study of Alzheimer's and vascular dementia patients. Alzheimer's and Dementia, 2020, 16, 908-917.	0.4	25
958	Trends in the public health significance, definitions of disease, and implications for prevention of Alzheimer's disease. Current Epidemiology Reports, 2020, 7, 68-76.	1.1	7
959	Predictors of accidents in people with mild cognitive impairment, mild dementia due to Alzheimer's disease and healthy controls in simulated driving. International Journal of Geriatric Psychiatry, 2020, 35, 859-869.	1.3	10
960	Prevalence of the Preclinical Stages of Alzheimer's Disease in Cognitively Intact Older Adults: The CABLE Study. Journal of Alzheimer's Disease, 2020, 75, 483-492.	1.2	1
961	Association of Plasma Oligomerized Beta Amyloid with Neurocognitive Battery Using Korean Version of Consortium to Establish a Registry for Alzheimer's Disease in Health Screening Population. Diagnostics, 2020, 10, 237.	1.3	9
962	Stability of Plasma Amyloid-1 β 40, Amyloid-1 β 42, and Total Tau Protein over Repeated Freeze/Thaw Cycles. Dementia and Geriatric Cognitive Disorders Extra, 2020, 10, 46-55.	0.6	15
963	A New Neurovascular Panel Discriminates Between Patients with Type 2 Diabetes Mellitus with Cognitive Impairment and Cognitive Impairment Alone. Journal of Alzheimer's Disease, 2020, 75, 461-469.	1.2	4
964	Attitudes towards prediction and early diagnosis of late-onset dementia: a comparison of tested persons and family caregivers. Aging and Mental Health, 2021, 25, 832-843.	1.5	18
965	The <i>ARNTL</i> polymorphism rs900147 is associated with the risk of Alzheimer's disease and amnesic mild cognitive impairment in a Chinese population. Biological Rhythm Research, 2021, 52, 146-152.	0.4	0
966	Comparative study of two Chinese versions of Montreal Cognitive Assessment for Screening of Mild Cognitive Impairment. Applied Neuropsychology Adult, 2021, 28, 88-93.	0.7	14
967	The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. American Journal of Geriatric Psychiatry, 2021, 29, 375-383.	0.6	36
968	Retinal changes in Alzheimer's disease: integrated prospects of imaging, functional and molecular advances. Progress in Retinal and Eye Research, 2021, 82, 100899.	7.3	71
969	Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative. GeroScience, 2021, 43, 1039-1051.	2.1	25

#	ARTICLE	IF	CITATIONS
970	Cognitive Impairment in Older Adults and Therapeutic Strategies. <i>Pharmacological Reviews</i> , 2021, 73, 152-162.	7.1	24
971	Systematic analysis to identify transcriptome-wide dysregulation of Alzheimer's disease in genes and isoforms. <i>Human Genetics</i> , 2021, 140, 609-623.	1.8	13
972	Effects of Folic Acid and Vitamin B12 Supplementation on Cognitive Impairment and Inflammation in Patients with Alzheimer's Disease: A Randomized, Single-Blinded, Placebo-Controlled Trial. <i>Journal of Prevention of Alzheimer's Disease</i> , 2021, 8, 1-8.	1.5	26
973	The Highlighted Roles of Metabolic and Cellular Response to Stress Pathways Engaged in Circulating hsa-miR-494-3p and hsa-miR-661 in Alzheimer's Disease. <i>Iranian Biomedical Journal</i> , 2021, 25, 62-67.	0.4	9
975	A profile of brain reserve in adults at genetic risk of Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12208.	1.2	4
976	Serum d-serine levels are altered in early phases of Alzheimer's disease: towards a precocious biomarker. <i>Translational Psychiatry</i> , 2021, 11, 77.	2.4	37
977	Brain structures and networks responsible for stimulation-induced memory flashbacks during fornix deep brain stimulation for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 777-787.	0.4	23
978	Communicating 5-Year Risk of Alzheimer's Disease Dementia: Development and Evaluation of Materials that Incorporate Multiple Genetic and Biomarker Research Results. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 559-572.	1.2	12
979	Vergeetachtigheid. , 2021, , 823-833.		0
980	Management of the prodementia stage of Alzheimer's disease, complicated with hypoactive delirium. <i>Russian Neurological Journal</i> , 2021, 25, 40-46.	0.1	0
981	Modeling the Self-navigation Behavior of Patients with Alzheimer's Disease in Virtual Reality. <i>Communications in Computer and Information Science</i> , 2021, , 121-136.	0.4	0
982	Progress regarding the context-of-use of tau as biomarker of Alzheimer's disease and other neurodegenerative diseases. <i>Expert Review of Proteomics</i> , 2021, 18, 27-48.	1.3	8
983	Private payer coverage policies for ApoE-e4 genetic testing. <i>Genetics in Medicine</i> , 2021, 23, 614-620.	1.1	6
984	The biological pathways of Alzheimer disease: a review. <i>AIMS Neuroscience</i> , 2021, 8, 86-132.	1.0	111
985	Accuracy of deep learning model-assisted amyloid positron emission tomography scan in predicting Alzheimer's disease: A Systematic Review and meta-analysis. <i>Informatics in Medicine Unlocked</i> , 2021, 25, 100710.	1.9	13
986	Association between ApoE ϵ 4 Carrier Status and Cardiovascular Risk Factors on Mild Cognitive Impairment among Mexican Older Adults. <i>Brain Sciences</i> , 2021, 11, 68.	1.1	2
987	Hippocampal shape and asymmetry analysis by cascaded convolutional neural networks for Alzheimer's disease diagnosis. <i>Brain Imaging and Behavior</i> , 2021, 15, 2330-2339.	1.1	24
988	Anti-dementia Medication. , 2021, , 73-104.		0

#	ARTICLE	IF	CITATIONS
989	Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. <i>Communications Biology</i> , 2021, 4, 63.	2.0	28
990	An organization- and category-level comparison of diagnostic requirements for mental disorders in <scp>ICD</scp>-11 and <scp>DSM</scp>-5. <i>World Psychiatry</i> , 2021, 20, 34-51.	4.8	100
991	Color and contrast vision in mouse models of aging and Alzheimer's disease using a novel visual-stimuli four-arm maze. <i>Scientific Reports</i> , 2021, 11, 1255.	1.6	13
992	Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) trial. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12199.	1.2	14
993	Development of molecular tools for diagnosis of Alzheimer's disease that are based on detection of amyloidogenic proteins. <i>Prion</i> , 2021, 15, 56-69.	0.9	12
995	Clinical manifestations and issues of diagnosis of chronic cerebrovascular disease (chronic cerebral) Tj ETQq1 1 0.784314 rgBT /Overlo	0.2	21
996	Clinical validity of second-generation tau PET tracers as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2110-2120.	3.3	33
997	Altered Neuroanatomical Asymmetries of Subcortical Structures in Subjective Cognitive Decline, Amnesic Mild Cognitive Impairment, and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1121-1132.	1.2	13
998	Implication of Nicotinamide Adenine Dinucleotide Phosphate (NADPH) Oxidase and Its Inhibitors in Alzheimer's Disease Murine Models. <i>Antioxidants</i> , 2021, 10, 218.	2.2	15
1000	Imaging Techniques in Alzheimer's Disease: A Review of Applications in Early Diagnosis and Longitudinal Monitoring. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2110.	1.8	79
1002	Resting state EEG biomarkers of cognitive decline associated with Alzheimer's disease and mild cognitive impairment. <i>PLoS ONE</i> , 2021, 16, e0244180.	1.1	98
1003	A Young Missionary with Problems Quoting the Bible. , 2021, , 1-5.		0
1004	Nanomarker for Early Detection of Alzheimer's Disease Combining Ab initio DFT Simulations and Molecular Docking Approach. <i>Biophysica</i> , 2021, 1, 76-86.	0.6	4
1005	Ophthalmic examination in the debut and during progression of neurodegenerative diseases. <i>Rossiiskii Oftal'mologicheskii Zhurnal</i> , 2021, 14, 104-110.	0.1	0
1006	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid β^2 and tau. <i>Alzheimer's and Dementia</i> , 2021, 17, 1575-1582.	0.4	51
1007	Machine Learning and Novel Biomarkers for the Diagnosis of Alzheimer's Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2761.	1.8	82
1008	Machine Learning for the Prediction of Amyloid Positivity in Amnesic Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 143-157.	1.2	11
1010	Defining early changes in Alzheimer's disease from RNA sequencing of brain regions differentially affected by pathology. <i>Scientific Reports</i> , 2021, 11, 4865.	1.6	23

#	ARTICLE	IF	CITATIONS
1011	Alzheimer's disease alters oligodendrocytic glycolytic and ketolytic gene expression. <i>Alzheimer's and Dementia</i> , 2021, 17, 1474-1486.	0.4	37
1012	Mild cognitive impairment in psoriatic arthritis. <i>Medicine (United States)</i> , 2021, 100, e24833.	0.4	9
1013	<sc>2021</sc> Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2021, 17, 327-406.	0.4	1,622
1014	Multiparametric magnetic resonance imaging and positron emission tomography findings in neurodegenerative diseases: Current status and future directions. <i>Neuroradiology Journal</i> , 2021, 34, 263-288.	0.6	4
1015	Brain Dynamics Altered by Photic Stimulation in Patients with Alzheimer's Disease and Mild Cognitive Impairment. <i>Entropy</i> , 2021, 23, 427.	1.1	5
1016	Performance of Mattis dementia rating scale-Chinese version in patients with mild cognitive impairment and Alzheimer's disease. <i>BMC Neurology</i> , 2021, 21, 172.	0.8	5
1017	Theoretical impact of the AT(N) framework on dementia using a community autopsy sample. <i>Alzheimer's and Dementia</i> , 2021, 17, 1879-1891.	0.4	5
1018	Diagnosis of Alzheimer's Disease by Time-Dependent Power Spectrum Descriptors and Convolutional Neural Network Using EEG Signal. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-17.	0.7	24
1019	Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation. <i>Brain</i> , 2021, 144, 2837-2851.	3.7	14
1020	Biocomputational Screening of Natural Compounds against Acetylcholinesterase. <i>Molecules</i> , 2021, 26, 2641.	1.7	10
1021	Direct Comparison of the Tau PET Tracers ¹⁸ F-Flortaucipir and ¹⁸ F-MK-6240 in Human Subjects. <i>Journal of Nuclear Medicine</i> , 2022, 63, 108-116.	2.8	39
1022	Investigating Neuroimaging Correlates of Early Frailty in Patients With Behavioral Variant Frontotemporal Dementia: A MRI and FDG-PET Study. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 637796.	1.7	6
1023	Low Doses of Ionizing Radiation as a Treatment for Alzheimer's Disease: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1119-1128.	1.2	28
1024	TMA-93 Validation by Alzheimer's Disease Biomarkers: A Comparison with the Free and Cued Selective Reminding Test on a Biobank Sample. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 401-410.	1.2	4
1025	Alzheimer disease. <i>Nature Reviews Disease Primers</i> , 2021, 7, 33.	18.1	784
1026	Ocular biomarkers and their role in the early diagnosis of neurocognitive disorders. <i>European Journal of Ophthalmology</i> , 2021, 31, 112067212110163.	0.7	10
1027	The nonverbal BriefScreen: A cognitive screening method for patients with limited language and motor abilities. <i>Applied Neuropsychology Adult</i> , 2023, 30, 186-193.	0.7	0
1028	An Insight into the Role of Artificial Intelligence in the Early Diagnosis of Alzheimer's Disease. <i>CNS and Neurological Disorders - Drug Targets</i> , 2022, 21, 901-912.	0.8	3

#	ARTICLE	IF	CITATIONS
1029	Astrocyte subtype-specific approach to Alzheimer's disease treatment. <i>Neurochemistry International</i> , 2021, 145, 104956.	1.9	10
1030	Hearing Impairment and Cognition in an Aging World. <i>JARO - Journal of the Association for Research in Otolaryngology</i> , 2021, 22, 387-403.	0.9	26
1031	Astrocyte Biomarkers in Alzheimer Disease. <i>Neurology</i> , 2021, 96, .	1.5	70
1033	PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 624330.	1.7	39
1034	Heterogeneity of Cerebrospinal Fluid Biomarkers Profiles in Individuals with Distinct Levels of Cognitive Decline: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2021, 81, 949-962.	1.2	4
1035	Machine learning-based tri-stage classification of Alzheimer's progressive neurodegenerative disease using <scp>PCA</scp> and <scp>mRMR</scp> administered textural, orientational, and spatial features. <i>International Journal of Imaging Systems and Technology</i> , 2021, 31, 2060-2074.	2.7	7
1036	Novel drug candidates targeting Alzheimer's disease: ethical challenges with identifying the relevant patient population. <i>Journal of Medical Ethics</i> , 2021, 47, 608-614.	1.0	7
1037	To Explore the Predictive Power of Visuomotor Network Dysfunctions in Mild Cognitive Impairment and Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 654003.	1.4	6
1038	Biological diagnosis of Alzheimer's disease and the issue of stigma. <i>Journal of Gerontology and Geriatrics</i> , 2021, 69, 195-207.	0.2	1
1039	Changes of Regional Neural Activity Homogeneity in Preclinical Alzheimer's Disease: Compensation and Dysfunction. <i>Frontiers in Neuroscience</i> , 2021, 15, 646414.	1.4	16
1040	Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 676744.	1.7	11
1041	Association between thyroid function and Alzheimer's disease: A systematic review. <i>Metabolic Brain Disease</i> , 2021, 36, 1523-1543.	1.4	13
1042	Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. <i>Nature Communications</i> , 2021, 12, 3555.	5.8	115
1043	International Practice Recommendations for the Recognition and Management of Hearing and Vision Impairment in People with Dementia. <i>Gerontology</i> , 2022, 68, 121-135.	1.4	20
1044	Plasma Levels of Amyloid- β Peptides and Tau Protein in Mexican Patients with Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 82, S271-S281.	1.2	2
1045	Effect of Statin Therapy on Cognitive Decline and Incident Dementia in Older Adults. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3145-3156.	1.2	38
1046	Specific White Matter Tracts and Diffusion Properties Predict Conversion From Mild Cognitive Impairment to Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 711579.	1.7	16
1047	Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). <i>The Cochrane Library</i> , 2021, 2021, CD010783.	1.5	72

#	ARTICLE	IF	CITATIONS
1048	Signal and Texture Features from T2 Maps for the Prediction of Mild Cognitive Impairment to Alzheimer's Disease Progression. <i>Healthcare (Switzerland)</i> , 2021, 9, 941.	1.0	2
1049	Study of the effects of mindfulness training on quality of life of patients with Alzheimer's disease and their caregivers (Dyad Mindfulness Project). <i>Aging Clinical and Experimental Research</i> , 2022, 34, 65-71.	1.4	2
1050	Event-related brain potential indexes provide evidence for some decline in healthy people with subjective memory complaints during target evaluation and response inhibition processing. <i>Neurobiology of Learning and Memory</i> , 2021, 182, 107450.	1.0	4
1051	Past, present and future role of retinal imaging in neurodegenerative disease. <i>Progress in Retinal and Eye Research</i> , 2021, 83, 100938.	7.3	60
1052	Regional brain volumes relate to Alzheimer's disease cerebrospinal fluid biomarkers and neuropsychometry: A cross-sectional, observational study. <i>PLoS ONE</i> , 2021, 16, e0254332.	1.1	5
1053	Volumetric measurement of the hippocampus in a series of patients with Alzheimer disease. <i>Neurology Perspectives</i> , 2021, 1, 149-159.	0.2	0
1054	Biomarkers for the Clinical Diagnosis of Alzheimer's Disease: Metabolomics Analysis of Brain Tissue and Blood. <i>Frontiers in Pharmacology</i> , 2021, 12, 700587.	1.6	11
1055	Harnessing forgetfulness: can episodic-memory tests predict early Alzheimer's disease?. <i>Experimental Brain Research</i> , 2021, 239, 2925-2937.	0.7	7
1056	Developing the ATX(N) classification for use across the Alzheimer disease continuum. <i>Nature Reviews Neurology</i> , 2021, 17, 580-589.	4.9	144
1057	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , 2021, 9, 36.	1.7	9
1058	Mass spectrometry-based methods for robust measurement of Alzheimer's disease biomarkers in biological fluids. <i>Journal of Neurochemistry</i> , 2021, 159, 211-233.	2.1	29
1059	Curcumin analogs as anti-cathepsins agents: Designing, virtual screening, and molecular docking analysis. <i>Computational Toxicology</i> , 2021, 19, 100174.	1.8	9
1060	Progression in Alzheimer's Disease Correlates With Epigenetics and Cerebral Formaldehyde: From Potential Hereditary Mechanism and Environmental Factors to Therapeutic Measures. <i>Current Pharmacology Reports</i> , 2021, 7, 187.	1.5	0
1061	Retinal Dysfunction in Alzheimer's Disease and Implications for Biomarkers. <i>Biomolecules</i> , 2021, 11, 1215.	1.8	15
1062	The Internet-Based Conversational Engagement Clinical Trial (I-CONNECT) in Socially Isolated Adults 75+ Years Old: Randomized Controlled Trial Protocol and COVID-19 Related Study Modifications. <i>Frontiers in Digital Health</i> , 2021, 3, 714813.	1.5	12
1063	Developing methods to detect and diagnose chronic traumatic encephalopathy during life: rationale, design, and methodology for the DIAGNOSE CTE Research Project. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 136.	3.0	30
1064	A novel missense variant in ACAA1 contributes to early-onset Alzheimer's disease, impairs lysosomal function, and facilitates amyloid- β^2 pathology and cognitive decline. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 325.	7.1	22
1065	Ophthalmic Biomarkers for Alzheimer's Disease: A Review. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 720167.	1.7	15

#	ARTICLE	IF	CITATIONS
1066	Alzheimer's Disease: A Molecular View of β -Amyloid Induced Morbific Events. <i>Biomedicines</i> , 2021, 9, 1126.	1.4	22
1067	JKAP, Th1 cells, and Th17 cells are dysregulated and inter-correlated, among them JKAP and Th17 cells relate to cognitive impairment progression in Alzheimer's disease patients. <i>Irish Journal of Medical Science</i> , 2022, 191, 1855-1861.	0.8	13
1069	Diagnostic Performance of Automated MRI Volumetry by icobrain dm for Alzheimer's Disease in a Clinical Setting: A REMEMBER Study. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 623-639.	1.2	7
1071	Longitudinal assessment of amyloid-beta deposition in initially amyloid-negative non-demented individuals with [11C]-PIB PET imaging. <i>Medicine (United States)</i> , 2021, 100, e27055.	0.4	4
1072	Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer's Disease Using Immunomagnetic Reduction. <i>Neurology and Therapy</i> , 2021, 10, 1015-1028.	1.4	0
1073	Association between Alzheimer's disease and risk of cancer: A retrospective cohort study in Shanghai, China. <i>Alzheimer's and Dementia</i> , 2022, 18, 924-933.	0.4	10
1074	Porphyromonas Gingivalis as a Risk Factor to Alzheimer's Disease: A Systematic Review. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 721-732.	1.2	28
1075	Investigating Changes in the Serum Inflammatory Factors in Alzheimer's Disease and Their Correlation with Cognitive Function. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 835-842.	1.2	5
1076	Unique regional patterns of amyloid burden predict progression to prodromal and clinical stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2021, 106, 119-129.	1.5	15
1077	Using big data methods to understand Alzheimer's disease. , 2022, , 125-149.		1
1078	Evaluation of the ATN model in a longitudinal memory clinic sample with different underlying disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12031.	1.2	9
1079	Expert Opinions and Recommendations for the Clinical Use of Quantitative Analysis Software for MRI-Based Brain Volumetry. <i>Journal of the Korean Society of Radiology</i> , 2021, 82, 1124.	0.1	5
1081	Modelling the value of innovative treatments for Alzheimer's disease in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 764-769.	1.0	9
1082	Plasma Neurofilament Light Combined with Risk Genes for the Diagnosis of Alzheimer's Disease. , 0, 83, .		1
1083	Enhancement of select cognitive domains with rosiglitazone implicates dorsal hippocampus circuitry sensitive to PPAR γ agonism in an Alzheimer's mouse model. <i>Brain and Behavior</i> , 2021, 11, e01973.	1.0	11
1084	The AT(N) framework for Alzheimer's disease in adults with Down syndrome. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12062.	1.2	12
1085	Soluble Amyloid Precursor Proteins in Blood: Methods and Challenges. <i>Neuroinformatics</i> , 2018, , 179-187.	0.2	1
1086	Antineurodegenerative and Antidiabetic Activity of Lichens. , 2019, , 215-236.		1

#	ARTICLE	IF	CITATIONS
1087	Digital Biomarkers Based Individualized Prognosis for People at Risk of Dementia: the AltoidaML Multi-site External Validation Study. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1194, 157-171.	0.8	5
1088	PET Imaging of Synaptic Vesicle Protein 2A. , 2021, , 993-1019.		10
1089	Gerontopsychiatrie. , 2012, , 353-394.		1
1090	Neural Circuit Models and Neuropathological Oscillations. , 2014, , 673-702.		3
1091	Prevention of Alzheimer's Disease and Alzheimer's Dementia. <i>Mental Health and Illness Worldwide</i> , 2016, , 1-26.	0.1	1
1092	Alzheimer Disease and Other Dementias. , 2017, , 935-943.e6.		3
1093	Artificial intelligence and neuropsychological measures: The case of Alzheimerâ€™s disease. <i>Neuroscience and Biobehavioral Reviews</i> , 2020, 114, 211-228.	2.9	51
1096	Biomarkers for Alzheimerâ€™s Disease: Searching for the Missing Link Between Biology and Clinic. , 2016, , 63-82.		6
1097	Testing Memory, Shifting Responsibility: Internet-Based (Self-) Diagnostics of Alzheimerâ€™s Disease. , 2016, , 141-161.		1
1098	Pathophysiological subtypes of Alzheimerâ€™s disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
1105	IoT-Based Healthcare Support System for Alzheimerâ€™s Patients. <i>Wireless Communications and Mobile Computing</i> , 2020, 2020, 1-15.	0.8	30
1106	Bilingualism Delays Expression of Alzheimerâ€™s Clinical Syndrome. <i>Dementia and Geriatric Cognitive Disorders</i> , 2019, 48, 281-289.	0.7	10
1108	The Mental Status Examination in Patients With Suspected Dementia. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 385-403.	0.4	12
1109	Mild Cognitive Impairment. <i>CONTINUUM Lifelong Learning in Neurology</i> , 2016, 22, 404-418.	0.4	377
1110	Radiological Evaluation of Strategic Structures in Patients with Mild Cognitive Impairment and Early Alzheimerâ€™s Disease. <i>Polski Przegląd Radiologii I Medycyny Nuklearnej</i> , 2016, 81, 288-294.	1.0	8
1111	Neuronal pentraxin receptor-1 is a new cerebrospinal fluid biomarker of Alzheimerâ€™s disease progression. <i>F1000Research</i> , 2018, 7, 1012.	0.8	34
1112	Forniceal deep brain stimulation in severe Alzheimerâ€™s disease: A case report. <i>World Journal of Clinical Cases</i> , 2020, 8, 4938-4945.	0.3	4
1113	THE ROAD AHEAD TO CURE ALZHEIMER'S DISEASE: DEVELOPMENT OF BIOLOGICAL MARKERS AND NEUROIMAGING METHODS FOR PREVENTION TRIALS ACROSS ALL STAGES AND TARGET POPULATIONS. <i>Journal of prevention of Alzheimer's disease, The</i> , 2014, 1, 1-22.	1.5	48

#	ARTICLE	IF	CITATIONS
1114	Prodromes and Preclinical Detection of Brain Diseases: Surveying the Ethical Landscape of Predicting Brain Health. <i>ENeuro</i> , 2019, 6, ENEURO.0439-18.2019.	0.9	9
1115	Alzheimer's disease and sleep disturbances: a review. <i>Arquivos De Neuro-Psiquiatria</i> , 2019, 77, 815-824.	0.3	42
1116	Early diagnosis and treatment of Alzheimer's disease: new definitions and challenges. <i>Revista Brasileira De Psiquiatria</i> , 2020, 42, 431-441.	0.9	42
1117	Moving from neurodegenerative dementias, to cognitive proteinopathies, replacing "where" by "what". <i>Dementia E Neuropsychologia</i> , 2020, 14, 237-242.	0.3	13
1118	Envelhecimento e doença de Alzheimer: reflexões sobre autonomia e o desafio do cuidado. <i>Revista Bioetica</i> , 2014, 22, 85-93.	0.0	4
1123	Diagnostic performance of new and classic CSF biomarkers in age-related dementias. <i>Aging</i> , 2019, 11, 2420-2429.	1.4	20
1124	Careful neuropsychological testing reveals a novel genetic marker, <i>GSTO1*</i> , linked to the pre-stage of Alzheimer's disease. <i>Oncotarget</i> , 2016, 7, 39108-39117.	0.8	10
1125	Epidemiology and Etiology of Alzheimer's disease: From Genetic to Non- Genetic Factors. <i>Current Alzheimer Research</i> , 2013, 10, 852-867.	0.7	174
1126	Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia. <i>Current Alzheimer Research</i> , 2018, 15, 777-788.	0.7	123
1127	[¹⁸ F]-florbetaben PET/CT Imaging in the Alzheimer's Disease Mouse Model APP ^{swe} /PS1 ^{dE9} . <i>Current Alzheimer Research</i> , 2018, 16, 49-55.	0.7	9
1128	Advances in Imaging: Brain Tumors to Alzheimer's Disease. <i>The Bangkok Medical Journal</i> , 2015, 10, 83-97.	0.2	1
1129	Memory loss in Alzheimer's disease. <i>Dialogues in Clinical Neuroscience</i> , 2013, 15, 445-454.	1.8	393
1130	Non-Alzheimer's disease-related memory impairment and dementia. <i>Dialogues in Clinical Neuroscience</i> , 2013, 15, 465-473.	1.8	34
1131	Association of Androgens and Gonadotropins with Amnesic Mild Cognitive Impairment and Probable Alzheimer's Disease in Chinese Elderly Men. <i>Journal of Alzheimer's Disease</i> , 2020, 78, 277-290.	1.2	7
1133	Mixed dementia in stroke patient. <i>Russian Journal of Geriatric Medicine</i> , 2020, , 236-242.	0.3	2
1134	Alzheimer's Disease: Implications of the Updated Diagnostic and Research Criteria. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 1190-1196.	1.1	29
1135	Clinical Impact of Updated Diagnostic and Research Criteria for Alzheimer's Disease. <i>Journal of Clinical Psychiatry</i> , 2011, 72, e37.	1.1	15
1136	Practical Diagnosis and Management of Dementia Due to Alzheimer's Disease in the Primary Care Setting. <i>primary care companion for CNS disorders, The</i> , 2013, 15, .	0.2	20

#	ARTICLE	IF	CITATIONS
1137	Alzheimer's disease: Unique markers for diagnosis & new treatment modalities. Indian Journal of Medical Research, 2015, 142, 369.	0.4	13
1138	Effect of apolipoprotein E (APO E) polymorphism on leptin in Alzheimer's disease. Annals of Indian Academy of Neurology, 2015, 18, 320.	0.2	7
1139	20S proteasome and glyoxalase 1 activities decrease in erythrocytes derived from Alzheimer's disease patients. Neural Regeneration Research, 2020, 15, 178.	1.6	12
1140	Optical coherence tomography: Is really a new biomarker for alzheimer's disease?. Annals of Indian Academy of Neurology, 2018, 21, 119.	0.2	11
1141	Alzheimer's Disease and the Conflict between Ethics, Morality and Politics. , 2012, 01, .		4
1142	Understanding the individual with Alzheimer's disease: Can socioemotional selectivity theory guide us?. Advances in Alzheimer's Disease, 2012, 01, 77-86.	0.3	7
1143	Disorders of cerebrovascular angioarchitectonics and microcirculation in the etiology and pathogenesis of Alzheimer's disease. Advances in Alzheimer's Disease, 2013, 02, 171-181.	0.3	5
1144	An Ensemble of Classifiers based Approach for Prediction of Alzheimer's Disease using fMRI Images based on Fusion of Volumetric, Textural and Hemodynamic Features. Advances in Electrical and Computer Engineering, 2018, 18, 61-70.	0.5	5
1145	Estimating the effect of a scanner upgrade on measures of grey matter structure for longitudinal designs. PLoS ONE, 2021, 16, e0239021.	1.1	11
1146	Demencia prevenci3: A korai diagn3zist3l a szem3lyre szabott intervenci3ig. Scientia Et Securitas, 2021, 2, 207-219.	0.1	0
1147	Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers. Frontiers in Neurology, 2021, 12, 619388.	1.1	1
1148	Tau for Long-Term Effects of Neurotrauma: Technology Versus the Null Hypothesis. Neuromethods, 2022, , 329-345.	0.2	0
1149	The Diagnostic Value of a Short Memory Test: The TNI-93. Journal of Alzheimer's Disease, 2021, , 1-11.	1.2	1
1150	Iron Responsive Element-Mediated Responses to Iron Dyshomeostasis in Alzheimer's Disease. Journal of Alzheimer's Disease, 2021, 84, 1597-1630.	1.2	18
1151	Inter- and Intra-Scanner Variability of Automated Brain Volumetry on Three Magnetic Resonance Imaging Systems in Alzheimer's Disease and Controls. Frontiers in Aging Neuroscience, 2021, 13, 746982.	1.7	12
1152	Diagnosis of Alzheimer's disease based on regional attention with sMRI gray matter slices. Journal of Neuroscience Methods, 2022, 365, 109376.	1.3	23
1153	Identification of early-onset photoreceptor degeneration in transgenic mouse models of Alzheimer's disease. IScience, 2021, 24, 103327.	1.9	11
1154	The Impact of Amyloid PET Disclosure on Quality of Life in Patients With Young Onset Dementia. Alzheimer Disease and Associated Disorders, 2021, Publish Ahead of Print, 1-6.	0.6	1

#	ARTICLE	IF	CITATIONS
1155	Bayesian inference and dynamic prediction of multivariate joint model with functional data: An application to Alzheimer's disease. <i>Statistics in Medicine</i> , 2021, 40, 6855.	0.8	1
1156	S18-1. Neurological Disorders: PMDA's Role in New Product Development. <i>Japanese Journal of Clinical Pharmacology and Therapeutics</i> , 2012, 43, 121-122.	0.1	0
1157	Alzheimer's Disease: Approaches to Pathogenesis in the Genomic Age. , 0, , .		0
1158	Hope for Catching Alzheimer's Early. <i>ASHA Leader</i> , 2012, 17, 20-22.	0.2	0
1159	CSF Biomarkers for Alzheimer Disease Diagnosis: Recent and Future Perspectives. <i>Journal of Neurological Disorders</i> , 2013, 01, .	0.1	0
1160	Apport de l'imagerie par résonance magnétique dans la maladie d'Alzheimer. , 2013, , 45-61.		0
1163	Diagnostic de la maladie d'Alzheimer. , 2013, , 3-27.		0
1164	Impact of the IWG/Dubois Criteria for Alzheimer's Disease in Imaging Studies. , 2014, , 309-322.		0
1165	Strengthening/Building Alzheimer's Disease Global Clinical Trial Site Capabilities and Capacity in and for Emerging Markets. Lessons Learned from Japan. , 2014, , 289-304.		1
1166	Increased Oxidative Damage in RNA in Alzheimer's Disease Progression. <i>Journal of Analytical & Bioanalytical Techniques</i> , 2014, s2, .	0.6	1
1167	Nanomedicines for Nervous System Diseases. , 2014, , 2125-2156.		0
1168	Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets. , 2014, , 3-14.		0
1169	Efficacy of the Phosphorylated tau 181 in Differential Diagnosis of the Alzheimer's Disease: A Systematic Review and Meta-Analysis. <i>Dementia and Neurocognitive Disorders</i> , 2014, 13, 129.	0.4	0
1171	La aplicación de biomarcadores a la búsqueda de nuevas farmacoterapias para el tratamiento de la enfermedad de Alzheimer. , 2014, , 79-120.		0
1174	Challenges in Production of Alzheimer's Tracer C-11 PiB. <i>The Bangkok Medical Journal</i> , 2015, 09, 70-75.	0.2	2
1175	Alzheimer and Markers. <i>Journal of Neurology & Stroke</i> , 2015, 2, .	0.0	0
1176	A New Public Health Paradigm for Alzheimer's Disease Research. <i>SOJ Neurology</i> , 2015, 2, 01-07.	0.1	4
1178	Syndromes of Brain Dysfunction Presenting with Cognitive Impairment or Behavioral Disturbance: Delirium, Dementia, and Mental Disorders Due to Another Medical Condition. , 2016, , 17-41.		0

#	ARTICLE	IF	CITATIONS
1179	Promoting Healthy Cognitive Aging: A Systematic Review and Analysis. IRA-International Journal of Applied Sciences (ISSN 2455-4499), 2016, 4, 431.	0.1	0
1181	The role of PET/CT in the diagnostics of dementia. Aktualnosci Neurologiczne, 2016, 16, 146-151.	0.1	0
1182	Biomarkers in Mild Stages of Alzheimer's disease: Utility in clinical practice and their relation with nutritional and lifestyle factors. Functional Foods in Health and Disease, 2016, 6, 627.	0.3	0
1183	Alzheimer's disease as a neuropathological continuum in clinical practice.. Neurologie Pro Praxi, 2016, 17, 305-309.	0.0	0
1184	Update on Dementia. Pathophysiology, Diagnosis, and Treatment. DSM-IV versus DSM-V. , 2017, , 477-493.		2
1185	Effects of Support Groups for Individuals with Early-Stage Dementia and Mild Cognitive Impairment: An Integrative Review. Research in Gerontological Nursing, 2017, 10, 35-51.	0.2	1
1186	Dementia and Other Neurocognitive Disorders. , 2017, , 226-252.		0
1187	Verubecestat. , 2017, , 204-251.		0
1188	Dementia and Neurocognitive Disorders. , 2017, , 646-655.		0
1189	Prevention of Alzheimer's Disease and Alzheimer's Dementia. Mental Health and Illness Worldwide, 2017, , 549-574.	0.1	0
1193	Early Identification of Alzheimer's Disease Using an Ensemble of 3D Convolutional Neural Networks and Magnetic Resonance Imaging. Lecture Notes in Computer Science, 2018, , 303-311.	1.0	3
1194	The Ethics of Biomarker-Based Preclinical Diagnosis of Alzheimer's Disease. Neuromethods, 2018, , 249-258.	0.2	2
1195	Development of Korean Occupational Therapy Practice Guideline for Dementia. The Journal of Korean Society of Occupational Therapy, 2018, 26, 75-89.	0.1	1
1199	After the Diagnosis of Dementia: Considerations in Disease Management. Clinical Handbooks in Neuropsychology, 2019, , 335-353.	0.1	1
1200	A New Biological Definition of Alzheimer's Disease: Introduction of 2018 National Institute on Aging-Alzheimer's Association Research Framework. Journal of the Korean Neurological Association, 2019, 37, 1-7.	0.0	2
1203	Neuroimaging techniques for diagnosing Alzheimer's disease and cerebrovascular diseases with cognitive impairment. Nevrologiya, Neiropsikhiatriya, Psikhosomatika, 2019, 11, 18-25.	0.2	7
1204	Postoperative cognitive dysfunction: progress mechanisms and clinical characteristics. Medical Alphabet, 2019, 2, 29-33.	0.0	0
1205	The neuroscience of dementia. , 2020, , 297-312.		0

#	ARTICLE	IF	CITATIONS
1206	A Comprehensive Visual Rating Scale for Predicting Progression from Mild Cognitive Impairment to Dementia in Patients with Alzheimer's Pathology or Suspected Non-Alzheimer's Pathology. <i>Dementia and Neurocognitive Disorders</i> , 2020, 19, 129.	0.4	2
1208	Magnetic Resonance Imaging: Historical Overview, Technical Developments, and Clinical Applications. <i>Progress in Medical Physics</i> , 2020, 31, 35-53.	0.5	1
1209	Changes in prevalence of cognitive impairment and associated risk factors 2000–2015 in São Paulo, Brazil. <i>BMC Geriatrics</i> , 2021, 21, 609.	1.1	5
1210	Psychopathology of Dementia: Psychology's Pivotal Role. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 61-69.	0.1	0
1211	Neuroimaging in Psychiatric Drug Development and Radioligand Development for New Targets. , 2021, , 3-15.		0
1212	Psychiatric Disorders in Alzheimer Disease With the Presenilin-1 L226F Mutation. <i>Cognitive and Behavioral Neurology</i> , 2020, 33, 278-282.	0.5	5
1213	Assessing clinical progression from subjective cognitive decline to mild cognitive impairment with incomplete multi-modal neuroimages. <i>Medical Image Analysis</i> , 2022, 75, 102266.	7.0	19
1214	THE TRIAL-READY COHORT FOR PRECLINICAL/PRODROMAL ALZHEIMER'S DISEASE (TRC-PAD) – A FUNDAMENTAL ALLY IN AD PREVENTION RESEARCH. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2020, 7, 1-2.	1.5	1
1215	https://link.springer.com/article/10.14283/jfa.2020.9 . <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2020, 7, 1-2.	1.5	0
1217	CCCDTD5: Clinical role of neuroimaging and liquid biomarkers in patients with cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12098.	1.8	5
1218	Functional assessment in geriatric mental health. , 2020, , 285-298.		2
1221	Multiple Causes of Dementia as Engineered Senescence. <i>European Journal of Medical and Health Sciences</i> , 2020, 2, .	0.1	2
1222	Retinal imaging biomarkers of neurodegenerative diseases. <i>Australasian Journal of Optometry</i> , The, 2022, 105, 194-204.	0.6	14
1223	CBIAT: Context Based Image Analyzer for Alzheimer's Therapy. <i>Lecture Notes in Networks and Systems</i> , 2022, , 187-200.	0.5	0
1224	Peptoid Nanosheet-Based Sensing System for the Diagnosis and Surveillance of Amnesic Mild Cognitive Impairment and Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4257-4264.	1.7	5
1225	The relationship between urinary Alzheimer-associated neuronal thread protein and blood biochemical indicators in the general population. <i>Aging</i> , 2020, 12, 15260-15280.	1.4	5
1226	Dementia and Other Neurocognitive Disorders. <i>Advances in Psychology, Mental Health, and Behavioral Studies</i> , 0, , 104-130.	0.1	0
1227	Amyloid imaging in Alzheimer's disease: A literature review. <i>Journal of Nutrition, Health and Aging</i> , 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
1228	The possibilities of diagnosing and treating cognitive impairment at non-dementia stages. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2020, 12, 78-83.	0.2	5
1229	Impact of the New Conceptual Framework of Alzheimer's Disease in Imaging Studies. , 2021, , 427-451.		0
1231	The Effect of Spinal Cord Injury on Beta-Amyloid Plaque Pathology in TgCRND8 Mouse Model of Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2020, 17, 576-586.	0.7	2
1232	The Parietal Atrophy Score on Brain Magnetic Resonance Imaging is a Reliable Visual Scale. <i>Current Alzheimer Research</i> , 2020, 17, 534-539.	0.7	6
1233	Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's disease. <i>American Journal of Neurodegenerative Disease</i> , 2013, 2, 40-5.	0.1	5
1234	Clinical implications of the new diagnostic guidelines for dementia. <i>Innovations in Clinical Neuroscience</i> , 2013, 10, 32-8.	0.1	2
1235	Are the revised diagnostic criteria for Alzheimer's disease useful in low- and middle-income countries?. <i>Shanghai Archives of Psychiatry</i> , 2015, 27, 119-23.	0.7	4
1236	Cardiac surgery, the brain, and inflammation. <i>Journal of Extra-Corporeal Technology</i> , 2014, 46, 15-22.	0.2	11
1237	Diagnostic performance of an automated analysis software for the diagnosis of Alzheimer's dementia with F FDG PET. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 12-23.	1.0	9
1238	Outcomes Assessment in Clinical Trials of Alzheimer's Disease and its Precursors: Ready for Short-term and Long-term Clinical Trial Needs. <i>Innovations in Clinical Neuroscience</i> , 2017, 14, 22-29.	0.1	34
1239	Advances in Imaging: Brain Tumors to Alzheimer's Disease. <i>The Bangkok Medical Journal</i> , 2015, 10, 83-97.	0.2	1
1240	CD200-CD200R signaling and diseases: a potential therapeutic target?. <i>International Journal of Physiology, Pathophysiology and Pharmacology</i> , 2019, 11, 297-309.	0.8	7
1241	Identification of Circulating and Exchanges in The Serum of Alzheimer's Patients and Insights into The Pathophysiological Pathways. <i>Cell Journal</i> , 2021, 23, 211-217.	0.2	0
1242	More Atypical than Atypical Alzheimer's Disease Phenotypes: A Treviso Dementia (TREDem) Registry Case Report. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 365-374.	1.2	1
1243	Protective effect of chronic administration of pelargonidin on neuronal apoptosis and memory process in amyloid-beta-treated rats. <i>Avicenna Journal of Phytomedicine</i> , 2021, 11, 407-416.	0.1	2
1244	Mild Cognitive Impairment: Current Aspects of Diagnosis and Treatment. <i>Neuroscience and Behavioral Physiology</i> , 2021, 51, 1033-1039.	0.2	0
1245	Effects of Meditation on Structural Changes of the Brain in Patients With Mild Cognitive Impairment or Alzheimer's Disease Dementia. <i>Frontiers in Human Neuroscience</i> , 2021, 15, 728993.	1.0	6
1246	Tau Imaging in Neurodegenerative Dementia. , 2022, , 111-120.		0

#	ARTICLE	IF	CITATIONS
1247	Improving 3D convolutional neural network comprehensibility via interactive visualization of relevance maps: evaluation in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 191.	3.0	21
1248	The Potential of Naturalistic Eye Movement Tasks in the Diagnosis of Alzheimer's Disease: A Review. <i>Brain Sciences</i> , 2021, 11, 1503.	1.1	13
1249	Patterns of Distribution of 18F-THK5351 Positron Emission Tomography in Alzheimer's Disease Continuum. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 223-234.	1.2	4
1250	Accuracy of the Brief Cognitive Screening Battery for diagnosing Alzheimer's disease defined by cerebrospinal fluid biomarkers and AT(N) classification: a case-control study. <i>Arquivos De Neuro-Psiquiatria</i> , 2022, 80, 23-29.	0.3	2
1251	Dietary Regulation of Gut-Brain Axis in Alzheimer's Disease: Importance of Microbiota Metabolites. <i>Frontiers in Neuroscience</i> , 2021, 15, 736814.	1.4	24
1252	A Practical Alzheimer Disease Classifier via Brain Imaging-Based Deep Learning on 85,721 Samples: A Multicentre, Retrospective Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1255	Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. <i>Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova</i> , 2021, 121, 6.	0.1	31
1256	The Therapeutic and Diagnostic Potential of Amyloid β Oligomers Selective Antibodies to Treat Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 768646.	1.4	10
1257	Age-related differences in white matter microstructure measured by advanced diffusion MRI in healthy older adults at risk for Alzheimer's disease. <i>Aging Brain</i> , 2022, 2, 100030.	0.7	10
1258	A New Perspective on the Treatment of Alzheimer's Disease and Sleep Deprivation-Related Consequences: Can Curcumin Help?. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-23.	1.9	6
1259	Structural Alteration of Medial Temporal Lobe Subfield in the Amnesic Mild Cognitive Impairment Stage of Alzheimer's Disease. <i>Neural Plasticity</i> , 2022, 2022, 1-11.	1.0	4
1260	Reactive astrogliosis: A friend or foe in the pathogenesis of Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2023, 164, 309-324.	2.1	43
1261	Practice effect and test-retest reliability of the Mini-Mental State Examination-2 in people with dementia. <i>BMC Geriatrics</i> , 2022, 22, 67.	1.1	11
1262	Peripheral reaching in Alzheimer's disease and mild cognitive impairment. <i>Cortex</i> , 2022, 149, 29-43.	1.1	4
1263	Prospects for the use of graphene-based biological sensors in the early diagnosis of Alzheimer's disease (review of literature). <i>Klinicheskaya Laboratornaya Diagnostika</i> , 2022, 67, 5-12.	0.2	0
1264	An optimized MRI and PET based clinical protocol for improving the differential diagnosis of geriatric depression and Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2022, 320, 111443.	0.9	6
1265	18F-APN-1607 Tau Positron Emission Tomography Imaging for Evaluating Disease Progression in Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 789054.	1.7	7
1266	The Tuokko version of the Clock Drawing Test: A validation study in the Greek population. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2022, , 1-13.	0.8	1

#	ARTICLE	IF	CITATIONS
1267	Importance of a functional measure in the evaluation of patients in a memory clinic: Validation of the Serbian version of the Amsterdam instrumental activities of daily living questionnaire. <i>Clinical Neurology and Neurosurgery</i> , 2022, 214, 107165.	0.6	1
1268	Treatment of noncognitive neuropsychiatric disorders in Alzheimer's disease. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2021, 13, 132-138.	0.2	7
1269	Tau-PET imaging as a molecular modality for Alzheimer's disease. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 11, 374-386.	1.0	0
1270	Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer's disease. , 2022, , 223-242.		0
1271	Alzheimer's disease detection using artificial intelligence. , 2022, , 53-74.		1
1272	Cerebrospinal Fluid Biomarkers in Cerebral Amyloid Angiopathy: New Data and Quantitative Meta-Analysis. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 783996.	1.7	13
1273	Poor pulmonary function is associated with mild cognitive impairment, its progression to dementia, and brain pathologies: A community-based cohort study. <i>Alzheimer's and Dementia</i> , 2022, , .	0.4	10
1274	Association of Plasma Oligomerized Amyloid- β^2 and Cerebral White Matter Lesions in a Health Screening Population. <i>Journal of Alzheimer's Disease</i> , 2022, 85, 1835-1844.	1.2	1
1275	2022 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2022, 18, 700-789.	0.4	1,135
1276	Alzheimer's Disease Drug Development: A Research and Development Ecosystem. , 2022, , 1-24.		2
1277	Alzheimer's Association Funding and Policy for Alzheimer's Disease Drug Development. , 2022, , 486-495.		0
1278	Association of Indication for Hospitalization With Subsequent Amyloid Positron Emission Tomography and Magnetic Resonance Imaging Biomarkers. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2023, 78, 304-313.	1.7	0
1279	Central Auditory Functions of Alzheimer's Disease and Its Preclinical Stages: A Systematic Review and Meta-Analysis. <i>Cells</i> , 2022, 11, 1007.	1.8	12
1280	Sharpening Working Memory With Real-Time Electrophysiological Brain Signals: Which Neurofeedback Paradigms Work?. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 780817.	1.7	5
1281	Computed Tomography Density and β^2 -Amyloid Deposition of Intraorbital Optic Nerve May Assist in Diagnosing Mild Cognitive Impairment and Alzheimer's Disease: A 18F-Flutemetamol Positron Emission Tomography/Computed Tomography Study. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 836568.	1.7	1
1282	Accelerated decline in white matter microstructure in subsequently impaired older adults and its relationship with cognitive decline. <i>Brain Communications</i> , 2022, 4, fcac051.	1.5	16
1283	Targeted Lipidomics To Measure Phospholipids and Sphingomyelins in Plasma: A Pilot Study To Understand the Impact of Race/Ethnicity in Alzheimer's Disease. <i>Analytical Chemistry</i> , 2022, 94, 4165-4174.	3.2	5
1284	Impairments of glutamatergic synaptic transmission in Alzheimer's disease. <i>Seminars in Cell and Developmental Biology</i> , 2023, 139, 24-34.	2.3	15

#	ARTICLE	IF	CITATIONS
1285	The Association Between the Duration, Treatment, Control of Hypertension and Lifestyle Risk Factors in Middle-Aged and Elderly Patients with Mild Cognitive Impairment: A Case-Control Study. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 585-595.	1.0	2
1286	Development of Alzheimer's Disease Biomarkers: From CSF- to Blood-Based Biomarkers. <i>Biomedicines</i> , 2022, 10, 850.	1.4	19
1287	KIBRA regulates amyloid β metabolism by controlling extracellular vesicles secretion. <i>EBioMedicine</i> , 2022, 78, 103980.	2.7	1
1288	Spillover: The Approval of New Medications for Alzheimer's Disease Dementia Will Impact Biomarker Disclosure Among Asymptomatic Research Participants. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-9.	1.2	3
1289	A Novel Way of Measuring Dual-Task Interference: The Reliability and Construct Validity of the Dual-Task Effect Battery in Neurodegenerative Disease. <i>Neurorehabilitation and Neural Repair</i> , 2022, 36, 346-359.	1.4	10
1290	The retina: A window in which to view the pathogenesis of Alzheimer's disease. <i>Ageing Research Reviews</i> , 2022, 77, 101590.	5.0	14
1291	Sentence processing in mild cognitive impairment. <i>Journal of Neurolinguistics</i> , 2022, 63, 101070.	0.5	1
1293	Alzheimer: A Complex Genetic Background. , 0, , .		0
1294	Abnormalities in Cutaneous Microcirculation in Patients with Alzheimer's Disease, Mild Cognitive Impairment, and Chronic Insomnia Disorder. <i>Journal of Clinical Medicine</i> , 2021, 10, 5718.	1.0	2
1295	Blood-based biomarkers for Alzheimer's disease. <i>EMBO Molecular Medicine</i> , 2022, 14, e14408.	3.3	122
1296	New potential biomarkers of Alzheimer's disease: markers of endothelial dysfunction and neuroinflammation.. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2022, 14, 35-42.	0.2	1
1297	PSEN1 G417S mutation in a Chinese pedigree causing early-onset parkinsonism with cognitive impairment. <i>Neurobiology of Aging</i> , 2022, 115, 70-76.	1.5	0
1298	CURVED MULTIFORMAT IMAGING OF STRUCTURAL MRI AS A BIOMARKER FOR PROFILING OF VARIOUS DEMENTIA – AN ALGORITHMIC APPROACH WITH MR/PET. <i>Asian Journal of Psychiatry</i> , 2022, 73, 103094.	0.9	1
1318	Association of the top 20 Alzheimer's disease risk genes with [¹⁸ F]flortaucipir PET. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2022, 14, e12308.	1.2	7
1319	Clinical Research Investigating Alzheimer's Disease in China: Current Status and Future Perspectives Toward Prevention. <i>journal of prevention of Alzheimer's disease</i> , The, 0, , 1.	1.5	2
1320	Correlation Between Brain Structure Atrophy and Plasma Amyloid- β and Phosphorylated Tau in Patients With Alzheimer's Disease and Amnesic Mild Cognitive Impairment Explored by Surface-Based Morphometry. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 816043.	1.7	10
1321	Deep Learning-Based Multilevel Classification of Alzheimer's Disease Using Non-invasive Functional Near-Infrared Spectroscopy. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 810125.	1.7	11
1322	Biomarkers for Alzheimer's Disease in the Current State: A Narrative Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4962.	1.8	21

#	ARTICLE	IF	CITATIONS
1323	Effects of animal-assisted therapy in older adults with cognitive impairment: A systematic review. , 2022, 1, 50-61.		1
1324	Alzheimer Disease Prediction Using Learning Algorithms. Smart Innovation, Systems and Technologies, 2022, , 331-339.	0.5	1
1325	Perspectives on Alzheimerâ€™s Disease: Past, Present and Future. Advances in Biological Psychiatry, 2012, , 179-188.	0.2	16
1326	Italian Case Report with a Double Mutation in PSEN1 (K311R and E318G). Neurology International, 2022, 14, 417-422.	1.3	2
1327	Prediction of Medical Conditions Using Machine Learning Approaches: Alzheimerâ€™s Case Study. Mathematics, 2022, 10, 1767.	1.1	3
1328	Brain-Derived Neurotrophic Factor: A Connecting Link Between Nutrition, Lifestyle, and Alzheimerâ€™s Disease. Frontiers in Neuroscience, 2022, 16, .	1.4	10
1329	Shared pathophysiology: Understanding stroke and Alzheimerâ€™s disease. Clinical Neurology and Neurosurgery, 2022, 218, 107306.	0.6	9
1330	Association between Cerebral Small Vessel and Alzheimerâ€™s Disease. Journal of the Korean Society of Radiology, 2022, 83, 486.	0.1	0
1331	Single-Channel EEG Features Reveal an Association With Cognitive Decline in Seniors Performing Auditory Cognitive Assessment. Frontiers in Aging Neuroscience, 0, 14, .	1.7	2
1332	Recent Advances in Frontotemporal Dementia. Canadian Journal of Neurological Sciences, 2023, 50, 485-494.	0.3	2
1333	Deep transfer learningâ€”based fully automated detection and classification of Alzheimerâ€™s disease on brain MRI. British Journal of Radiology, 2022, 95, .	1.0	9
1334	Nonalcoholic fatty liver disease, serum cytokines, and dementia among ruralâ€”dwelling older adults in China: Aâ€”populationâ€”based study. European Journal of Neurology, 2022, 29, 2612-2621.	1.7	17
1336	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimerâ€™s disease. European Radiology, 2022, 32, 7789-7799.	2.3	3
1337	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected nonâ€”Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2023, 19, 807-820.	0.4	4
1338	Classification of early-MCI patients from healthy controls using evolutionary optimization of graph measures of resting-state fMRI, for the Alzheimerâ€™s disease neuroimaging initiative. PLoS ONE, 2022, 17, e0267608.	1.1	11
1339	Digital biomarkers and sex impacts in Alzheimerâ€™s disease management â€” potential utility for innovative 3P medicine approach. EPMA Journal, 2022, 13, 299-313.	3.3	10
1340	Multiâ€”Omicâ€”Based Autophagyâ€”Related Untypical Subtypes in Patients with Cerebral Amyloid Pathology. Advanced Science, 2022, 9, .	5.6	9
1341	Association of Cardiovascular Health Metrics with Dementia in Rural Chinese Older Adults: A Population-Based Study. Clinical Interventions in Aging, 0, Volume 17, 947-956.	1.3	2

#	ARTICLE	IF	CITATIONS
1342	Combined therapy for Alzheimer's disease. <i>Nevrologiya, Neiropsikhiatriya, Psikhosomatika</i> , 2022, 14, 74-80.	0.2	3
1343	Low-rank sparse feature selection with incomplete labels for Alzheimer's disease progression prediction. <i>Computers in Biology and Medicine</i> , 2022, 147, 105705.	3.9	4
1344	Deep brain stimulation of fornix for memory improvement in Alzheimer's disease: A critical review. <i>Ageing Research Reviews</i> , 2022, 79, 101668.	5.0	16
1345	Association of Depressive Symptoms and Cognition in Older Adults Without Dementia Across Different Biomarker Profiles. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1385-1395.	1.2	2
1346	Four Distinct Subtypes of Alzheimer's Disease Based on Resting-State Connectivity Biomarkers. <i>Biological Psychiatry</i> , 2023, 93, 759-769.	0.7	20
1347	The Role of Psychobiotics in Supporting the Treatment of Disturbances in the Functioning of the Nervous System—A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2022, 23, 7820.	1.8	6
1348	Evaluating measurement properties of subjective cognitive decline self-reported outcome measures: a systematic review. <i>Systematic Reviews</i> , 2022, 11, .	2.5	7
1349	Introducing a gatekeeping system for amyloid status assessment in mild cognitive impairment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 0, , .	3.3	0
1350	Clinical Staging of Alzheimer's Disease: Concordance of Subjective and Objective Assessments in the Veteran's Affairs Healthcare System. <i>Neurology and Therapy</i> , 2022, 11, 1341-1352.	1.4	3
1351	Review on the roles of specific cell-derived exosomes in Alzheimer's disease. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	9
1352	Are we ready to use anti-amyloid therapy in Alzheimer's disease?. <i>Arquivos De Neuro-Psiquiatria</i> , 2022, 80, 15-23.	0.3	2
1353	Biomarkers for the Diagnosis of Alzheimer's Disease in Clinical Practice: The Role of CSF Biomarkers during the Evolution of Diagnostic Criteria. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8598.	1.8	9
1354	Spatio-Temporal Dynamics of Entropy in EEGs during Music Stimulation of Alzheimer's Disease Patients with Different Degrees of Dementia. <i>Entropy</i> , 2022, 24, 1137.	1.1	2
1355	Sex specific EEG signatures associated with cerebrospinal fluid biomarkers in mild cognitive impairment. <i>Clinical Neurophysiology</i> , 2022, 142, 190-198.	0.7	2
1356	Risk Models Based on Non-Cognitive Measures May Identify Presymptomatic Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2022, 89, 1249-1262.	1.2	2
1357	The Role of a Gut Microbial-Derived Metabolite, Trimethylamine N-Oxide (TMAO), in Neurological Disorders. <i>Molecular Neurobiology</i> , 2022, 59, 6684-6700.	1.9	24
1358	Contribution of blood-brain barrier-related blood-borne factors for Alzheimer's disease vs. vascular dementia diagnosis: A pilot study. <i>Frontiers in Neuroscience</i> , 0, 16, .	1.4	4
1359	How segmentation methods affect hippocampal radiomic feature accuracy in Alzheimer's disease analysis?. <i>European Radiology</i> , 2022, 32, 6965-6976.	2.3	7

#	ARTICLE	IF	CITATIONS
1360	Predicting progression to dementia with "comprehensive visual rating scale" and machine learning algorithms. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	2
1362	Perspectives of ozone induced neuropathology and memory decline in Alzheimer's disease: A systematic review of preclinical evidences. <i>Environmental Pollution</i> , 2022, 313, 120136.	3.7	9
1363	High-performance medicine in cognitive impairment: Brain"computer interfacing for prodromal Alzheimer's disease. , 2022, , 105-121.		0
1364	Roadmap for ecosystem-based approach for patients with Alzheimer disease in Russia: current needs, barriers, and possible solutions (resolution of the scientific and practical experts meeting). <i>Zhurnal Nevrologii I Psikiatrii Imeni S S Korsakova</i> , 2022, 122, 121.	0.1	1
1365	Agreement and Reliability between Clinically Available Software Programs in Measuring Volumes and Normative Percentiles of Segmented Brain Regions. <i>Korean Journal of Radiology</i> , 2022, 23, 959.	1.5	2
1366	Understanding the Relationship Between Age-Related Hearing Loss and Alzheimer"™s Disease: A Narrative Review. <i>Journal of Alzheimer's Disease Reports</i> , 2022, 6, 539-556.	1.2	5
1368	Memory markers in the continuum of the Alzheimer"™s clinical syndrome. <i>Alzheimer's Research and Therapy</i> , 2022, 14, .	3.0	6
1369	Clinical efficacy of acupuncture combined with Western medicine in the treatment of mild to moderate Alzheimer disease: A protocol of a randomized controlled trial. <i>Medicine (United States)</i> , 2022, 101, e30705.	0.4	0
1370	Comorbid Neurodegeneration in Primary Progressive Aphasia: Clinicopathological Correlations in a Single-Center Study. <i>Behavioural Neurology</i> , 2022, 2022, 1-14.	1.1	1
1371	Tear Biomarkers in Alzheimer"™s and Parkinson"™s Diseases, and Multiple Sclerosis: Implications for Diagnosis (Systematic Review). <i>International Journal of Molecular Sciences</i> , 2022, 23, 10123.	1.8	14
1372	Preliminary Validation Study of the French-Quebec Version of the Mild Behavioral Impairment Checklist. <i>Cognitive and Behavioral Neurology</i> , 2023, 36, 9-18.	0.5	2
1373	Targeting the cannabinoid system to counteract the deleterious effects of stress in Alzheimer"™s disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
1374	Animal models of Alzheimer"™s disease: Applications, evaluation, and perspectives. <i>Zoological Research</i> , 2022, 43, 1026-1040.	0.9	29
1375	Altered metamemory precedes cognitive impairment in subjective cognitive decline with positive amyloid-beta. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
1376	Functional magnetic resonance imaging, deep learning, and Alzheimer's disease: A systematic review. <i>Journal of Neuroimaging</i> , 2023, 33, 5-18.	1.0	30
1377	Synaptic Proteins as Fluid Biomarkers in Alzheimer"™s Disease: A Systematic Review and Meta-Analysis. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1381-1393.	1.2	2
1378	Deep learning-based diagnosis of Alzheimer"™s disease using brain magnetic resonance images: an empirical study. <i>Scientific Reports</i> , 2022, 12, .	1.6	10
1379	A practical Alzheimer"™s disease classifier via brain imaging-based deep learning on 85,721 samples. <i>Journal of Big Data</i> , 2022, 9, .	6.9	21

#	ARTICLE	IF	CITATIONS
1380	Effects of probiotic supplements on cognition, anxiety, and physical activity in subjects with mild and moderate Alzheimer's disease: A randomized, double-blind, and placebo-controlled study. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	15
1381	Impact prediction of translocation of the mitochondrial outer membrane 70 as biomarker in Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	2
1382	The Global Impact of Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 1-14.	0.2	1
1383	Changing Diagnostic Concepts of Alzheimer's Disease. <i>Advances in Biological Psychiatry</i> , 2012, , 115-121.	0.2	13
1384	Need for an Update for the Guideline for the Management of Mild Cognitive Impairment. <i>Dementia and Neurocognitive Disorders</i> , 2022, 21, 107.	0.4	0
1385	AChE as a spark in the Alzheimer's blaze – Antagonizing effect of a cyclized variant. <i>Ageing Research Reviews</i> , 2023, 83, 101787.	5.0	4
1386	Differentiation of Subjective Cognitive Decline, Mild Cognitive Impairment, and Dementia Using qEEG/ERP-Based Cognitive Testing and Volumetric MRI in an Outpatient Specialty Memory Clinic. <i>Journal of Alzheimer's Disease</i> , 2022, 90, 1761-1769.	1.2	4
1387	Multi-stage classification of Alzheimer's disease from 18F-FDG-PET images using deep learning techniques. <i>Physical and Engineering Sciences in Medicine</i> , 2022, 45, 1301-1315.	1.3	3
1389	The miR-146a-5p and miR-125b-5p levels as biomarkers for early prediction of Alzheimer's disease. , 2022, 34, 201129.		2
1390	Identifying opportunities for hepatic encephalopathy self-management: A mixed methods systematic review and synthesis. <i>Canadian Liver Journal</i> , 0, , .	0.3	0
1391	Graphene as the basis of biological sensors for the diagnosis of neurodegenerative dementia. <i>Izvestiĭ Rossijskoj Voenno-meditsinskoj Akademii</i> , 2022, 41, 421-428.	0.1	1
1392	Patch-based deep multi-modal learning framework for Alzheimer's disease diagnosis using multi-view neuroimaging. <i>Biomedical Signal Processing and Control</i> , 2023, 80, 104400.	3.5	9
1393	The role of magnetic resonance imaging in the diagnosis and prognosis of dementia. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	0.6	1
1394	The Utility of Arterial Spin Labeling MRI in Medial Temporal Lobe as a Vascular Biomarker in Alzheimer's Disease Spectrum: A Systematic Review and Meta-Analysis. <i>Diagnostics</i> , 2022, 12, 2967.	1.3	4
1395	Cell type-specific changes identified by single-cell transcriptomics in Alzheimer's disease. <i>Genome Medicine</i> , 2022, 14, .	3.6	14
1396	Alzheimer's Disease: A Systems View Provides a Unifying Explanation of Its Development. <i>Journal of Alzheimer's Disease</i> , 2023, 91, 43-70.	1.2	7
1397	Amyloid β PET in Alzheimer's disease: A systematic review and Bayesian meta-analysis. <i>Brain and Behavior</i> , 2023, 13, .	1.0	17
1398	PR-957 Suppresses Th1 and Th17 Cell Differentiation via Inactivating PI3K/AKT Pathway in Alzheimer's Disease. <i>Neuroscience</i> , 2023, 510, 82-94.	1.1	3

#	ARTICLE	IF	CITATIONS
1399	Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease. <i>Nature Communications</i> , 2022, 13, .	5.8	22
1400	How far is the goal of applying β -amyloid in cerebrospinal fluid for clinical diagnosis of Alzheimer's disease with standardization of measurements?. <i>Clinical Biochemistry</i> , 2023, 112, 33-42.	0.8	3
1401	Predicting Progression from Normal to MCI and from MCI to AD Using Clinical Variables in the National Alzheimer's Coordinating Center Uniform Data Set Version 3: Application of Machine Learning Models and a Probability Calculator. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 0, , .	1.5	1
1403	Localization, induction, and cellular effects of tau phosphorylated at threonine 217 ¹ . <i>Alzheimer's and Dementia</i> , 2023, 19, 2874-2887.	0.4	6
1404	A novel cascade machine learning pipeline for Alzheimer's disease identification and prediction. <i>Frontiers in Aging Neuroscience</i> , 0, 14, .	1.7	3
1405	Use of the Laboratory in the Diagnostic Workup of Older Adults. , 2022, , .		0
1406	Deamidation-related blood biomarkers show promise for early diagnostics of neurodegeneration. <i>Biomarker Research</i> , 2022, 10, .	2.8	5
1408	Effect of Cognitive Reserve on Physiological Measures of Cognitive Workload in Older Adults with Cognitive Impairments. <i>Journal of Alzheimer's Disease</i> , 2023, , 1-11.	1.2	3
1409	Dementia and Older Persons in USA. , 2023, , 1-20.		0
1410	Association of Central Auditory Processing Dysfunction With Preclinical Alzheimer's Disease. <i>Otolaryngology - Head and Neck Surgery</i> , 2023, 169, 112-119.	1.1	0
1411	Beta-Amyloid Peptide in Tears: An Early Diagnostic Marker of Alzheimer's Disease Correlated with Choroidal Thickness. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2590.	1.8	5
1412	Cognitive and behavioral abnormalities in individuals with Alzheimer's disease, mild cognitive impairment, and subjective memory complaints. <i>Current Psychology</i> , 2024, 43, 800-810.	1.7	4
1413	The effects of spirulina intake on clinical and metabolic parameters in Alzheimer's disease: A randomized, double-blind, controlled trial. <i>Phytotherapy Research</i> , 2023, 37, 2957-2964.	2.8	5
1414	Structural polymorphism and cytotoxicity of brain-derived β -amyloid extracts. <i>Protein Science</i> , 2023, 32, .	3.1	4
1415	ExHiF: Alzheimer's disease detection using exemplar histogram-based features with CT and MR images. <i>Medical Engineering and Physics</i> , 2023, 115, 103971.	0.8	7
1416	Diagnosis of Alzheimer's disease: recommendations of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology. <i>Dementia E Neuropsychologia</i> , 2022, 16, 25-39.	0.3	2
1417	Liver-Specific Polygenic Risk Score Is Associated with Alzheimer's Disease Diagnosis. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 395-409.	1.2	4
1419	Literature review on the interdisciplinary biomarkers of multi-target and multi-time herbal medicine therapy to modulate peripheral systems in cognitive impairment. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	1

#	ARTICLE	IF	CITATIONS
1420	Associations Between Levels of Peripheral NCAPH2 Promoter Methylation and Different Stages of Alzheimer's Disease: A Cross-Sectional Study. <i>Journal of Alzheimer's Disease</i> , 2023, 92, 899-909.	1.2	1
1421	HomeCoRe system for telerehabilitation in individuals at risk of dementia: A usability and user experience study. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	5
1422	CSF A β 42 and A β 42/A β 40 Ratio in Alzheimer's Disease and Frontotemporal Dementias. <i>Diagnostics</i> , 2023, 13, 783.	1.3	4
1423	Diagnóstico da doença de Alzheimer: recomendações do Departamento Científico de Neurologia Cognitiva e do Envelhecimento da Academia Brasileira de Neurologia. <i>Dementia E Neuropsychologia</i> , 2022, 16, 25-39.	0.3	5
1424	Machine Learning-Assisted Nanoenzyme/Bioenzyme Dual-Coupled Array for Rapid Detection of Amyloids. <i>Analytical Chemistry</i> , 2023, 95, 4605-4611.	3.2	8
1425	Toxic agents and health disparities in the socially marginalized. , 2024, , 169-176.		1
1426	Missorting of plasma miRNAs in aging and Alzheimer's disease. <i>Journal of Neurochemistry</i> , 2023, 165, 149-161.	2.1	0
1427			
1428	Efficient Pause Extraction and Encode Strategy for Alzheimer's Disease Detection Using Only Acoustic Features from Spontaneous Speech. <i>Brain Sciences</i> , 2023, 13, 477.	1.1	2
1429	2023 Alzheimer's disease facts and figures. <i>Alzheimer's and Dementia</i> , 2023, 19, 1598-1695.	0.4	490
1430	Polygenic risk score penetrance & recurrence risk in familial Alzheimer disease. <i>Annals of Clinical and Translational Neurology</i> , 0, , .	1.7	2
1431	The Progression of Current Biomarkers for the Diagnosis of Alzheimer's Disease. , 0, 36, 621-627.		0
1432	Circulating long non-coding RNAs as novel diagnostic biomarkers for Alzheimer's disease (AD): A systematic review and meta-analysis. <i>PLoS ONE</i> , 2023, 18, e0281784.	1.1	8
1433	Early Alzheimer's Disease Diagnosis Using Wearable Sensors and Multilevel Gait Assessment: A Machine Learning Ensemble Approach. <i>IEEE Sensors Journal</i> , 2023, 23, 10041-10053.	2.4	3
1434	Toward a new nosology of neurodegenerative diseases. <i>Alzheimer's and Dementia</i> , 2023, 19, 3731-3737.	0.4	1
1435	Natural language processing techniques for studying language in pathological ageing: A scoping review. <i>International Journal of Language and Communication Disorders</i> , 2024, 59, 110-122.	0.7	2
1436	Mapping the long-term delayed recall-based cortex-hippocampus network constrained by the structural and functional connectome: a case-control multimodal MRI study. <i>Alzheimer's Research and Therapy</i> , 2023, 15, .	3.0	2
1438	Volume changes of hippocampal and amygdala subfields in patients with mild cognitive impairment and Alzheimer's disease. <i>Acta Neurologica Belgica</i> , 2023, 123, 1381-1393.	0.5	3

#	ARTICLE	IF	CITATIONS
1439	Characterizing Early-Onset Alzheimer Disease Using Multiprobe PET/MRI. <i>Clinical Nuclear Medicine</i> , 0, Publish Ahead of Print, .	0.7	0
1440	In vivo Acetylcholinesterase activity and Antioxidant property of Cucurbita pepo ethanolic extract in Alzheimer's disease induced by Aluminium chloride in Sprague Dawley rat model. <i>Research Journal of Pharmacy and Technology</i> , 2023, , 1065-1071.	0.2	2
1457	Applications of fMRI to Neurodegenerative Disease. , 2023, , 819-860.		0
1459	The GABAergic system in Alzheimer's disease: a systematic review with meta-analysis. <i>Molecular Psychiatry</i> , 0, , .	4.1	4
1464	A Comprehensive Review on the Identification of Blood-Based Biomarkers for Alzheimer's Disease Detection Through Computational Approaches. <i>Lecture Notes in Networks and Systems</i> , 2023, , 435-449.	0.5	0
1465	Machine Learning for Alzheimer's Disease and Related Dementias. <i>Neuroinformatics</i> , 2023, , 807-846.	0.2	1
1468	Neurogenetic motor disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 183-250.	1.0	0
1471	What Is Neurodegeneration?. , 2023, , 1-13.		0
1472	Computational Analysis of a Light-Weight SUVr Processing Technique for Neuroimaging Alzheimer's Disease. , 2022, , .		0
1477	The use of neuroimaging techniques in the early and differential diagnosis of dementia. <i>Molecular Psychiatry</i> , 2023, 28, 4084-4097.	4.1	2
1479	Gait dysfunction in Alzheimer disease. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 267-274.	1.0	0
1487	Weighted Kernel Ridge Regression based Randomized Network for Alzheimer's Disease Diagnosis using Susceptibility Weighted Images. , 2023, , .		0
1492	Investigating the mechanism of learning, memory formation and defects in humans. , 2023, , .		0
1493	Dementia and Older Persons in USA. , 2023, , 1723-1742.		0
1525	Impact of Physical Activity on Physical and Cognition Function among Community-Living Older Adults. , 0, , .		0
1534	Attention-based CNN for CT-Kidney Classification. , 2023, , .		0